var title_f34_34_35360="Lidocaine: Drug information";
var content_f34_34_35360=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Lidocaine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12618243\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12618244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/30/4579?source=see_link\">",
"       Lidocaine (ophthalmic): Drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/54/14184?source=see_link\">",
"       Lidocaine (systemic): Drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/3/20535?source=see_link\">",
"       Lidocaine (topical): Drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9558 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-85.214.214.87-89768E4622-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_34_35360=[""].join("\n");
var outline_f34_34_35360=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?4/30/4579?source=related_link\">",
"      Lidocaine (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?13/54/14184?source=related_link\">",
"      Lidocaine (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?20/3/20535?source=related_link\">",
"      Lidocaine (topical): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_34_35361="Anti-La staining";
var content_f34_34_35361=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F86983&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F86983&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 481px\">",
"   <div class=\"ttl\">",
"    Staining pattern produced by anti-La antibodies",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 461px; height: 421px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGlAc0DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD334k+OtN+H+i22p6vbX1zDcXK2iJZqjPvKO+TvZRjEbd/SvOW/aW8KIu5tF8SAevk2/8A8fpf2uVL+ANEUHBOtR/+k9xXmnwf+Fnh/wAaeDta1vxHq2rWSWF5JC32WSJY1iSCKQsd0bHPzt36AcVhKc+fkjba56dDDYf6q8RX5vi5Va3a/U9BP7UngwHnSPEn/gPB/wDHqT/hqbwX/wBAnxJ/4Dwf/Hq4v4YfCP4Y/EvTb290PU/GEP2SYQyw3clskgyuVbCxsNp5xz/CeK+aY1LBfUitW2tzkhThN2jc+yv+GpvBf/QJ8Sf+A8H/AMepR+1J4LPTSPEv/gPB/wDHq+RLexZ+SOK0IdOTGTzWEsSonqUMlqVdT6tH7UPg49NH8S/+A8H/AMepf+Gn/B//AEBvEv8A34t//j1fJ7ssMoVEGBwTirW1PL5AGah4prodVPIqcrrnd0fUjftR+DF66R4kH/bCD/49Tf8AhqbwV/0CfEn/AIDwf/Hq+Trm1VkJUYbr0rIlUq2DWsK3Oedisu+rvXY+x/8AhqfwV/0CfEn/AIDwf/HqP+Gp/BX/AECfEv8A4Dwf/Hq+NDSYrTmZx+xR9mf8NT+Cv+gT4l/8B4P/AI9R/wANT+Cv+gT4k/8AAeD/AOPV8Z0oHajmYexR9mf8NTeCv+gT4k/8B4P/AI9R/wANS+C/+gT4k/8AAeD/AOPV8aAVKEyKTnYuOGTPsf8A4al8F/8AQJ8Sf9+IP/j1J/w1L4L/AOgT4k/8B4P/AI9Xx15RI6U1kIo5xvCpdz7H/wCGpfBf/QJ8Sf8AgPB/8eo/4am8Ff8AQJ8Sf+A8H/x6vjXFIRT5mR7CJ9l/8NTeCv8AoE+JP/AeD/49R/w1N4K/6BPiT/wHg/8Aj1fGlIaOZg6MT7L/AOGp/BX/AECfEn/gPB/8eo/4an8Ff9AnxJ/4Dwf/AB6vjI0UczJ9lE+zf+Gp/BX/AECfEv8A4Dwf/HqUftT+Cv8AoE+JP/AeD/49XxkKBRzMPYxPtGP9qDwdIcJpHiQn/rhb/wDx6rC/tJ+FWHGieJP+/Vt/8fr420/l+R9K3nyluGA5rmq4iUHZHuYHJ6GIg5zb07W/yPuD4Y/E3SPiI+ppo9nqVq2niIy/bUjXcJN+3bsdv+ebZzjtXL61+0D4b0nWNQ06bR/EEstlcy2kkkUUGxnjcoxXMwOMqcZArh/2MiTd+NM9dlj/ADuK8z1qyTVvi5qGlTSSRQ3vimW0keLG9UkvyjFcgjOGOMg16mBpwr3dW9km9PI+azG+HqclLvbX/gHuN1+054RtQvn6N4lXdyP3Fuf5TVX/AOGqfBH/AECvEn/gPB/8ergfGPw9+HejaxrmnXzePbxdChhmvri3ksPLiSUDaRuCs3XBAUmuP/aC+GegfD618L3Hhq71O5i1eOeRjfOhICiIrgKi4/1hznPbpSkqTlane3nYmHPb37X8j27/AIap8Ef9ArxJ/wCA8H/x6l/4ao8EnppPiX/wHg/+PV8fWFi0xBIwDW9b6XBGgMgJPt0rro5dKqro56uMhT0PqaP9qLwbIfk0fxKf+3eD/wCPVL/w014Sxn+xPE2P+ve3/wDj1fNGnafCVZtoCDv3pLqBQCsJJFd6yRKHNKRxPNLy5Yo+lW/af8HrnOj+JR/2wt//AI9UJ/ao8Eg86V4l/wDAeD/49XzPLYK8YDAZ9a5vVtPaAFxyuetcmIyx0lzLY6qGNVV8rPrz/hqrwR/0CvEn/gPB/wDHqT/hqrwR/wBArxJ/4Dwf/Hq+LsUV5/s0dtz7S/4aq8Ef9ArxJ/4Dwf8Ax6j/AIap8Ef9ArxJ/wCA8H/x6vi3tR3o9mgufaX/AA1T4I/6BXiT/wAB4P8A49R/w1T4I/6BXiT/AMB4P/j1fFop6xk9BTVJMTdj7P8A+GqfBH/QK8Sf+A8H/wAeo/4ap8Ef9ArxJ/4Dwf8Ax6vjPyH7KfyprRsvUEU3QsLnR9nf8NU+CP8AoFeJP/AeD/49R/w1V4I/6BXiT/wHg/8Aj1fFx4pO9L2aKufaX/DVPgj/AKBXiT/wHg/+PUf8NVeCP+gV4k/8B4P/AI9XxbRS9mgufaX/AA1V4I/6BXiT/wAB4P8A49R/w1V4I/6BXiT/AMB4P/j1fFlFHs0Fz7T/AOGqvBH/AECvEn/gPB/8eo/4ap8Ef9ArxJ/4Dwf/AB6viylo9mgufakf7UvguRgqaT4kJPQfZ4P/AI9Wgf2jfDIxnQvEv/fq2/8Aj9fFGl7Rdxbum4V3vmK0yKe4r1MFl1LERbm3/XyPOxmMnQklFI+mJf2kPDEUbSSaF4lCKpYnyrY4A6/8t69ur869ZnK2t5GnA8px9Rg1+ilc2Y4WnhpqNNt+ptg8ROvFymjwz9r1/L+Huit6azH/AOk9xXHfBvRNZ8W/ADxZo3h25tLW71DWGgkmumYKsJgt/MxtUkkqCuPc811P7ZrbfhlpB/6jUX/oievjRgHOWAya8lq0+byPahNzw3sP71/wsfePgT4Zah4H+IUupaVqi3fh+70yKzuorrYk4lhAWJlWKNUKhAF555JOa+H9MtSYUlb7uB+NV7O1WR/uKQOvFb9uqGPYvAUcACsMRW0sj18ny68nUn8h0TJ5f909PrU0Jidtq5GKo3COGHHy06yULISewrjcdL3PpadaSmoOJbktk3k9QaqzxZlyDgCrD3SKAMjPqKjBS5+QMASO9THmWrLrKlP3YbkSygkhVyAKxb5QshxW2Ifs6uSevFYt8+6Q/wA66qHxaHiZmmqSU9yoR1pO3vQTSE11nzjYdqVBk00datW6AkUm7IulDnlYfFBnk1ehijH3hVm1g+Tocdqti0zGSSMiuKdbofTYXLWo8yRUFnE6kjt6VUuLXAJXpWgkbsSAvApY0+cLLkj6VKqNdTeeEhUSXLbzOcdNrc96jPvWnqVuI3yvQ9qzGGK7YS5lc+ZxVF0ZuLG5xSGg0laHI2A60tJSjpQISlFJSigEW7JtsorolcNEMk46ZFcvEdrVvWMyyIFftXJiI9T6LJ69r077n0b+xsmy88aDIOUsT+txXnDyoPj3HHkbz4zPH/cRr0v9jwKL7xmE6eXY/wA7mvnL4ryE/E3xgh+6NZveP+2716mAqcsH5xaPmM3o3xUl2lc+sfHfwo1jXfGXi/Vbex8N3kWtWcFtaXF/NIs+nukYUyoBC3zZ5GHXoMntXB/tWaPNaaV8NtMu7x72eztLmKW6kHzTMi2ylz7k8/jXzJaQefOqADJNdjZaWkMO6KNQwHLBeTXfgcDKrPm6I8rF4pUo26sfFYbI0I7HpV82pZDgdB0pdgkhC5w1RxPMZNqcD3r6mNOENLbnz8pynrfYVJSsbRBcBuKmtkVQcjkcVGVVW+ZsHNWFQCQIrZbGcVpBO+pnNq2hD9nU9TgZyM1i6/Gq2XykHBrXvJQzFQdrZxjFYfiGQLAsXGeprkxjiqckjpwqk6kTkm60lK3U0gr5Nn0wUoHNJUkK7mAFOKuxN2LenWT3UyqoOO59K77RfDUCgGRQ2fWoPDdhHBbhmHzEda3ortopFQKWcd6+uyzL6VOKqVlds+YzDHVKknCk7JFafRYk3hYQeOgFZ914fSW3YFNpPSu2hKmElx8xqGUrIu3A3dj6V7dTL6M1sePTx9WL3PFdX057C4KMDtPQ1nV6b4p00XVpJkAypyCK81kUqxBHIr4fMsH9Vq2Wz2Pscvxf1mnd7oZSUtJXmHeFFFFAwpRSUooAntW2yL9a9AtNs0MLjG4qPzrzqM4Ndp4duN8QjyARyK9nKaiU3B9TyszptxUl0L/iK38zTp5RwVhbIx7Gv0Lr89NTeT+yb0Sc/uX/APQTX6F1ln1vaxa6oMpv7OSfc8D/AGz/APkmGk/9hqL/ANET18bAV9k/tn8fDDSf+wzF/wCiJ6+NR1r5+R9Dh/hNjTdoHJ5rQtniE2cn5uuaxdPkAbazYrSiVA24NkCvPqx1dz63L6/uR5UtDT8tWcBTuUDkGmXSRRRNjAY/rUAuCg3IDkcGnXsTTqjqcnuK51Fpq70PbnVjKnLkjdlLG7GRk0IAkobuO1WbcBRufgiqd/OgfKHmt4tydjyqijSgqjeoaldnJRSCprElfcxp88pY9c1Ca66dNQR85jcVLETbYZzSUtFanEKvJrU0+PJXis6IZat2yjCRhmOF96wrSsj1Mso89S/Y07aLYoIPXtUpPmAhQN3TFUIrxPNGWOR0NXQ6ibeCST37V5sotPU+0oVaco2g9OpXjeWOTLDJFS3O9plZVGDVma4VQA4A46kVVaUlSM5ShNvWxU4RpxcOe5najGQNz9c1hSjk4ro7sq6Ag8CueuRhz9a78O9LHyWcQSlzRIDQKSlFdR4IdqKKPagYYoHHSgUUAOU1etJyp5NZ4p4bB4qJRurG9Gs6cuZH1d+xqwa68ZEf887H+dzXzj8Vv+SpeMf+wze/+j3r6D/YkcvJ40J5+WxH/pRXz58Vv+SpeMf+wze/+j3row65VY4cZU9rWlPuZWhLuuQR2rs7W48pTGx5PBriNHnWG5DOcCu0s2jmUvwcjrX1OVS920XqfN5jH3rtaEm51JBHvmkt5mcsF5NWRGT8zEY9KjbbbXIxgqRzivXcWrO+h5iknpbUqzl3mwmQ1StJLEwJGHx1qb5SDIpyc8VRnughLO2MVlL3NWy4+/okMurhRuml+92HvXL6vdGeQknk1Pq18XkLA9eg9KxXYsc5rwcbiuduCPaweG5feY2iiivLPRFFa2g2v2i9QEZA5NZS9RXZ+DbVS29hXdl9H2taMTjxtX2VJyOotI/KUKq5HTFX7eKPduz8x7VLZS2bKU86MS9smp4rQm4+ZQMjh6+/pUkkranxNSrq76E0BjdBgjPQ1GsUSXWS3BH61HJZgScMc+3enLDgbJfwPpXRq90c9lumZmshPnjXknnNeVazH5d9KMd69c1CEgFmO5cYBrzTxPEDeOy9q+Yz+k3FSPo8kqWlynPUlOpK+RZ9OJRRRSGFFFFADga1NJvGhcYOCKyRTlYqcg1rSqOnLmRnUpqceVnfXdytzot26f8APB8/98mv0Rr8wINQkjt5o88PGyH8Riv0/rXMsSsQ4Pqkc+Dw7ocyPA/20P8AkmGk/wDYai/9ET18aA9a+y/20P8AkmGk/wDYZi/9ET18ZV5Mj1qL90kVsHI61ahumQYJJFUxS7vSs3FPc7KdaVN3izWTUscbRT/7Tz7ViE80obFZuhE7I5rXWlzSmvS+ccZ/WqMkpJxTC2egppOTVxgonNWxU6vxMSloozwKs5hKB70vajFAWJ7YZkGK1bgnYgBO3FZEDbZAfSughjF1AOxHeues+Vps9vLIOrCUI7meFPBzWnE7LACSeKZ9k2KCxwKkcBIxycYrnnJSPWw9CVG7ehFcy74x82TUluf3ZIGRVXZ5hxGMt71NbM8CHfyDzihr3bIdOo3U5pbdxlwvTFY12u1uvetK6f5+OBWXdMC30roopo8fMpxd7EHeilo7V0HiJBSU7FGKB2Eo7UuKTFAWEzRmikpkn1L+w/y3jX6WP/txXz78V/8AkqXjL/sM3v8A6PevoH9h773jb6WP/txXz98V/wDkqXjL/sM3v/o962pHJU+JnLqcHitDT9UmtG+Vsj0NZtKDXXTqypu8XYxnTjNWkjqk8R7wBKnI9DUn9uREHK9feuSo3V2rMq3VnI8BS6I6d9cCZ8voayrjUWkcsetZuaKyqYypU0bNIYWnDZD5pC7kmo+9FBrlbvudCVgoooFIY9B8wr0PQIni0jzI+SVrzxDgivSfCl3H/ZiZGSnBFe5kii6zTfQ8jN3JUk13MsylXIJIPau58N3Tz6cvn5IU4BNUDYWF24kKlTnoprat4Y7eJEjUKvpX1GCws6U3Jyuj5rG4iFWCjbUnd1EiqpBPtS3EkYU84OKpy28wlLQyABj0x0qtLblZmlM+UIwRivQcmuhwRpxdtSDVLhY4vlO4Ec1wetRh45pD1J4rp7xyHZFyUP8AOuY8RzRxwLCh56k187mtTni3LofQ5bT5JJLqco1JSmkr45n1QUUtJSAKSloosAlLmkopDAniv1Rr8rj0r9UayqAjwL9tD/kl+k/9hmL/ANET18ZE19m/tof8kv0n/sMxf+iJ6+M8VhLc6aXwid6KMc0tI1EoFFKBQAClAp2KfGhY8A0rmkYtuyIwKMc1eWyfblqedPfGVFR7WK6nUsFWe0TPwe1IferEtu6ZyDxVduOtUmnsc84OGkkCnmtzTbgKAvpWEKsQuVI5OBUVYc6sdOBxDw9TmR1TzKTnA56YqK4cNhWAPuKx470qQD2qVr09eBXH7Bpn0rzSFSLuy80aqAchTVSW5RQQp596pXF2WOc1UllLdK2hRfU83E5lFaU0TTy7jgHIqq3JOaM0V0pWPDqVHUd2AHNOCk9qVV3GtKzs9wBbipnNRWpth8NKvLliUFgZs8VOtm5/hOK2orYKuSMilMyqx2IMd653Xb2PahlMIJOozF+xucgA5qvLAyHoeK6RNkqsQMEmopLZSCPvHvSjiHfUVXKIuN4M5ojA6U01oXdrs5AxVErzXVGSkro8KtRlSlyyPqH9h773jX6WP/txXz98V/8AkqfjL/sM3v8A6PevoH9h/wC941+lj/7cV8/fFf8A5Kl4y/7DV7/6PeummeZU+JnK0UUVsQLRSUtMQUUd6eiFugzVJXBuw3FGK2LHRJ7lQxwi+pq+fDZ4XzVz711wwNaauonLLGUoOzZzGKSti+0S4tgW27k9RWXJE0ZwwI+tY1KM6btJWNqdWFRXi7jB1rpPC+oCCUxufkb+dc3UkchRgQeRVYau6FRTXQivRVaDgz1az2iTfuIDdADxWvE4IHJDCvNNM11kKLKc44B9K6FddtxEAZPrzX2OEzOi43vY+WxOX1VK1jqJ78RLtJyTWRd6iNvDYHcVzt5rcZZvLkzWNd6sSp2nLHqaxxWcR1SZrh8rlu0a19qqrI2W6dAK5fULk3EpPaoJZWkbJPNMJr5nE4uVfR7H0FDCxo6oSl256ClRSxAFdHo2iNIBNOuE6j3rKhh515csUa1q8aMeaRjWunz3P+rQketaUHh24cAtgD6119tDHEm1FA+lTyxJCTuOc84r3aWUU0rzdzxqmaTbtFWOPbw1JtJVxgVn3GiXcSFxGWUdxzXeybSm1QetJlzH9zjvVzyqhLRXRMMyrLV6nl7KVOCKaa6/XtKSVTNbrh+49a5JlKsQeMV8/isNLDy5We1h8RGvHmQ09K/VGvyuPSv1RrhqHQjwP9tD/kmGk/8AYai/9ET18Z4r7N/bOGfhjpP/AGGYv/RE9fGZHNYS3OuivdExRilPuKCKk1sNpQKSnxrk0BFXdiSGMyHAFatpb4ySvSjT4AFBNXGlKrtA71yVajbsj6PA4KMIqpMl8oRx5dGwaa8yjgdqsMrsiA4xis5lPmMvvXNH3tz2K7dJLkQXBSUY56ccVkXUBQmtULubAHIpmoxbY1PcjGK6KcuV2PIxdD28HN9DDpy0MMMaQcCuw+c2ZIGAHNNZyR1ptNY0WG5uwpNHWm0opkCjk05RmkXk1NCpLjrUt2NKceZ2Lllb7iDWsYSiBgenam2flwIM4BNWUZZcnrXn1Kjb8j7HBYWFOnb7TJEy8BJHNZrfLkHg5rWyFIA6VQuIN77lxnuKzpy11OzF024px1aIIiRKrD17VblXGXbgVAFEB3P17AU37QZeD2rRpt3RyQkqcXGe76Fe9JIOOQR3rGl+8a27phtIHpWJL9+uqhseBmnxXPp/9h/7/jX6WP8A7cV8/fFf/kqXjL/sNXv/AKPevoH9h773jX6WP/txXz98V/8AkqXjH/sM3v8A6Peu+kfOVPiZytFFFakBS0gpyjJxVJCZLbwtK4VBk12ej6PFbW/m3SgyHkKap+E7BfNM0oyq9PrXW+Qly3zEfQV9JlmAXL7WSu+h4OYYx83s4vTqZp++qrwp6n0qw0McWDKw29jUk8CqQu0qfQ1HPBJPahcbiDxivV5HG+l2ebzp21sie1W3uGKbk24/irm/EmjiGQuoxG3T2NaQt3yGQEY4I71Z1COSTTWWb7wGQD2rGtTjiKTjKOq6mtKbo1FKMtGeayoUYg0wVf1NPmDAYzWfXyFSPLKx9RCXNG44HHSneYfWo+tFRzMqw4sTSE0goouOwU4c02pYV3SAULVieiN3w5pf2pzLJwi+veu4hCgpCqgr0zWTpVuI7KNFOwEZJPc1pwIyAhSM9sV9jl9BUYJJavc+WxtZ1Ztt7bDr6MQyqE796p6irl0ZQSuByKlIdpcu3HvU6RM8QQscV1yXtLpKxzRfJZsp2kxa6QKpAPWrsrhJGjXscinW6Jaks7gk8ZPapxFEy7gwZzWlOnJRtfUic05XtoZM4T5gRnNcBrMYjvpAowM1394mxm3dM1w+uri4Y55zXgZvG8F5Hs5W/eMk1+qNflca/VGvl6m57yPCv2wk8z4c6Mp76zH/AOk9xXxlcJscg19o/tcjPgDRAf8AoMp/6TXFfG2oLiQ+ua5JS/eW8j2MPSTwftP7z/JFLpRxQetNqjnDvVuyj3OM96qd609MGZBgCoqO0TpwcFOqkzZtkVCOcN6etTyRjIHv6UyMDOB94c1FC8u7EhO3PIrzXdu59vFxhFQa3L4MZXBbGKrzRICcHJqpPKxlIXjHWmq7FgAfmoVNrW4qmLjJ8riWo4l+8ByKpak4KAAfWr5cx24ZgAx96x9QYKcgk561pSV5HLj5qnRsupmS8OaiPWnuctmmGvRR8ZN6iGkpaKZmFKPSjHFA4NA7D1FT2uRMM1XXk1Ij7QMVElob0pJSTNZySR2z6VZtS28Yxke9UraUEBWwTWihiVDj73sa4p6aH1GFam+dMsmTOFI5HemIQHPPXio1KZ3Z/ClDox44xWNj0/aNtNsgvHxIQ1QRAM/HpVq5RWwcgn1FVgViTrzWsXpZHnVotVG5bFa7baxGcisuU5Y1buZdzE1SOSa7KcbI+cxtTnlofUX7D/3/ABr9LH/24rwr4u2rJ8RPFM/8MmsX36XMg/pXu37D/wB/xr9LH/24ryH4uAN4k8TZHK63f4P/AG8yV6mCpKpz36Rv+KPnsXUdOUbdXb8GeYmilNJUs0FqxZx75h3qsK09DUPeop7kVrRjzTSMqsuWDZ3mlWvlWqRqBuIyaswR7Jwrcd8mpY0bkIfuUqkpJGWwUJ+avu4U1FJdj46dRybfcS5SSWVtoyD2pIBOjKpXgda0pWjhRpAOgyKolprqZBGdoXk471vOmoyvfUxhNyVraF37kJfABxWdfxeZA7k9QavXT5iVAfnPBx61m65L9jsivUsMD608Q0oNvZIKCbkrbs4DVxiME1j961dam3Mq4xgVlV8BimvaOx9ph01BXCig0lcx0C0lFFAC1a0/b9pTd0zVSnK20g1cJcskyZK6sd/G7yWsWz+E1bspWe6BPC965/Qb8OixMfmByMnrW+kuZAV4DV9ZhqqqJTTPmcRTcG4NF4W6yP5gY4HapkkYDgcGq/nFY2WMcn1pqs+0FjzXpKSWxwuLe5Lexl7Y+XgtuyfaqlkJUbLE4HPtVm3lIk2sAQeKLoLHGdny496iSTftF0HFtLkZXv508rLYzmuE1191yR+NbmpXoZ9oPyryTXL303mzFu2a+ezTEqouVHu5dQcHcrHpX6o1+V56V+qFfO1Nz2EeIftbHHgLQyRn/icpx/27XFfHGqkGY44r7E/a8bb8PtFPprMf/pPcV8aX8m+UmuKa/e38j3cLUSwDj/ef5IqMfzpCeKGpK1OFsVetbOjqpbnkisdTWlpchWUVlWV4s78tko14tmvcbo5PlJANNtZtrfMcqeoqWVTJHkHkHIqKOAjb5hH0FcCty2Z9ZJTVTmhsWJ7cMd0XQjnNVxGqSDDZPtV8shXYM7fc1XkjRBwQTj1qIyezOitQjfnjYr3D/JknAxWNdyA57k9Kt31yACAenFZUj7ia7aMOp8xmWKUnyoa1NooPtXSeG2FApO9KOtMBR1o4zzRSkc0ihOh4NKGxRim0C1JY5NrZBq1Fd7cZqjSlqlwUtzaniJ09may3inoBTmul4Oaxg3vTt5NZ+xR2LMp2szVe9B4qnLOW+lVt3vSbqqNNRMquNqVN2DsSaQdaSnoNxArTY41eTPqH9iH7/jX6WP8A7cV5D8WePEvijGcnW7//ANKZa9k/YpTy5fGY/wBix/ncV4j8Xbjb4y8SxZH/ACGb8/8AkzJXpZdNLnb/AJf1R5WYU2qkY9pfozzw96SlJpKzZYCtTQD/AMTGL3YVlirVjL5VwjA4wQa1w8uWabM60eaDR6pYzJGzlueKrJqJWYsQrJnG2q9o25RIBkMM5+tW4LK2BDZJyc7a+5jOpNLkZ8fKMIt8xaZxdBUbIQjIqW1VYZAN3Pqf5VG+Q+RgAdAKY2WlQlSCveupOzu9zC11ZbGhcKiHcxBOc/SuK8R3/mXBDH5Ura1/VY7KBhvHmEcCvOb69e4djk8mvIznHxgvZR3PSyrBym/aS2ILyczyljVc0tJXyEpOTuz6iKSVkFFFFQUFFFFMAopaSgRJHIyEFTg1r2WtSRABzuFYtGa2pV50neLM6lGNRWkjs7bXoCBvyKvf23abOHFef7sUbz6mvQhm9WKscMsspSdzsptct0OUYk1m6hr7TKVjBArn8+9IfrWNTMq01a9jWngKUHe1yaW4d85JqLOfrSfSnRruYVxXcnqdllFaFi3tnmjlZRwiMx/AV+o1fm3Dapa6Dcsf9ZJC2fpg1+klVjaHsVC+7VzHD1vauVtkeDftkNt+GukH/qMx/wDpPcV8aSMSSa+yP2zv+SY6T/2Gov8A0RPXxox5rzZLW56tGT9ny+Y1uabTqT8KBscpqaBtpzmoB709T3pNXNKcuV3N61mOBkjmrqZdlZeQOOK52Cdk7bhVyPUdoxjGetcVSi76H0uFzKmopVGazkFhlsA9aoahdFThWqnPfM/Q1Rkcsck5NVToW1ZljM0TTjTCVyx5qInmlJpveutKx87OXM7i0n40UUyQFKOtJUsSFjSZUYuTsgRSe1SiJm6A1pWdiCAX4q+sKJgY7elc066Tsj28PlMpx5p6HONCw7GoyvX1rpJYlKAlRzWfNZh8lO1VGunuZ4jK5Q+B3MjFIankjKEgioTW6dzyZxcdGJSiko6UyEx1JSZooC4oq3ZoGkHtVRav2K85HJFRN2R1YSPNUR9Rfsbf8ffjP/rnY/zua+dPiw5PxO8XqTwNZvf/AEe9fQ37FzFrnxqT/dsf53FfOvxXP/F0vGX/AGGb3/0e9dGG0j8jhx7U8RJ+ZytJS0lbnKLTlOD1ptAoTA7fwzqCvbeTI/zL0z6V0VnPGrMzMNteZafdtaybl5HcVtR68FxlMj0r6TBZnGEEpvVHg4vL5Sm3BaM7tbqMliMEE1V1XUoba2aR3AfHyj1rjpvEJK/uk2n1rFvb2W6fdI5JrfEZ1GMGoasxoZTJyTnoh+p30t5cNJIxJNUjSZpK+YqTc25S3PoYQUFyoKKKKzLClpKkjQuwUDJppXE3YaqljwKsxWc0n3UY/StnStM3IXZeB1NbceI4hGiBa9Shl/Orzdjz62O5XaCuchJps6LkxsKpyRsh+YYrtlBQfP1NQ3ljHLHmRACehFXUy5NXgyIY5p2kjjDSVev7NoGyBlfWqJry5wcHZnowmpq6CiikzWdyxaKKKAFFXtJh868jQjgkVRHJrf8ACsIe73t0QZrqwlP2lWMTnxM+Sm5HQarbg6bdkDASFsf98mv0Rr86tdvytlPBGoCmJgxx1yDX6K10Z24upFR7HJlakoNyPA/2z/8AkmGk/wDYZi/9ET18ZH3r7N/bQ/5JhpP/AGGov/RE9fGRrwpbnu0fhDrQcAe9FNNI0Yo6U4HFIBxS96Q0ODc0ZzTaP5UFXFzSHmg0lArgaSlNNpksKWkpRQJDlGTWpp9sXcHjHeqEC5kFb6KYrUbRgt1Nc9abSsj2Mrw6qSc5bIsxqpOGPT0p8hAyBj8R1rPjZlJYHjPepPMaRsDjJrjcHc+kjiVy2tqTQbJUKv1FMXbG5QAgVCR5Z+Y8j0q9bFZkyQC64olpr0FSftGo7SRk30IOcZJrIkUqxFdTcKjM2MfnWBeoFckV1UJ30PDzXCKD50UTSU896afauo8FoSiiigQ4dRWrYfcwB1rKXrWpZnK4rKrsehl7/eH0z+xehS58ag/3bE/rcV85/Fg/8XT8Zf8AYavf/R719HfsZnN14z6/csf53NfOPxY/5Kn4y/7DV7/6Peuig/dR5uOSVeaXc5Wiiiug5AooooAXNLmmilppgLmkoop3AKKKKQBRRRQAorW0a2Mkyn1NZSjkV1+hwiK0WVupHFd2Bpe0qa9DjxlX2dPTqa20JGEjXAApkKsVZiPpRG7mNiWGR2FSCRnVMLtwck+tfSqzPAd0VbjAXaTg9aiefch3HJ6Yp9/H+93FicntUHlMWfjpyK55uSk0jeCTimxHt1mj2OBiuV1C2a1uGRh34rq0DkHH3RWV4hizHHJ3HWvPxtJTp8yWqO7CVHGfK3ozn6SlNJXhnrBRRRmgBR1rr/CMa+XKzd8CuQFdL4duQkbKT716OWyUaybOLHxcqLSNbXoxJbXDx4G2Jsg98A1+i1fnNqUgbTrkn/nk/wDI1+jNPObOpFozyy6g0zwL9tD/AJJfpP8A2GYv/RE9fGWa+zf20f8Akl+k/wDYZi/9ET18Y49K8SR7NLYXrQKXHNHFSbWFpKKWkUFJR3opiCj8aKDQAhpPxpTSAUEi05RmgCnCkWkWLMDzV/rXSSJ5lvGUAY965qB8ODXR2dyohBHWuPEp3TR9NksoOMoS6lXZgkbTU0MEiRh8HGasGVVBZhg1XW+ffg4IPGKwvKS0R6fs6NKV5SEltZGO9VLA1YS2aK2JJwzfpUomYDA4pjMxQFgSPQVHNJ6HSqNGLcle5RWMjdlutZuoDacHvWzdMir098Vz93Lvb2rqoXk7ng5ny0ocnUqmkPvSmmmuw+aYlFBopkjlNWbaUqRziqw6UoNS1fQ1pzcHdH1X+xa26fxmc5+Sx/ncV86fFj/kqfjL/sNXv/o96+hP2ITufxr9LH/24r57+LH/ACVPxl/2Gr3/ANHvW1JWVjkxE+eo5HK0UUVsYBRRRTAKM0UUAGaWkFLTQBRRRQAUUUCgCSEbpFGR1rtrWNxbQhSMAda4hDhga7TTJfOsY9j8gYxmvXyy3M0ebmF7JlwQShRxn3HSnQltpVuvQVZtmZUCkkk8Gq9+5idRGuT3r3XBQjzI8ZScnyivGikM5yO1JIyo+MBt46jtVeVwdjMCc9qnnKGNccNjip5k72HZq1x+IkjJQDmsHXZFa1k4+lXi7K5RmyOxrn9YuBkxq2fWuHG117No7MJRbqJmOaSlNJXzTPeCiiikAA1e0248idSfu96o0oOK0pzcJKSJnFSVmdZeTrLp823BHlt0+lfpLX5ZrcSIjKGOCCDX6mVeMr+3aZlh6PsU0eBfto/8kv0n/sMxf+iJ6+M6+zP20f8Akl+k/wDYZi/9ET18Z158tz0aK90KKKKRqFGaKSkAZpc8UmKKYhe1FABPSikMKKWlAoGkIKUCig0AOVsHir1teFODzWdigZqZQUtzejiJ0neJvCfz0w2Ac9fWrNtCiuGY5HWufinZMc1aS9YDk81zzovaJ7WHzGm2pVNzcnbapKmqb3RRNuTVKS/3JjpVR52boamFB9TXE5pG96bJ7m4LEkZH41Sck80rMSck5pnvXVGPKeDWrOq7sQ0h6UGg9ao5mJQvJpKBTJFNGOaKKBn1J+w997xr9LH/ANuK+ffix/yVPxl/2Gr3/wBHvX0D+w797xt9LH/24r5/+LB/4ul4yGB/yGr3n/tu9awOSfxM5SiiitSAooooAKKKKYCiiiimAUUtGKdhCUUtFOwBmr+m3z2sg5ymeRVCiqpzdN80SZwU1ZndWd6soDo2fxrQaRJcF1+YCvPLa6eBwVJx6Vs2+tkAb+a9zD5lFq0zx6+XyTvA3Jj+9+bn0pZZ4wevTrmsafWo3X7uD7VlXeoPLkJlVp1cdCF3F3Cng5ztzaF7U9RAJWLP1rDkYuxLHJNNJyeTmkrxK1eVV3Z61KlGmrIKKKK5zUKKKKACiiigAr9Uq/Kyv1TqJjPAv20f+SX6T/2GYv8A0RPXxl1r7N/bQ/5JfpOTj/icxf8AoievjIMv94fnWMjootcoUUjOM8EfnSbh6j86VjRyQuaWm7h0yPzoDL6j86LBzD6KbuH94fnTgy/3l/OgaaDFPVCcULsPV0/E1ZjMQxmWP/voVLdjenTUnqxiQkmpRbEn3q/A1qEXdPCD/vipy9qvIubc4/6aL/jXPKq77HsUsvptXcl95ltZtgnBwKgeEgZIxW6k9sVIkuoDn/poP8aq3TWpJK3EJ/4GKUasr2aHWwFJR5oSX3oxytIO1TzmIH5ZEI9mFQFl/vL+ddKdzxqkVB2uJzmkoLr/AHh+dN3L6j86djJyXcdmkJpu8f3h+dJuHqPzp2JckPzzRmmbhnqPzo3D1H50WFzElJTd49R+dG4f3h+dFg5kFFJuHqPzo3D1H50xXQtFJuHqPzoyPUfnQFz6l/Yd+941+lj/AO3FfP3xY/5Kn4y/7DV7/wCj3r6B/YdI3eNcHtY/+3FfP3xY/wCSp+Mv+wze/wDo960gc092crRSUVpcgWikpaAClFJSj61SAAKcBmhcZ6j8619Isba4cfaLy3hXvvkAP863pUnUlyoyqVFTjzMz7e1kmbEak/StWz8P3E5HQZ9a7ayj0C0hRY9QsSxGGJnT/GrFvqWk20mBfWRAPBEyH+tfRUMnoxs6tRfejw62a1ZXVKD+45A+ErgMV3Cs688P3lvnMZIHpXq8+raG1sM6lYGQcjE6f41lXWp6XIoK6hZE+8y/411VcowTXuzt80ctDNsU370H9x5I6FWIYYIpprqfEkFhIDJbXVs0nUhJFOf1rljjPUV8tiaHsJuN7n0mHre2hzWsJRmg49qQ1zXNxc0lGfpRmlcANFJRSuAtFJRSuAtFJRQAtFJS0XASv1Tr8rK/VOokM5D4n+P9L+HOgW+r63b31xbT3S2irZojPvKOwJDMoxhD39K8x/4an8E/9AnxJ/4Dwf8Ax6j9tH/kl+k/9hmL/wBET1478Jfhp4Q8QfC3XfGHjHUtYs4tLu5ImFjJGAUWOJhgNGxLFpCOoHT61BaStdnsX/DVHgn/AKBPiT/wHg/+PUf8NT+Cv+gT4k/8B4P/AI9XO+Gv2f8AwZrkyK9v4+02KWAXME95JZ+XMhxjDRq+1uQdr7Wx24OPlReVH0pNtFRjGWx9m/8ADU/gr/oE+JP/AAHg/wDj1H/DU/gr/oE+JP8AwHg/+PV8Z0UuZmnsUfZn/DU/gr/oE+JP/AeD/wCPUf8ADU3gr/oE+JP/AAHg/wDj1fGdFHMw9jE+zP8AhqfwV/0CfEn/AIDwf/HqP+Gp/BX/AECfEv8A4Dwf/Hq+MiKUCjmF7FH2Z/w1P4K/6BPiT/wHg/8Aj1H/AA1P4K/6BPiT/wAB4P8A49XxnRijmYexR9oJ+1B4Of7uj+JD/wBsLf8A+PU8/tN+EQATo3iXB/6YW/8A8er46tJNuD+laErb4VxkYrGVaSdj1KGW0akHJt3+X+R9an9pzwgOujeJf+/Fv/8AHqB+034RP/MG8S/9+Lf/AOPV8lQSb2RGxjPU1cuETYAgBxWbxMk7WOunklGpFzjJ6en+R9UN+094PX72j+JB/wBsLf8A+PUq/tO+EG6aP4k/78W//wAer5Jm2KCXXI7VHBH5nK5Aq/bytcweU0lPlTb/AK9D67b9prwivXRvEn/fm3/+PVE/7UXg1DhtI8Sg/wDXvB/8er5QlbYGGc9qzLo5bkc9acK0pbmeKy2jRXut/h/kfYH/AA1N4KH/ADCfEv8A4Dwf/HqT/hqfwV/0CfEv/gPB/wDHq+NjTcVtzM810In2X/w1P4K/6BPiT/wHg/8Aj1H/AA1P4K/6BPiT/wAB4P8A49XxnTelHMS6SPs7/hqfwV/0CfEv/gPB/wDHqUftTeCv+gT4k/8AAeD/AOPV8YZpy9qOZgqUT7Th/ac8ITf6vRvEjf8AbC3H/tapD+0t4UAydE8Sj/tjb/8Ax+vjrT5QpGTW2wJtzsGQeR7VzVMRODse5g8ow+IpuTbv6r/I+4Phf8T9H+Iz6oujWepWraeIjL9tSNd3mb9u3Y7f882znHauN8QftJ+ENC1/U9Iu9M8QSXNhdS2krRQQlC8blSVJlBxkHGQK5T9jQYu/GY/2LH+dzXh3iDS4dd/aD1LSLt5Etr/xTLaStEQHVJLwqSpIIzgnGQa66b5o3Z4WKpKjVlTj0Po3/hqjwT/0CfEn/gPB/wDHqUftT+Cj00nxJ/4Dwf8Ax6vPNW+Ffw507X/EWlLD8Qbw+H0il1G4tXsmjhjkQOHAIDsACc7VJGDxiuO+Ovw+8M+CtN8J6j4P1O/1Gx1uKeYS3UiOCqCIqV2ouP8AWHIPp25q0kzn1PfIv2mvCMuPL0bxIc/9Mbcf+1qsJ+0b4Zc4XQvEZP8A1ztv/j9fFVtdNFwDx6Vr2eqbGyW/A13UKOHn8bf4f5HHVq14/Cl/XzPr9v2i/DSgk6D4k4/6Z23/AMfph/aQ8LgZOheJMf8AXK2/+P18rRaxAEbceTWVqOr7kMcJ4Peuqrg8JCPMpP8AD/Iwp4nEzdnFfj/mfWMn7UnguNiraT4kBH/TC3P/ALWpv/DVHgn/AKBPiT/wHg/+PV8Zuck5pteS4LoeipPqfZ3/AA1P4J/6BPiT/wAB4P8A49R/w1R4J/6BPiT/AMB4P/j1fGNJRyIOY+z/APhqfwV/0CvEv/gPB/8AHqfH+1F4NkOE0fxKT/17wf8Ax6vjBFLEACul0ux2xcj5zya6MPhXWlZGNfEeyV2fWS/tLeFG6aJ4l/782/8A8epx/aT8LA86H4l/782//wAfr5XMiq+0DIFTxAPEXA6cV6McrpPTmf8AXyOF5hUWtkfT6/tLeFG6aJ4l/wC/Nv8A/HqH/aW8KIuW0PxKB/1wtz/7Wr5gWIKDggn+VLLATBnDZx6U/wCyYW3f4C/tGd9kfSrftSeC1OG0jxKD728H/wAepv8Aw1P4K/6BPiT/AMB4P/j1fLN3pyXETNnDCudmjaKQq3UV51fBui9djuo4lVdtz7J/4an8Ff8AQJ8Sf+A8H/x6j/hqbwV/0CfEn/gPB/8AHq+MTRmufkRvzM+zv+Gp/BX/AECfEn/gPB/8epD+1P4KH/MJ8Sf+A8H/AMer4yzSZpciDmZ9nf8ADVHgn/oE+JP/AAHg/wDj1H/DVHgn/oE+JP8AwHg/+PV8Y0UciDmZ9nf8NT+Cj/zCfEn/AIDwf/Hqt2/7S3hS4XdDoniVh0z5FuP/AGtXxhYw+fcInqa7SxtikOyEAbfWu/B4BYh3lexx4rGOirLc+oZ/2jPDUEDTS6D4lWNQWJ8q24A/7b17ZX56apI50u8RucQPz/wE1+hdTmOEp4aUVTb17jwOJnXi3O2nY8C/bR/5JfpP/YZi/wDRE9cz+zz4VTxt+zt4t8PSTm3+26rIqS4zsdYrZ1JHcblGR6V037aP/JL9J/7DUX/oievjHAOeBXmN2Z6cY80bH6S+Ek8VRJBb+I4dFjgt7cR+ZYzyyvPIMDfhkQRrgH5fn5PUY5/NtB8q/SgKvoPyqRFyOKTZrSptMbinbatw2+4ZxV2OwDKG6/SsZVYxPTo4GpVWiMbYaUJW6NOZhwvFLJphzg5/AVH1iJ0/2RWtexg7KQitGW0MZKk4BqFrfC5HIJxWiqJnHPCTg7NFTFJj2qV0IPSmkVd7nM4tbj4JApGe1a1vIsqYP3RWIODU0UxQ8GsqkObY7MJivYu0tjbjhjQlt3TpUQkCSE1n/aie9KbgAVl7J9T0frtOy5NLF6eSJlbJPPNVhcCMFUPBqq8+4npULN71pGnpZnJWx15XiW5LhmUiqzNuPPWmBuTRmtFGxxVKzqbhSUZyaQ9TVGIUhGaXtScc0yWNIxS5oxSUEvQmifB61tafeAYEjcelYAqRXK96zqU1NWO7B4yWHlzI+sf2O3R73xkY+nlWI/W5rxn/AJuh/wC5z/8Ab6vV/wBiNi0njUn0sf8A24r5/wDir/yVHxjkf8xm9/8AR71vRjyx5TzcbV9tXlU7s+xNS8CeLYvGvj/U9GbQjaeKLe3tklubmUSWqpD5bMY1iIc8tgbx0GT2rx39qzw9D4T8KfDTQraV54rC3vIRK4wXI+z5bHbJycdq+dNo9B+VKAB0GK0UTlbFFKDSUVZA7cfU0hOabRTuAvWkoopALRSUooA0NKh8y4Ut0HNdZBGcNnuOgrl9OfGCOorprOYuy5HFe7lyio2PJxvM3ci+z7fm6kdRUkCtlwPukdKuIsSuVL85zUVxcbJNkaDA7+teh7OMPebOHnctCCBGAYtkY5FWYLgSqwJ5HY0quJBlcA1WZQzkjhl64pr3LcoP39wZRJKQv0rG8QWgWMSKfmHBrX80E4Q/NWbqjYtmEnU1yYpRlTdzpw7lGasc0aSlam186e2LSUUUhi0DrRQOtCA2/Dcavdhm6LXVqsgkzCfl9K5bw66pMdxrqYpQSvOCK+ly3l9kjwsff2jIdXbZp98D97yHBH/ATX6F1+det3Sy2l0AefKcH/vk1+ilebnUlKpGx25XFqDueBfto/8AJL9J/wCw1F/6Inr4yFfZv7aP/JL9J/7DUX/oievjIGvDke5S2HCr9lFvbpnvVBetamnkqp2ct0rGq7R0PTwMVKormvawIEO7pU9tHsZtoyDwKagYw/NwR1IqxCF4Ib8q8ycnqfc0KUVy2VrEILBZOxGTiodNkeWYrJll9fSrswxwKSCAKV2DjPalzLlZp7Cbqxs9FuU9VAif5R19RVe0QTAowBXHFb93axzRqZO3HFU0S2tThiBnqSacKqcLLcnEZfJV+eTSiZNxppGSOCR0NZFxCUz1GOMV2IMVwmFbI7E1j6pbKpJbH0rejXd7SPIzPKoKHtKWxzxFIRT5MKaZ2r0EfIyVnYSkpTSUEMOaTtS44opiEpc0lBzQA6g036UDpQO46koFJQDF7U2lpKCQp3Wm0CgD6l/Ye+941+lj/wC3FeBfFX/kqHjH/sNXv/o9699/Ye+941+lj/7cV4D8Vf8AkqHjH/sNXv8A6PetYHLU+JnL9qWijFaGIUAVNBbvMwCCtSPR2B/eHr6VvToTqfCjKdaEN2YuKMV0D6OqjIJNRLpasxDZFavBVU7WM1iqb1uYhorTudNaL7rA/hVFoXXgqaxnSnB2kjWNSM9UyKinFcdeKSsyy5p7hZhk1vWM27jIyDXLK2KuQXZTB7iuzDYj2ejOWvQ59UdifLkAZsgj9anQK0JBXk+tc9bampUbsH8aurqiBOo+te5TxVN6tnkzw81pYsqHidhjjNPuJo1hzgDPBrIfU08wlnzmqN/qO9SsZ/KsZ4yEIuzNY4Wc5K6NOa4gQkqce9YeoXhnO0H5RVNnJ6k0wmvIr4uVRWWh6VLDKm77iGiiiuM6gopKO9AB2ooopAWbSYxSAjiup064WZQSfmFccDU8FxJCwKMQa7cLinReuxy4jD+1Wm51upp/xL7pwuD5b/yNfovX5jTavcPayws2VZSp/Kv05qcwrwrSi4DwVGVKLUjwL9tL/kl2k/8AYai/9ET18Yivs79tL/kl2k/9hqL/ANET18Y15sj1KWw5TzV6xl2OuD35rPzUsTlSMVnKN1Y7KFX2c1JHUCQsAB90jrUlrdN52zBK1lWV6AAsnQelbEM8RG5VG8jAJrzakOXRo+1weJVa0ozsJLcoJsFSRnFaNqNkO7HFc8HdLj513EnvW/Dcbjt/hA6VlWhZKx6GXYhVJyc3Z9DP1O8cMI1YgdzWczF2BJzU99GXnLKNwNRrD5YO8hfxreCjGKseTipVatWXNsTWG4zqF6dTRrVwjggc4FMe+ht4QIcl+5NYtzOZXJJ61dOk5T5mYYvGwoYf2MXdvchlIZsimcYpSaaTmu5Hysnd3A9c0n0oooIAUGinQxyTzRxQxvJLIwRERdzMxOAAB1JpiFhikmmjihjeSWRgiIi7mZicAADqSaua9o+o6Bqs+ma1Zy2d/BjzIJRhlyAR+YINeu2dtY/BLSo7/Uo4L34kXkW61tGw8ejxsP8AWSDoZSOg7fTJPjmo3t1qV/cX2oXEtzeXDmSWaVtzOx6kmm1YiMnJ6bFU0UvelApGlhM0hqTYSM0ojpXHyNkNFTGP0FIY6Lh7NoioqXZSbadxcjPqH9h773jb6WP/ALcV4F8Vf+SoeMf+w1e/+j3r379iD7/jX6WP/txXgHxV/wCSo+Mf+wze/wDo961gcVXdnL96ntYvNlVfU1BWloqB7tc100Y881E56suWLZqW8AgAwOnetOM+YnPUDio/KCnBIAqRiFOFWvoqcOTToeJUnz6jkhPk5JyRUaPtuFUx5zxmiFmVv6VbjdfMA28jvWsUpWtoZNtXvqQNaiSVsjgVX8lJ2ZFiXcBgGrM0vlyZzjFCJsLNGCGb17UpQi3ZfMalJIyrrT0aLDKA1YtzZvESRytdXIpYZI5FUJ4wWK+vtXBicLGWqOyhiJLc5g0VNdx+VMy1BXjSXK7M9RO6uOViOhp5lbbgk4qKii7Q7Ds+9JmkopXAOtJRS0gCkoooGFFLSUALSUUUAFLSUtACP901+plflk33T9K/U2s5FRPAv20v+SX6T/2GYv8A0RPXxhX2f+2j/wAkv0n/ALDUX/oievjGs2dNLYKBxRRSNCRHK9KtxXRUAEniqFKDxUOKe5vTryp7M1Retj72ec5qVtRc4y2CBjisfdzS7uKh0Ys7I5jWWzNNtRcZ2sR+NVZLhmPJqtupc5pqnFGdTGVanxMezk9TTM5oqWKFpGwoqtEYpSqOyIsUbTitSOxC43kD1zVpbRGUBSDWTrxR308rqzWuhz5U+lBHrXQvp20gMuc+neqdxpxAZgMYojXixVcpr01exd+HvhO88ceLrDQNPcRy3JYtKwysaKpZmP4D8yK9KtbSy+CGmpe6klvffEm7i3WtocSRaRGw/wBY/YykdB/TJPN/CP4gRfDKfV9Si0c6hrVzEttbPLJshhjzucnA3MSQnAx061g/ELx/rvj7U473xDJbM0QIijggWNUHpn7xH+8TXQmraHjzhPms1oc7qN7danf3F9qFxLc3lw5kmmlbczsepJqADmkzzSg1JqrdBQOeKevamDrU8K5PqKTZrTXM7D4o8sOKuJallz1NWNPtg/JA6VpwQrHkMwyea4qtazsj6XBZZ7SKlLZmatgB1x0qCW1VSMDNWruVvMKhsqKLdc5J9eaSlJK7ZpOhRlL2cImVNbMvbiqzJtPJzW/JECrkEdelZN3CVye1b06l9GeVjMF7NcyR9KfsP/f8a/Sx/wDbivAPir/yVHxj/wBhq9/9HvXv/wCxB/rPG30sf/bivAfir/yVDxj/ANhq9/8AR713QPmavxM5armmy+VdIx4Gap05Tg1vCXLJNHPKPMrHZgLK3ykYxmrDuiRIGOM8VhaXej5RLzjitQt577lwVHSvoqNaM480d2eJVpOMrPYnUhV3Ej0zUrt8nYEiqk0jIqKAGyanuIj8m47RgcVupOzsYuOquMjhVkJkOQOTUbXLKMLjb2xV1E/0SQL3HT1rJdTj5VI+tRVvBKxVO027ksbMJgRn3FOlUFmb0qOORYUy7AN6k1l6hqWUMUPQ9W9a551oU43kzeFKU5e6UNQcPcuV6ZqpTicmkrwpy5m2exFcqsJRRRUFBRRSUCCivQ/hl4Bh1y2ufEfiq5bS/BmnHN1dnh7hu0MI/ic9OOmfXArnvH2uad4g8TT3uiaNbaNpoVYbe0gGMIgwGf1cgcn+Z5KvqOxztFLSUwCloxShc8UWEJSVII2PAU0jIR1BFOzC6G0lOwaSkMa33TX6m1+WTfdP0r9TazkVE8D/AG0OfhfpP/YZi/8ARE9fGFfZ/wC2f/yTDSf+wzF/6Inr4xPWs3udVL4RKKKKRYUUUtIYUA0Yo70ALThTRVi3haRgBSbtqzWnFzdkOtoTKR6VrRBIACRzU9la+VGD1P1qO5hLTnHQDpXFKopu3Q+loYKWGpqdveZA5MxbH3hU1hzIM/KVPfvUGGXlOSOtPi5kBJORRJaWHSlaopPc0ml8sN5hAbnAqK3uSZSsmNpqrMTLgg5I/WrMFuWjyD81YuKS1PRjWqVKlobL8R1xapLluMVzt9D5UnAwK61EH2bBxvHFYusQ/KTxmtMPUtKxy5xglKl7RLXcwu9A60pGKK7z4+1hwPNW7YBhyePSqXNWLZ9rg9qma0OnDySkrm3DP5QVQODVp3JkVguTjBrNKGVVYfpWjblorcb+uK4KkUtUfW4WpOV4vYia2GWO/HPU1Nb7RHtjIJrPeRnfLH9amt4sHzCcAUSi7asVKrH2n7uJNJMImKyDJNUb4jZuznPQU+6lSRixJzWddTDG0dhWlKnszix2KXLJN6dD6X/Yi5l8bfSx/wDbivAPir/yVDxj/wBhq9/9HvXv37EBy/jX6WP/ALcV4D8Vf+SoeMf+wze/+j3r04HxdZ3kzlqWk7UVoYkkUhRsg1qWmobOCSKyO1KCRW1OtKm9DOdOM9zoY78A/eB9OasHVMn94Qfxrl9xo3H1rqjj5pWOd4ODOkk1gRphW59qoS6tIR8mBnvWVn3ozUTxtWfUqOFpx6E01xJKSXYk1DmiiuVyctzoSS2CkxTgpNPMLgAlSB9KFFsLoipMVJtNJiiw7i28EtzcRW9vG0s8riOONBkuxOAB7k16B8N/h9Hq8V5r/i+d9J8H6W2Ly5YYeZx/ywiHdyeD6Z9aufs9waJD4/i13xTqFpY6Voqfay1w4HmTdI1VerEHLYAP3K1/2iviH4e8bXVjb+FpNU+x2bMfLdUhtGZiS0iRgby5J5Zsd+OTnNvWyKS6nH/E3x7N4wubazsbZdL8M6cPL03S4uFiXpvb+857n3+pPD0UpppWFe4UoFJU9tGZZQtXFNuyE3ZXJrK1MzjIOPatuPTI0ZRt4qTToFQKQOBWzlHA4IYd693CYOHLeW54+JxUua0djKNiqn5FHvxTjpiNH865BrYMYhhMjdP50yBzMrZPA7eld31WF7NHH9Yna6ZyV3pLhm8sY9qypoWiYq4wa9AdB5eAOc1h6vYh0LAfMOc15mKy9RXNA9DD41t8szlW+6fpX6mV+W0yldwr9Sa8Kasz146o8E/bN5+GOk/9hmL/ANET18ZOMGvs/wDbJGfhrpA/6jMf/pPcV8aypg4rCT1sd1GF6XN5lfvSmg0D3oABRSUooGKKKKUDNAxKv6ZIFlUMeDVHFSQHDj61E1zKxth6jpVFJHWxMQOBkYqqZdm5yOelT6awkgxj5hUF+FR8EcelebFe84n3FWT9jGrFjYyGOV4BpJId0oI4Heo4mBODgD0qw8qlAOmKt3T0OWHJOHvEfkMZcL0FPXzEbaSQM9qlM3yDGSMVHtbcHckrSu3ua8kIv3C3bEsCWOATWfrI2qRkE+taZlDLiJceprB1iYmQ8UqCbmVmdSNPDNXv5mQetANJ60oFemfDbi96fGjE8CnQx72AxWmkaRj5hkjsKznPl0O3DYV1feeiK0Zmjx94D2q7Bcg4SUnHSp0OEGwAnr07VI1isyBwuM9eK5ZVIv4j3qGEqw/hO/kypIkavlW3Ieaa9wFQqpODUN1bSRZ8tiQOuKzXZhwa1hBS1ucGJxUqDa5bFiacnPNVGbJpCab1NdCikeLVrSqPU+pP2H/v+NfpY/8AtxXgXxV/5Kh4x/7DN7/6Pevff2H/AL3jX6WP/txXgXxV/wCSoeMf+w1e/wDo963gedV3OWoopa0MhO1FFFAC0UUUxBS0lKOtMBantbd55NsYyahA5rr/AAWIEkc3CqQwwCe1deCw6xFVQbtc5sVWdGm5pXJtK8NE26TSYx1PrWzLpkdxB+6iVkQYNa2nKJgGjOU6MavWtssCvtwQxzgV9vhstpRglFaPc+Tr4+o5NyeqOGfR4Tav5cYMrNgL3FVLfw2slu4k3JMBkDsa9Eit03iXbhiScelQ6ntjjDhec44rOeT0bc8uhcM0q35Y9Tx2+sntpGDKRg4zVNq7zxets9oHgcCQcMtcKa+Px+GWGquCd0fT4PEOvT5mrDKKKK4DsFFa+kxKyMx61kCtHSpNsu3OM10YZpVFcxrpuDsdXZQBYcjNWg6x7lGSGHOKghuPIsj5fLEcUW7MQGmHPoK+og1FJRPnpJtts0JmRrZUdhx0IqtHH5bcthT3ps8wUBU/h65qOCR5M5bK+hrWVROXmZxg1HyJmj358tycc1QuB8rBiS1X4nFvEQ/VugrNvbpNjFqxruKjd7mtJScrI5jVwokYKADiv09r8u7yTzZJG9c1+olfI4h8020fS0VaKTPCf2wxu+HGjgdf7Zj/APSe4r44ulAI619l/tef8k90X/sMp/6TXFfHF6QWOAB7VwTfv2PdwkF9UcvN/kjPYc001KRzTCK0RyyQ2ig0CggcKXNMBp45NBa1FGKVPlbNIKcBk0i0jc0iY496uaorPtfbxjtWFYTGGVTniukU+bbbgdwArz6y5J8x9fl1RYnDOi3qjHLFWU9eKnZsw8Kd1SSRAksAOOgppYCNgOp46U73sQqTp3TZEhYxgc5zyK0LaNpU2447ZqnGoUZY9+9XFmSGNnz24FRUu9jowkVF3m9BsrmCMjpn1rnL2UvISTkVav7syFuePassnNdVCny6s8LNcaqr9nDZC0q9eaYDTlNdJ4qZesgPMBz36VsSqBhh0IrDtXAI6VryO0sabOg9PWuOqnzI+iy+cfZNdSS3cQgkjJPT2rRidZrUhW2n0rPtIWmOxgcnvV23iSH5WLHt+NctS3zPewXtElp7r0Kgg3oxDjCnkCsK7i2u3bnpXTYSFmVd2G6k1iajEVZiTkGt6E/ePLzXDr2SdtVuZBFNp7U3vXefJyPqT9h773jX6WP/ALcV4H8Vf+SoeMP+w1e/+j3r3z9h773jX6WP/txXgnxUH/FzvGB9dZvf/R71tTOGrucpS0lFaGYdqKKDSAKWko70wFpVpKUUxEiDLAV23h3TZJLUGPByK4qI/MDXovg+cFUCYOPQ17WS04TrWkeVms5QpXia8MFxp1oxGGXGSBVrSb1bhSMbSPU1okAggjINUk06NbgyKcD+6K+3VGVOS9nt2PknVjUT59y2sqMSFYZHWhwjoQwDL6VUvrBbhQEZo2/vA1myyPp8vlFndSOCaqpWdP41p3FCkp/C9Sj4jtYJLaeURAYyBXmb9TXaeJb6eSNwqHbjBI6Vxbcmvhs6qQqVfdR9dlVOUKXvMYaSlPpRXinrAPapoCwcFetMRSzADrXTadp4gjVnTLnnJ7V04ahKrLQ569aNJajLK4dFXzY32n2rdt3R7cFmG/6Y4pyhGkjVxgeoqWaG3zgjk/xDivpaFGVNb3PBq1Yze1ilLH5nzZI9feopZwFAT5celLdxSqrNbv8ARTXNXF5PHIyvww6iuXE4hUd1udFCj7XZmtdXhB+Z92Kw769adsDgCq8s7yHkmoc141fFyqaLY9Sjh1T1Bvut9DX6lV+Wp+430NfqVXDM7InhX7YTbfhzo5P/AEGY/wD0nuK+N7htxxX2J+2T/wAk10j/ALDMf/pPcV8bSZHPrXLNe9c9XDTaoOPn+iIzTTQTSZpmbYHFNxTjSUyWIOtPXrTKkjHNDHHcsRx7jwOKvQwKCCRSWwAAXHzVd28YA/SuSpN7H0GEwsbXZA8ce7BTgjqKI2ktOUJ2dxVwQ4wTyAO9MaPhsj8ay509Gd7w8ovmjoyeG5gnX5xhjzxxVqJYUyQN7EYy3asCVOcoSCKrm6nj43Hml9X5vhZSzb2L/ewu+5uXghT5s/N7Vi313vbCnjpVWW5kfqx5quSTya6aVDl3PGx2ae2uqashWOabQaSuix4zdw70oPNJQKBFm35YCup0yEGDgc1ykLbSDW/pd0UTC/rXJiotrQ+jyKrThU98vyzGDO3G7tVX7VIJMmm3LEzfN1pigNgAZYmuaMElqezVrzlO0XaxdeVDGWbIGKwrycOGC1qagVjgXnmuenfk+9bYeF9Tzc4xLjaDIXPNM70E5NFdx8s3c+pf2HvveNfpY/8AtxXiPxZgH/CfeKZR1Os3wP8A4EyV7d+w997xr9LH/wBuK8b+LTKPGHiZcDd/bd9z/wBvMlduFipc1+36o83FSalG3f8ARnn5ptOakqGAlLSUUhhS0lFMBaUCkApwpiHL1rsPAbg3wVmA9j3rjwK0dIuja3KuDjFd2ArKhXjN9DkxlJ1aUoLqe00VlaPfme3RpWU/KOavyB8FoznI6dq/SYVVOPNE+DnTcJcrJqx/ECHyPM4AUVozXCxL83WuW17VCkEhdSVYcbuxrmx1eEKTUjowdKc6iaMTVb6B9PfaQJM7cetcex5qWeQu7H1NQmvzzF4l15XfQ+2w1BUY2QhoFJS1yHUWrDH2lM8812Tt5tvxwVriIGxID6Gu0svmiRjj5hjBr2Msd1KJ5WPVmpFuIbrTPA9zUUiONrk5XtVsQSCH95tAB7U8ujW+yNM17vs7qz0PJ57O6KsQVVLSNn04rmvEltiQTKOvBrozCzbh071R1hBLZMpGCBmuLF0/aUWmjqw1TkqJo4w0lOcYJplfLs+gHH7jfQ1+pVflmfut9K/Uys5lxPBP2zP+SZaT/wBhmL/0RPXxm7enSvsv9tA4+GGkn/qMxf8AoievjEmsZLU66MrQsJRRSUihe1FFJQAtSR/eFR05DgihlRdmbVqAUDdGxV8AQpyevrWbp0nIHUirl2DuUk8e1cE171j6zCzSo86Wo2eRm/iOKsxN5ka4PPQ1RJBIU1atRgnGOD3qZKyNqFRyqeokkWwsMDn2rLvI8N8oyK22YZbJGMVTnjRovkIb8KdOdnqRjcMpxaiYcgqE1alXDVXZcV3pnylWNmNoopKoxFoooFICReDVu2nKHg1RzTgamUU9zopVXTd4m4lwsq5Y8jvUi3KQxk8Fj09qwVlZaDKTWLoJnpRzWUVe2pdvbnzMYPFZzHJJpWbNMraEVFWR5levKtLmkLRR3o71ZgfUv7D33vGv0sf/AG4rxD4tSf8AFwPFCA9NZvjj/t5kr2/9h373jX6WP/txXgvxUOfib4wHprN7/wCj3rooy5b+aOKvG7+ZyjUUGimyQ7UdaSikAUo60lOXrTQFi1t2nfaoNblppKKv7wZNJoUH+j7wOSa1o8Ywete1hMJHlUpLc8rE4mXM4xZXi0yFiy7FHoar32h7UMkDDI7etbJbbtwOg60iS7idx5zXoSwtGS5WjiWIqp3TOfsdXurD5CWwDjB7Vst4yZIsQRlW+vFNv7FbiI5QfXvXJ3lu9vIVYfQ1x1K+KwStCWh1Qo4fFu8o6nQp4onZ2Mx3Z5rJ1XVp744kb5R0FZZNNJrz6uPrVY8kpaHbTwdKnLmjEUmmGlJpDXEdQUUlLSGSRfeFdZauVtoyDmuRQ8102kyCa1VM4IOK9LL5Wk0cONjeKZ0CM0sILPgelQpNDEzIGPHOaeVH2YKOT3NZssJZsKck+le9UnKNmlqeNCCldMus425Qk5qnqzbLFmbgkcU+P5JAD90cVka/eBwIkJx3rlxFZRpSbOihScqiSMFutNoPJpK+ZZ7wN90/Sv1Mr8sm+6a/U2s5FxPAv20f+SX6T/2Gov8A0RPXxjX2d+2l/wAkv0n/ALDUX/oievjCs2dNPYM0UUUixaSlFFAwpV60lKKQIv2UhVgR2rZjCzrgn3zXNo2O9aFvdFSP5VzVabeqPdy/FxguSexoSQbTlecVCJGXPXNW4biOVcMecdBUb24zlWOCa51LpI9edJNc9FhC+8FWBzjrTgiorAZGalUKsRwcVTmnIDZ44pK8noVO1KKc9WZl3jeSOOfWq1SXEhZyc1BurvirI+TrzTm2KRTKduoyDVnPoxtFO70lArCUUUtADaWloIoFYbRS4oxQFhKUUYpQKLhY+pP2HfveNfpY/wDtxXgfxVP/ABdDxj/2Gr3/ANHvXvn7D33vGv0sf/bivAvir/yVHxj/ANhq9/8AR71tTOWrucvSUUd6syDtRSUooGLSr96m9qcpwaaJZ2OiP5emgY5zzVldrS45y1YuhXQI8piK3N2wggZavpsNNTpx8jwa8HCo/MLlzb4XG4nnmnwYuEBC4Oeahn3yESKM8cip7C52lkZAua6ItOdnsYyTULrctQMGDR/3awtdtd6Mdp9q2gBklSeaWXbJDtaM9OprStSVaHIyKVR0p8yPOWBBIpprT1u2FvdHHQ81lmvkqsHTm4vofSU5qcVJBRRSVkaC0GkooAUcVdsLtraUEZx3qjSg1cJuDuiZQUlZnbWl8HiO1gQfWlV9h3JjJrkra6aI4BOKsvfnYQpP5168MwTiubdHmSwTUvdNjU71Yo/lPz+1cxNIXYk0SytIcsaiNedicS60r9DtoUFSXmLSZzR3oNcp0iN90/Sv1Nr8sm+6fpX6m1EikeBftpf8ku0n/sNRf+iJ6+MK+z/20v8Akl2k/wDYZi/9ET18Y1mzopbCUUtGKRpYBS02lpDCiikoEOzTkcg55plKvXmgpNou21wY2DVoLeggjJFY2KcM5rKVNSPRoY2pSXKjUmvOwHH161SnmMhJPHtSRwtKcDmnvaOo6GpioxZpUqV68b20KT5zTKsSRMOcVARjrWydzzJxcXqJRRRTMxRRSGigdxaKKCKACgU2igVx3QUZ5ptFFguLmlzTaKAufU37D33vGv0sf/bivAvip/yVHxj/ANhm9/8AR7175+w797xt9LH/ANuK8C+Kv/JUfGP/AGGb3/0e9awOWpucvRRQK0ICjvRSUALR3oooEy5p83k3CsTx3rrraf8AdKw5NcOpxWxpOoeXiOU/L2NengMT7N8rODGUOdcyOkBJYlD1PIpryL5hJTa/TimQMrEsjAnHGKs7UmVfMGGHSvbj7y0PJfuvUfZBnRwWGV71KLgrGYxg1UlyjkRkgE1IsYaIsTjFaxk1ojKUU9WYviJA8O/+IdxXMGt3XLgf6sGsE181j5KVVtHvYOLjTVxKWkpa4jrCkNFFIYUZoooAUUZpKKAsGaKKKAAUUlFAwb7pr9Ta/LJuhr9TaiQ0eBftpf8AJLtJ/wCwzF/6Inr4xHrX2b+2l/yS7Sv+w1F/6Inr4w3D1H51mzem7IcTnk0Z4pu5fUfnRuHqKVjS47FGKAR/eH50u5f7w/OkVoJSUEj1H50mR6imTdC0opu4eo/OlDLnqPzoGmidRkCpoIy5x61Ajpx8w/OtCxktw3zyov1YVlNtI78LGM5pNl+GxkAUgqBVzCIqxueR19qga9t1iGLiInp98VC97blf9dET3+cVwtTlufUxnh6CtBr7ySW1USNuwVPQjvWPdwAMQBW2l7bhNpuIDx/fHFVbxrXHFxA3H8Lg/wBa0pTlF2Zx42hRqw5oNfeYBG04pKluDGWyrqfxqHcvqK7lqfKzSi7XFopNw9R+dLkeo/OmRdAKXNN3L6j86Nw9R+dId0KaSjcPUfnRuHqKYroKKNw9R+dJlfUfnQF0LRRuHqPzpNwz1FAro+pv2HfveNfpY/8AtxXgXxV/5Kj4x/7DN7/6Pevff2HTlvG30sf/AG4rwL4qkD4o+Mcn/mM3v/o960gc89zl6SjcPUUZHqPzrQgWikyPUfnRuHqKAFoFJuHqKMjPUUAOFKpxTNw9RRuHqPzoTJaNKw1B7Zwc5FdDb6lDNgk4PvXGhh6j86eJMdGA/Gu2hjZ0dN0ctbCRqa9TuZbiNvnVhj0rNv8AWAiFI+TXNiYnjzB+JpSAf+Wif99CumpmM5r3FYwhgYRfvaiTSNK5ZjkmojUhVf76f99Co2K/3h+deZK97s715BSGk3D1FGR6ioKFxRSbh6j86Mj1FFxi0UhYeooyPUfnRcYtFN3D1FGR6ikA6im5HqKMj1FAC0Ubh6ikyPUfnQArfdP0r9Ta/LFiMHkV+p1TIaCiiipGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Human serum containing anti-La antibodies stained the nuclei of HEp-2 cells in a finely speckled pattern (A and C). DAPI staining in panels B and D indicate the location of nuclei. Note that in dividing cells (white arrow), anti-La antibodies did not react with chromosomes. Human serum containing anti-La antibodies was provided by the Centers for Disease Control and Prevention from the international ANA reference serum panel.",
"    <div class=\"footnotes\">",
"     DAPI: 4',6'-diamidino-2-phenylindole; ANA: antinuclear antibody.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Donald B Bloch, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_34_35361=[""].join("\n");
var outline_f34_34_35361=null;
var title_f34_34_35362="Sacroiliitis grade 3 example 1";
var content_f34_34_35362=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F68009&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F68009&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Sacroiliitis grade 3 example 1",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF6AfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5akdxIw3t1Pc03zH/AL7fnRL/AK1/qabQA7zH/vt+dHmP/fb86bSgZoAXzH/vt+dHmP8A32/OlC4BBHPb2ppU/WgBfMf++350vmP/AH2/OmYPpSigCTzH/vt+dSxyPnh3/Oq4PNWI+Bx1oAuRSy4xuOPXNPVyG5c569TVcMQMED8KmiwwNAFlJmxkM2frVqKRwc72/OqCYHFTxuB16etAGgszf32x9TUqzk8bm9RzVJHxwOlSIVHB/OgC0ZXA4dvz70xJWZ87mOOcZqDcCDg4zSowBz0PegC3vk5y565pGlkzncfz/lTFcMf9nrSsMjjp+VADXkfBy55HrRFI2Tyw/GmtzjOOaawKnuM8UATeZLxtLYxjg1G0rHqWz6ZoVsKR0HtTuXOMZ+ooAktWZiTuJA6HNdBp0M7hSFc98jNVdEtotxd0yFGSOua6KCVncFMKg4x2FAEttbXBt/u9DnqcmrdrCQvzudx6+1WrBCURmXgYGAev41rRziNB8isnfKjNAGM9uNp2jaefas66iccHJBH5HtXWb43fPlR/d47Z96oXcSLtxGgA5POaAORkWRU++eap3t8bSMhCTK3AJPSt3WCtvBGGRdzHO3FczKC7FnK5znlaAKek3Ex1WCV5H4bJJbrXTT6hIfOZWK7ge/61j2gVLlWcJjPJK9Pet57eLyVIKkHnIFAHJXmoTpcqGkJVl5yTwahinZ7xG3HnrzWjqkMRuWAjV8Lg44qlZiJLxQISRg5GTxQBtafGzzD52A6881spGdygk8+vr/hVzSbOLylcW+d+OQc4q+/kpJjyV2j+91NAGQ1qxXJLcdwe9V7m2mEfBLDGeDz710AvBsVVVPYBOg96iu4RKA6MSCOeO9AHIXfmLEuWb6ZrMZ33cMwOPWt7UogCVYEbhnPpWVc2kkfYH0NAGY8jeaRuPtzSBmHG8/n1pJVYyE7c+1JsOcselAEyu5X5mb86kDMTwWI+tIkQA56/0qdIiMY/lxQA1C4OQxxThK4BG8/SpQmDjHanbM8Yz6UARb37Mx+hoLvjiQn8acUwSowCPwzTCAD/ADoAeHcL989fXvTld/7xP41ESO1OByMnoO4oAdvbdnLc+9RO7YPzEenNOJ4I9fWoJOvcCgCOaRgMbj0z1qlPK5Xl2B+pqw46nuaqT/MpH60AQPK/Hzt/31UDStn77fnQxI7VWkOD2NAD5LiTOd5+mapTzSblIdvoCak5PXtzUE3yjIzyelAA0r4OXYc9jUZmfacu350E8Y55FMcgZ7Y9aAFSSQyLl26jvRTYiN6/UUUAQy/61/qaaKdL/rX+pptACjipE6Z61FUinHQ0ASAZI5570pwD0P0pqmnc4J7g0ASKu7vwf0pXiGeAMZxmmjJxyKlQcgZ6daAESz38qeR1FLJZTRjKkYPQ1atyN5bcPpVxM+nymgDI8ll5cEjpU0Z4Pb61s+SrjBUn3qvPp3y/u8luoOOKAKStgnPPanIeufxpHt5Uf5lJ9xSZ9enrQBaVlGBnNSjjuQTVVcfLwM1ZU8becUASZyMEd/WkUEdeCeKbnOBnHenYz6e1AChmyMDpTzK4XJwxJ7imLncCcetOJB47n8jQBJFLGzAMdp9xxUrptAwOvQelVJFznp060W87REKeU9PSgC0ImJ4Jx/WnqCjdOe9TxlX2+WdwPr1pwXMh/QYoAtafJtiAGRI2cc9a6XRGMxPyjcBwT1rlVXDLnggfStvQ7l/tcSsMA+ncfWgDoBcMgw2Suegq3HceYAd21ivSqc67g6YI29CT1qG2mUFUyVc8AHjP40AbMUp4yM+1NnlCtuYEbRgDPT2qCKURqZHYkHGAO1Z91cbp0LE89h6UAZ2q7rqdmLZHTPpWM6MOpX8D0redGYYJ681F9lXHPXIIyKAMZIZZGARevrxWo/h/UhbpIhyWGQgNaNhabrlOByRnnpXYwTQG5igjwET5Tk4z/n1oA8j8uWOXa6srAnOa0tMtAJC7KCcfkK3fElgkeqSqAAM5FZ8K7CTnjpxQBuadcAKFyMDjr+VMupQsjDa3UZ9aoszwyK4XIHrVq4mBZZACNy5II7CgBIzl228kds9KsWkux1UMScjisiOdnO8MVHbae9W7eTaZJWY7zwOOh+tAGfq0m+d3I4z8tVlbzUMb5Eg6e/tUl2o8zB6jjnpUCqVYMucZzk0AZcy7WbqCD3NRAb29Pwq/Mu5jvxknIx2qIR4b5R70AOjGB6H86eFz/wDXqWOPK9OKlCBQMkfjQBEFOOOQKR+AcHJFKXXqGyfYVHu3Ag4waAIiWyScEnnmmHkHnFTADJwOnao2GOaAGcAYBwe2KcnAzk8e1LjKj9aaF9+PT0oAXPBzyKhk4Azz7VIcDJPSq7tkkAfnQBXlOWOMkd6qTMMkHgdc1clJxjH61Qu1J+XoRQBVlcF+arzdO+aeysu7NVj8/Tr9etACcAZIIHvUEw3EHNPYgvjqB60yQZBxQA0Meg69qilznrxTmGQSOPamnJAz0oAYmRIn1FFOQfvV/wB4UUARy/61/qabTpf9a/1NNFAC09elN7UooAf0qVRnnHHfmo04NSAZyT296ABeG46/SpY9wHJpiAkZHSpQOfQYoAsx8oW29ulW4+VwSVx696rW/AXvjtVpTg4Gckc80AWImY49farcT7eg98Vnpkc44HXPpVxG+XK85oAn3qxO5QCKjlsoZM4UZPORT4+T2/EU/LJg46elAGVLp0sBJX5h+tQrkdOncV0kJVgVI5HXNU9SsQVEkS4PsetAGWpP0xTwPlGeB3pi5zhjz9OlP5ByRQA7BMeen9aRVII9vWnr0HGD6dqXaDxjpQA05b6fyprr6DB608gjJzz2NROxyD6etACeY8O0r92rVrqiscOpyO461VcjbtwCD2qtHBsfigDqI3STo3PXB44rR023lMysuVwQVOc4+tcrbSyo6iMk/Wug0+6cuNxw3XNAHc21tJMNz7cZ5HXP0p76XtIDEkKcgmsjTb+5hlyPmQgZVu9bsWoho8KuwkfXBoAhvIQuBkyHjn09qy5YQJBljuxwvatC5lTeHw2e+TWdJKzYLEE84GOooAicqmBwePypwkwVwcqcDBPJplymWC7RgL37U6OAjYWK5J5HrQBbs5Nt0WfI9CB1p7zMJC4OMPwVPJ/CmWxJcbjgk7Sw5q29upnUMoILfePWgCLW5fMumOTwASD9KzN3JOBx2zzWlqeDcMSMqflGeKpi2O8uPu/3vSgBU+cDOSuevpVyJUJ25ypA57VTY+TIUbkYB4NSIRu+QnJ5/SgC2dP4AKjkc4FNubYxQ7VHHepkmKnIKkYHXof/AK9R3188YGzaTjnIzigDFubWQZyhHfJPWolhY45A9CT0qtPezvI5mmZvrVZtQOCEDE+vrQBclhGTg9DnJqBmii/6ae3SqLzyPyWwOtRZfdkk5oA0TdEZGBt7D0qCRmc7mJOahGAeBx05qYLlc98dKAAgkKce/FPIGzP50i4Xg/Sl/DnPFABwD2pCAT0PvS9jz05phPPJ47UAHfBpjHGeM56mkJPGSBzTWGVwBk54OaAGu/HTj+YqCQcEdqvxWEknzOCo7euatLZRxgEjnp680AYJhdwdik1C9lMf4fzro5ERScKPbiq0zAcEDnpgUAc5Pp7Fckn8qgOnbVy5atqaQhj6d8VVkk3Aknp60AZ32KNQMgfSmC0h2k7MgcVZkbDjGM44HpUZHXr9KAKn2ePnKjGaX7PGDjB4qUNtBLktUbNk8HPqPWgCMwRiRfl53DIopysTIm4dSKKAMSX/AFr/AFNIKdKP3r/U0nagBaUUgpwFADl61IvAOR7imL7U9z8uCD9aAFQn1/SpBn3xVZD8w5/Grsecjbzn+VAE9uWbkjIH61dTBXjn2qrEoB/UZq1EQCOx6UASwgkYyeTVmIE+v0qIKAmepHapYQWwW6dc0ATKQvL/AExmpQQQQBnuTUYxxn6Y9amt8Kcjp3FAD0QoRgHPoatR4ccjPtSMBgFf0p0Y2yA89e9AGHq0Hkzll+6/IPvVWPk5Offmulv7VbuAqv3uoGa5zBRijKAR19aAJU9RjH0p2OopsCF+3A5+tW0wBtX9RQBUbPYc+lQuAckgVoySZGOpqlNCX+4QOPzoAgkARCTUQY5GFqCcSCYgZ4qzbKZdigEDuaANTT4dyFjwemK2LazJKtz16Cq+nIGAVeo4xW/apj5c8k+lAGpbQ+XGCBtBWppAUAxjn+dPKnYFjzxxyaRVJ+UDAP6/hQBXlAJywxzgjPSq5UqwyAd3XirZAAO7jHQ+lVZCIwzHPoDigCE43LtJJXI3UrMxGBuLAYFQIcY7HOTk9alaZIFLyfe4IHr6UAaFlE3mKMHHAyK2/I2ag25cIPmwOc8VxVpqty1/DuIKbwDkYrtJZXWa5mwFXZgEDGaAMa9DNKeg3flUedpx0Le+apHU5vPbKqyZxtNXkkjmClfvgfd7/SgBjxrMjZG1ux9Kr2p8uX94Qc5x71dC4dSAff0qPyQZjgbSPzoAsYyBj5R/OopIiUb5Tg8HNWoYjsAHOP51NImFbaOf1NAHIS2LmYsGBU9ATVe5tPkyqnK9eK6JI1ztx1OCTVadB1A79KAOYKnk80KDu6HJq7cwCOQhfunoM1WKjcCMcc0AAU4x+VSxZBA6e1IFB59KekZyMA8+1ACnBOW5HqO1IDzUnlNtJA5NM8puTjjHrQAn4Hj1qM/L1xj61Kc4zj86jWMyOEUEk9AaAEjjMsgWIbmNbNpYpCAzjc47+lS2lqttbZwCxPNPlLMNobn+dAELyZXC8YPBIqqVzkg4/pUzBV6n8PWq7vjOPy6UAQS/xYNUZn5xn8qnlkOTuPT1qq3fJ/pQBAyfNkGqzgJk85q0zHtj1qhdMQwz2oAryJ84I6+9RTf7p2jvmneZn3ANKrcg4z6gjNAFVwQBzkH3qMMSPlXB9zVuREI5GAOcDmomjUJtAB9M0AMhyJlJ+bkciinRhQ64JPzDj3ooAxJB+8f6mkp8i/vH/wB403FAC96X0oA460AfWgCRBT2GVOfrxTUzkgfjTgeQKAK2MHitC3ycHOB19aiwjMOxqzblVz39PagCxH09qsjoO9QochsVMmdo7UATI2RnuOKni5xznvxVYZDZGMDvViIjBwM96AH7yH4PB6VagxjnHpxVSNd0gLc5zVqEAAhQGoA0LcbzhuMdqnRB1XPH8qZbKdyg4z6VbUELzzn160AV84IHT1rH1a3Bldlxzz9a3JQcjA/Gqd6gaPAHQ4oAxLb7vP15qypGR3+oqIxmOTgcn0qVR0JJGfSgBsmDnnr+FMYALwOPXFSsOoO0e9NC7m64x2IoAo3MBdcryQfzFLY4DFeM8dO9aQTAIC4PqO1XrKwgVfOZfn+9toAdpylGGcjPrW5Y5MvmnhB6nvWPIfnJGducEY4BrZtF2xKV6Y5oA0oZAFwTkHtirMaj+EAn1rNjO08YPHaraSY9On0AoAnaDJyzrnsOpqpqCQJbHczMxP8ADTvNDycnH6Vn6q7mFljByRyRQBWkvLVI8B2Hp3Jqn5sUgVzN7cjpWXJknBOPrQj7WGTgnrQBsQGFbiNjIMg5+7+VdRdX8JsijSds9OtcRA3mTKvIyelb1paiYLnJC44PNAEKPbA8+Yec7qmt54EywRgM54NNvoFjQ4TBA44rMR2B6Hg96AOmhvbdyNysueCc961GtozN8jYyo4PH41x0Sl3UYbJOcY/WutjctEjSckDHBoAnWF9nP3f51C4xznIHympXm2xD+IEYOKozTbwd2MfWgCORPLkY4znmqt3ghgcc+3WrjkmH1+prNmkwpz0z+VAGddp5gJzz2BrMK9QQCRW48PmZEYyTyBWWtu7TOCrKAec8ZoAW3jLrnoo6kVcEYVOABjqKjgQoBuz/AC/Kpjj86AGHBxg+wqInPTnHOfSpDkHPp29KhkJyAg5z0zQBG6eYwAyW6VpWVmtuCzHL9D7UtpblDuft+poaUMxxx2BoAnkk3FgoCn61G0pHXBJ4NQsRz2FQM+1CTxn1oAdI2W4Pv9aozvn0I6c1MzZAyaqSkc4zkd6AIZOdzDpUb9c9j3pxbrz+BqMgAkH0oAryjA/pVO5UEDC8jpVyQEDOOc9ulVJmBxyBjsKAKKja+enrz0FPViWwQeO9PbPt/jSY3E98DFABkHnGf6VGwBFTYCfXrURJ54x+FAESZ3qDnqPzzRQ5/er169KKAMeX/WN9TTBT5eZW+ppBzQAAE08KSQaQdOOfapExge/WgBFGDk/nTwMGgY6cDNA6n60AAXLE1PGVUYY1CSeueabgjBOc0AaCHbk5P5VaiYHgkj0I71kxuzEjJz71Zhlbfgjp0P8AjQBp4DY3cetSgjaD09R/npUAlG3HPrT42yWyM57t1oAtRuvAOSPc8VbjDEjYD81V7ZSQAw+YVehGDnrzjHvQBctxtHy8gEZq793vxjrVOA4YYPNXpM787s+vHFADHwV4OSKozlV3b/4hmr2dx4BORx9apXq/Nnv6UAYl3Mw+YD7vf2qCG5ZjkYI9KsTRbjIADuH+cVV8so3Q89z6UAW1cMu4jg805cggjhvSmRLnBGMVLbguQMfhmgCePGMsuSfzq5EW25XHTGB2qoeTtRcnuQasAgDAIB/vf560ATIcvhSCAMf/AF6vQymJUUn5f73pVGILyG/T1q3b/OrBhgdfpQBqW8kUjHDZJ45rRjjgZSVkH51z3OPlGRnJAOaeJHznafUZHWgDf+zhgxjwQp59j6VUkiBbOcqKitlneMs24DGNxHH0NAPkxgAliffvQBnTWI81gEzz1quLE/3Bj1rRkdVkJYnPpmoGkIJKkj0xQAllpgEisdoIHOO9dlptjbW9nu2tlupPGOK5W0Yeam5iBnpnpWxNdGRtq7lVeF9xQBe1XTo5Yi8WBxhufaua/svnBl6cnHet23ugwMcuTGV71nzMqhicDb3oASxgSOUYC4xjr1rRyrErleO1Z8RDN8y44qVER3DDp3x2oAuF1JwDx6VSuFKsMocHv2p0l2sLjAOB/EKia88yPJAOTjHpQBDNcPsCkZb6fzqsEMjbs81YZBuy3OPboKQkISMgYxnH6UANA2NkYB69elNmkJ7DHvSsw+Ur37471Xdsy7uSenFAEb5JzkH0pjH5c5welDkHPHPamythf/r0ANYguMYA6Yqxa23zBieBz0plnF5sgJ6Dv2NXm+UFVOM98daAGXU4QFVHPTHp71SiXGCT+OKmkPzlGGQON1RLjdgnJ7k0AOkO1VAI55+lUnfjnp6VeuVwi8ZJ6/hWdLwwHy5POKAF6rzwKryc5OCMVLuyuD6frTGGByMk88UAVwCzEnt1pGVRjjmpWGM+vYegqGY/LkdBxxQBXuTg5ABB4NZ8wwGKnjvjrV6Rg/T9egqjI3UKeOhOKAK6EnOf5U4MNppF6YPB9qaxA5PUflQAoZdw6e1MLAnJFRM5JGenWnHgZzg46UAR5/epz3zRTP8AlshHqKKAKTJ+8bP9496ZjJx1FWJf9Y/1NMC4PTigBipkehpyjBwOAKk2mlCjHH4UANPXsKAvGP8AOakZKQLj2zQA1lIU4HXviq4YgnPerv3l68e1VxGWbpQA+LLDK8+xp44bGcEVYs7c9W78D3q0LSMtnB3H9aAGQIzx5U8E81dgT5tsi5wP0p0ChFwMbR2xU8YHHFAE8I6Ade+asoMsMdPrUMeeCMCpogpIwcHqDQBbhHPzZB96tXSlXG3PT/JplshxjH4DvV+8QbiF/WgCmgO1e5A5PrUc6bz8+RgVZVCuSRx3yaGTnGMH/PWgDIntgoyucmojbAwAN945xWwICQC2AmOfeq1wuAA2Qp68UAYwAViv5+9Sg4XaoIJ4z6e1OuozycDd2A9KgZ9uQO/vQBPuCOO2P7pp/mEvtZifr0qo37xeDz1NWYgWUK5wR3xQBbt2IABBwD265rViYqmAMgDsP51jRMyjJyNpwP8A69aFkHI4JDfxGgC7AiS4ABDE8jNb1hpjsFPynocHqKzrK3AcOwG7jBHFbb6mIYQi4Mj8HtigCnfKyuApYBR8wA6mqTxMx+YEjpnv9RWgJd/OAcDqR2qldTMnKEDcduR2oAp3MRV+RtIHXNVHyoyf071anOBgtweORnH+NQyMoICgY6cmgBID5bbjk45Ge9XRLudSSQW7DmqHyOrBSdwPPvTomZgnOAD0x0oA0C5hO1idxPbt7UuNzDAHI6dqqtIPMbJyRwfWrEUoZGyOPUHmgC1ChZcHgjj8as28Z8wBQMdOahicEZzkcflWgrKu3LcnsKAM2TTSs8gjYgZ4B6VF9n2SbQMdx710YjWWISEkgDDZrI1OMA749xX7xAOBQBQm2oQeAPTPSorhyFH3cVWmmLTHO5wvPHQVG8pZOMcdO9ABNcHdjcWDeowKYzES9e2B2x+NQH5WKsTknjvipAAy8sMdzQAOMH73X8qakZlb1x1Bpw+c7Rj3bFW4IiqKcYNAEsK+UmBgmorqQp0P4mrUa/Jn8yecVnzkFmYfjz2oAYx3d84qSJPm3nP41FAu7AY8n1q9Au8qGA56CgCG7yfLA4A55NZ0sXU9q1bxMOAT90YHtVBgSccgmgCBI169BUMoxkA8CrbqFA9qqv1PHH1oAhkU4wB+tUZycYBI960CwHb/ABFVJ15z2NAFR1yQSfbiqs64Y4zgj1q45zjIIHaoXxgd6AM9cq3fbnvSupAwACKlfIBwox9ai3HcNwFACFR2x6nNV5j7gL9ancgHrmq02cnnJFAEcf8ArVxnGRz+NFEXEqj/AGgKKAEaMmR/cmnxx9OcgVZlixKw6jdn/wDVTduCcg47Ac0AQ+X8vY0LHjPp1+tS9CCf16ilCgjJwF6UAQAKSMrigggHv6+9TbOccc85PNKVHAHTtQBXGBxnGeTipYY0Lnjj3oKYyCcj9KfCvYEYxQBYT5R0yPSpwAADyfY9aqNwu8nAz696dk7clsjv7UAXlKjByBx27VIrcggjFZc1yCdqKdwHU1Yt5SYxuxkelAGpHuIwDz19KuQdSFyCO5qjAVfb82DnH1q9vCDIH0zQBcgmbcoGQf1FXJGbzmABPH69KzrRSZAD/EckitWRV+0NwQB0+tAE/lGSPAGM9B6e1DQnaFHBJ9OasW4wFyfTA9qlVQxIx0PHPQUAZ23awbBz2P8AOq13FmMHgHPP0rSuEKt7dD9aoltqlW5GcEUAY80Z9KzHADcde9dDOg54GCM5rCu4SJz8uB1GelADFbHfB7AVYhcgnjH4ZqrsIOTxnqT6VJG3U5/GgC7H80mM7s9K2rJVRBxg+v8A9asK2Yggj8B61sQSHYDkbj/DjrQBsRyb1x9319qZMhPz5OQcZqsknJBOD69fyqRpxzg9BnPegCUTHBXgHtjt9ar3UyRmMMee+e9IskjsoXaxHOcUs9i8i+cxxt7nuKAKk0wKqFbcF6etRPMSuDtHfP8AnvS3NsYm2qTjOfxquygE+v8AKgB0EpxkZ4bPI61cRxyAu3vj1qgFKng4U9faphKvmhhnI6igCypyCGzk9/SrUMowFx+JrOiYbgWHXueg9qvRKsigr1P8J/pQBpI42cMoK8nH86sqwYBsgqBnd7VhyQvHKgbO0c7/AOhq1Fcjywu8gnk8cAUAacd48cm370bc4P8ASpJWErckEkcfWqCSbhycdxn+lOJAVcEhR+dAFa9tlKME4GMkjrWZCeSANoB4PXJrXlbMTd89P8axucbs4B4OBxmgBrId5VmAXrye9RSOCxxyPYd6ikcg7eM+h71JZjMnQ5oAv2EePnbGR196vxrvbceh6VDDFwAOp/vVeiAUBiDkjPSgCaNFETbgWPsOgrDvE2ysq8HOeP5VuLnaxH38fjVC+QMqngNzgDvQBmw5Vgo5PXrVuA4bBBJ3Z+tQLkyFM4NWLJMye+D17UARSuWlIY5G44qHYeoGCe2OlPkC+awyeO1Ojyw24w3uevtQBVlGPl44Haqb+gHPuavT4JZcf/Wqm69D1PbtQBBIOTjrUMu3byPwNTOQeBVeYYTI6570AVJGyRg49M1EXGMD/wCtUjHLEEYPUZqJ1yo25/GgCrKdp4zgjNMABGeuRUsiEhhyR2PcU0IFXp+XrQBDIu1Sf0NUpO5I9ua0XICDniqjR5OMUAQR/wCsQYA5H480VKqESRnGfm6YooA2b62Mdw+BySelUCo//VXW6rbK5LgZ5PI7GudmQozcEn1oApsMbuRxwRUeMcDB54+tWSOc7eeuabsKk9GNAESg7sYzxTgnIAGQO1SBSOh79TRg9Oue1ADJEHTvSKnzj1A5qdflAA5/XFJtGM84P6UARyIGUAKM9ahlUqeMhcdKs7FB3c59qiBMh+bJHQg0AUyCx7gVes8upU8HqacsOB8g/SrFvCN5JGOPSgCeEDeMAjAq7Em9lGcdzn9KI4l4xnmr0EY8w89s49B7UAS2KYeMOOR0rWkT984TpjA//XUFrH86jb0wTWky4kOAOc/jmgBtuNrAMuCB1/pUpcq/rxycVEqEEHkY4+tLGhMiMScH8eaAHv0yw465JrHnUySHH3Rz061ruARwSRUMsK/wr05//VQBnxoSm5sYII+tZ2pPhtoHXkcda34osLuYEA/MBisbU0QzOGHIoAzCc/I6gDplR0/CmXFodu+L5lA5Uf0qzs/2gPw/zip7XAlUAjGcj3oAzLcvvCgHPpWxEGjOMbu2anZU+YlRknrjFIIgOhbPbNAEgcYAUjOc5qGSV1dsLlD196sRxgkY3Hjk1ds9Pad97JhVOcHjPsfegA02AqGds4xgj/CrsjNIGAYAegHf0pXjIGdx65H0qAyhXYOeOcf5+tAFO/QbGKkc1lybUcg/ePfHU1rzuCzE4J9KpyIpYgjIA7CgCtjzAVXjJ69KR1KuCxO7vWlbwAKzuBjooz60s1urxlkOMccdhQBmqQJMAgknpitCzjJbJAIXHHrVeGHbLkqDg4PFaNsoGAfujnk9DQBowRie3dHyHPf0rGlga3lKN68EVuQNtCgDkHg5zirGqWLSW4mwMEdB6+lAGFvVFTjec8U+SQFgW4C9fc+lRRoN5xwx7EU8QNKQoxk8detAFS+ud3yqQCfujPSoCQ0XT5cZOPWifT51uC2wkE9qv21g4UM4wSeVz29aAMKRTI4UAgDoV9a0tPhEaAnBY/nU15aiJ8kgKwzjvS2aeYVGRjOMZoAvWse85JBTPAq2y/KegOcU20jCqOOvHHp61a8nK5HXn8AKAIG2qAdyqPu5JxVORgZHXGQD0rSeJTEN3J/nVOVAckA5PoKAKE0PO8U6AMTvGMhSM+tWREecA59McUsKBZnAHUHpQBjuB5nynj1p0Y+cEZPr9atSQ7iOMAGm+TtXLEZ7UAQXEe4Fs5z096oSrjrke3pWncfcGQDxnI4rKmYZOcjuKAK8h2k5Hfn2qFup9M+tTSZySOg/Gq7+oPagCrImRkcc/nUQjODggD3qc/Ln096jfgD8aAKzjBI5x3JqFhjvVmQ4IyMg+tV8ZPHPPNAEL52HJJHXNRgYzz+VTyAY6c0zbwRxjHNABGPmQjPJHvRSxjMiDOORRQB3KKJ4XUn5s/lWLfW+WIxyDzitm1fZclSe5zxTdUgAO8YwwzxQBybx4BGDx0qJxtwec+1aF1HtbIB5/lVVxlccc0AQKowcAH1pSNoAAB96kCnPHHbOabgYYNwvWgBoIVRjhqcBxx+WOKQYPJ6GnbduQM5xxQA1lIHbn35pPLHmDGTUwUSdTx6ZpwQqDgdeDQBAjMXGxhnr9a0rcdR69frUEUKqTtGKtRDg4/SgCxEoyCMjGB9K0LcFSG6An0qnDv42nGDjJrRijMo2g8nvQBq2ycjBzjksBzmrTrh8EAkjgdPwqrACkYVuuDk5q02XIPzDPf37UAOdVC7W5Gf4jUKL95SWwCf/AK9SF85PJwelTW0YEW/HJ+b6/wD1qAIoVDR45J7imPGVPygkYzjviplZ48YABOcUySU+XhmJJORntQBCHEg4GeT+FZN4hLZZcnuQK1WdCuWyMDOfes2aYFCilifQ9cUAY7KwIU9B0J70G58rIXBcjBz2qO5mXzCATgHBIqCMnDEjrzz6UAWftDpj58k+vSrEFwsuASysPasp2yBwdx7k1NbIzvsT2ySeBQB0mnxecc9focVsySC3g2ANke9VbZFtrYAYZgOTn9Krzyea2N5AJ9c4oAma4CRFmYhifX+lZtxKSABgkdzxTppSWJByB0z0NUvOO4q33D0B4NAD3dic9wQOacpO7LH5vTrSbcrgHJI6+tKwwuO36CgCzuJEYBGEzT4ZsEoxxkY46D61UDEZyQCB+GKI5N77QPQDmgCzcYRwBkDrweCaYsxDMducj6ZpZTknJyvYGoUXLEk4A9eTQBtafMxKbiCeDnNb0NzG6PE+4sepJ71ylszoeRgHtjrWosg3JIoPIG4D19KAIrjyVuJAFZT146UIyg5Yrg8jJ5qDWCEbzlyqMvI96yI7iQnKEfT0oA7CzxcSIGxgn7wHap7mLysfLz29qw9L1MwsikfL3NbjTtOu4seMgHvmgDJvUjlRt2Qy8DPQn0qtaxeVGGK5br1/lVuQfM5cfxYzRhSRtkBx1yORQBbjjGwKAw4zVmLbsxzkdc1CjhQp4JxjrTlPzrjnNAC7SuMde+OagkhOQX4x1xVscE7SMj3qFgT0HAPbr9aAIFQ87Tz069PeiGAs0gzxjpWhBADk5y3bvx71JaAb5CwIIHXtQBjPals7jwOmBjNV/LQhu5Fbc0ak79xIHYVTuIQjNgYzQBg3a4LKAOO5rLuRxk8+g9q27xSQSDu45+lY9ym37v8ALpQBnPkr14HH1qDI9PwNTzK3zcYqIjAw2T+lAFdzxkdhUb8cDv6CpHBBJHSoX54zjHHWgCCQndjGfWmHDc5xj0pZWI6A/UUkQzwCMZxQA3BLc4yaNuAQDnHFS4APYH0po6jBoAjRMyrg55z9aKljHzqfRgBRQB1rgGUnHHQYNaEiCezbGfl6Eiq0qtHMxPdiauWJDKQD2IxQBzV9Fy3HI4HtWY6nJxyB1xXS6hFsJHfGBWHLGM4P4UAU2wTjJz6nuaa4GMYzUzKN+e3f0pCo3fMNuaAIQD3OMmlwGJOT7getOZMdMZ7U4DaTwDjrnv70ANVRjpzU64YY9DTEQYJ+9j1qZBlwy8L3FADU+ZhwCvpjpVpW2Lnr7Y61WKlGbbke5qRZTnBAGOBQBoQP8ue/+e1W1uRGUGOT3NUI0ymRwW65q5awFtoHOTgH2oA1LRzLKAAcA5z6n2rZVMxg9+uR/KqOm23lAnGfr25rUZf3ZJOPTAyKAM2ZTuckBXI6dvxq7Z58gYIPbJPaqcv+sxgZ6/WrNsSIioGW4oAbcNnA5GO9U2OWH58VPcOoJ+96CqYceZnpzjPagBki7d46A9x0rInkUZIHJrQvJcoyjbnqST2rHcFsIOpOcUAZ5V/NkwDk459Kkk4AUYP1q06LbjYMGTPU0w5RcHGCecCgCljJ+Yde4rV05ScNxheeahiiBwCEOeR2xU+PJUHnYe9AGpPciOMA5wR26mqa3sZchSFkOentVS5l+XqT+NVAu8/KePU0Aa0mXBYMQOuKoSbt+G5XPB9qni3BQCx/HtSSKhAzjB6f59KAJ7P5gCDjHpU0gzgkDjuT3qG0Q7VY5APQDvV1VJ6gYBHHtQBUuEO/Cr1Wn28TBslcKRz71baMbicHrtA7E+1JNwUjThR0x0NADWxkHrntTSp3ZU4z3qZfmG0Hdnv6fjUZBjcLjp1yfWgBysVUcgdq0bR0liKHvzn0P/16zivoOc9ulOhYxEqB8vagC7rEe7TXOMMp4HYVzMLbeSoBzxW5cSvNayBjwPX0rn1brwevagC9bzfMCex6iujsZ9yAd+26ubslG4M/QnoOp/wrYtZEXaApB9PSgC+8oDNz9QagEg5HO0cZ9KkuFEkTSRk8D5gRyKomcNgjO4ev9aANmFw6qy5yOD7GkQ5GM9D2qhazDDDJ2k/rV+Ar5nK8nv2oAvRfvdowcdCan8tY1YjdjBGT3psSLs+Xn2B/KrLp+6AUEt0IHpQBTWXYQqDnvg9afbuVDlcMSCD9BTZYVXcQApU9c9jRbRkyYQfMRnpQBLCq+VnAPOAAelVryEOMjPfnNWVHUJuznoaZeckYxkccDHNAHOXWEUlxgHrWNKMkkgH8a3r9d5IONoPWsadRwFOM9qAM+XGc9ePyqnKMZ7jp1/lV+YcEgYA/OqUo+bnAJ7UAVm2gen8qryKQcnPoMVZcLngHA9aryjK5xgdKAKhTdyeQO1PCkL0wcU9VbAzgDqadtxyueR0oAj6jBPNRkckY/MVMRySf0pvfHOD+tADYwTJHxxnminx5MqnrkjpRQB3tzAWlduozg/40y2GJiVwR3HerMbC4iWXru59jTFXDcklRjHv/APXoArajEChYA5Pf0rnpYsOeOnb1FdVqAzEzEHBAGPasK4j4O3HPTNAGU0Y2nuewqIphDwPx/pV2RTtxjr3qvIh6jrQBV2jcctwBinqmTkjj0z1qXYuBtFLtw248nHr2oAaqLja3C9fpUqqCdvfsKIk439eOMetCqyqN3JJznuKAJtisvTtnFJDCrkL0H0qSNRlum7HQ1Zhg6le/c0ASW8A6EdfT/PFalrEBgEDPYj/GqUULZJDfL3rWtowAADkYAznrQBoW8eRlCcj7x75q0V3RgABTjvTbWMBMr06++asTr+7LDOD2PagDEnTa2BgDuKnthwSSMnikbh9qjPGachARgDyQSBQBRvHCyE9x796psThsqWz3FaE8PzDzBx71WeHqTkAHpnrQBRmhL8oMnGePX/CoJIxADkAP2zU09wIwwXI9MdazZG8xye+MUARt88mc9T3ok+9gDpUZfDjIyM9fSoLif94oXd15x0oAuKwX/DOTVmB1dSGAwRyM1k7snk59TVmNysW4nOeAaAJpYEIwrEA88jmmBUQhQARnJJqMTMzE5yucUqyR9GIHPUmgC6rR4AOcA9j/ADqR44klG4bgOc4/SmW0XmNlPmzycGpr0q0hCjCjpjtQBLD8xycD+gqZ92Mf1xzVEMFGFBPUEg9akGWIJ6Y9aAL1oxcdD9SOn/16YSXcgDPHYYosQ28lieAMU8xEO0o6Mcnb2oAfDGY17ADg7uM047JRtDAMOhqrM4ICA5yefaprSPaAcHHbPagCRIGAO5RgHjv+dMZRgbsHPUn0qzctGtuHJwSegP8AKqTXCtyAc56ntQA9odkZy+FI4FY6wqsnzZGfTvV55txbnjPXPIqtKpDE880AM3/3Tj0HrV6CUYIJ3enFZuSpIAyD+lWIWKHnkGgDXtZxHjOSmMMM1FdwFXLpgxscg57981UMuWXt8vHtV2yuCAyv88Z6qehoAW0yvfAPrxWjbZXGT0OappGhf5ZQq+jVoRRtHjd8x6j60AbdmMoFHAPH41Zxk7VHPdQcZ7VSs/kJbjbjJJ5q9IVZCGPHqOSfpQBXIUzg9QeTkdqms1hDSAAk4wOOtMWBoYyVJO4cZ5/Wks5CHKEEEDr70ASSRbSA2eOvvVObIYhNpJ6gDqKvliVICkMOp7Vn3rgqen5UAYl8MOdpwqnkYrGul4I+UnPHPSti5J3tnAU9cVmXSgsW29e/qKAMu4XI6Y5yRVaRcE5HT261bYEnqSD3qpIDkjPegCpKp9s45qB04IByKtMoDdOvWoZFyuOSD3oAhUYQAkE+p70Mv90dOakCg+vFIRjJPSgCFlyAD69M03+IDqBzUjLgj29qMAthuB1BoAZEMSqDzyOPxoqVEJkTnkH1ooA6PwZd/aLGSNzlomI/Ctxo+c524POR1rz/AMBaht1RoDkGTK/XmvRnALLnBHT60AU70HGGIxjpisuZOWODgDt3rXuRtbdnOe/cVRlT5io7ZzigDHeI7247fhUDx849K0JAV4A59PQVXdfmyRjvx3oAptGGPB/Gmgc5YZx1+tWZF3KOmBTCNwOfqR/hQBGcAqcfe5qVdpABB5HWnRruUc4KjjinxrnBH3cdDwKACJN5G4Ekcg1eiGMYPA/Q1FEAsYJJOeQcVYToCvU9vSgCeBGwSxG08e+a1rUcEZB7dO9Z9sN2CBj0B6GtG1+8Ec4TOPp9KANWDk8/dxgDNF46iJTuyT2HaoYAdoA5BH14zUk6MMH7qkZAI5xQBQ25YE/e6+1Otj++BA/EjrSugj2kE4J6dzToN28NjOWwaAHTIM/cB77vWsHVHkaZkiyAvU1t3L468j371mSAucc565/rQBhSKFGB1FVOo46c1evnAkIBBJ71R+ZiQqgnvxxQBCyhpOvHSnLH3Kjn2qwIAygYA96kWF+FVcAnigCgkJaTavO496lnUsnysNo4HGK14rJYULuQHYcE9qzr28trbdk7z0oAypnMZKqpz6jjiokIYZcnBPTpVC91/wDessNupB4BJqtFq0u/5o0PPvQB2NgGUIQcM3O4HtUzSPknqffpis2O9Sa3RzmMkYA7U6SUE7t20n07mgC+pHGcAAYzVqELu5bHsR0rKS5PVcE9MVJHOW+oHXHNAG9uRYVCk7sZJNR27qzupJIwdozVBZVYMA25ux9abBNtkZ2OAAeR60AWml2urKmOe5p3ml1XcSeefes+Vg5JVm57U6KU7QO35igDXXmBwAMk4A7Cs6Utnau0HPJz1qzbS7m2vnGMD2NVZRsZ/NwMfqKAD5ivABI4phIxk8UxriLIAkUHtzUhUMuUIPrjnigBJASisB9T/jToxhhg8d8d6khQE4cnB4JphRo2Kk85yOOooAWQbSuRjPr0qaCQZGchh7U10MygdXXhh7UgjYMQevvQBcX55Mnle4ra02VkYK+DGenrWfpyZwOCc4B9PrWj5IV4+gwOfw9KAOgt4g0asCDgZ4FIch/n4ZegP86lsh+7QYOBg+9RXnMxJOcD170ABm3YVGyO/Hb2q9bwZtwGwOc4x2+tY0BfecfcA9a14ZNwVeOmcc0AMuSoiwSdxxnj8qyb5wE+Ubgcg4rQv1KBgDwRuJzWHNhlGW45HPH0oAozDeTjp2rPufu5bp9etaE2eTwCOv8ASqEzE7wBn1PvQBmXAAY4xyahmX05UDmp5RkdckdFA6VEOOnXGOD0oAqMCM988VCUyeCce571aYHd0wPeogAFHOOTigCBwBncvH86aQCB0qZxg4zwO9RnIIKj/wCvQBE2MZHBHHWm7eT2+vNT9TxxjvTdnPXrQAkYw6/UcUVNCuXUk9CKKAOK0m7Nlq8coJA34P517bE6zW6SDJ3AEGvBZP8AWvjruNex+Dbv7XoEDM2WUbD3zigDScE9SMD1qhMuVbPHcetX5Sfun1qpMeCMjHQ+1AFKVAQCdvXk+tVJEYAr+NXjtDfMOp79veoJEG5lbqe69PwoAq7CByenGKbtHHOCOuanII+U4yOmBSqpG4YyO9AFZQSMkYz2qaFOAT16YqSNT8oIzj2qcpsfDY9uOlACKBx0wOuOgPpUsYHJOcE56Uirj19KkhQBjgjB9TgUAWYycEEDPcjrV62Yngn5DxjH+e9VoAdoX5W9yavwr7LnjIxx9aANO3UpHg4IPGc9KkmVdh+fn/PWkhQBAwxuODn/ABptyA0e1cKD0GOfzoAyrh1LqMcLxn29qliUEHDAen+fWqFyrJLjqQeMdSKv2g8zDKSPUUARzkeW3PQ/5FUI90gZxgLjt61duBvb0VRwTVaFcWRwcndg4oAwrqLfJ8xyOgpqxJjBbCDGB3FXZYxuYk1CEyQTz6gCgAjh6lcbcdegqZzFaQmd22g9yOfwpksi28YMo3HqIxx+JrGv7mS4bzJGyTwB6ewoAj1HUpZyxRmRT8uSeTWBeOQh5xgdTV5uoUAnJx61R1CNtuCAV7kdqAMAqWl+Xkj1q5AiDLuOnbHWovLw2VU8GrVuHcgYP1IoA2LcNIq8cAA7fSrEo24yPl74NRQJtYHLEkdzgCrEMbHOSOuST6UALbr+7YYIzxzUysEKhj16EimnaW+TOBUagtKox3zjPX1oAuIxy/Pb6AUxpgsYywBPIApB94jOR24qjcHM+MZxQBsRMkkYIOBjnNQmZUPLfMOoFU4ZcA5wFPTFK7LuDA4IP1xQBoSXuxSFHzEdO4rMmvSpKk7h6elK3llsAsB19TVCVVD7i3T0NAErzxzp8/yN2b0pEeaDG1zg9NvQ1VZN7gqQR1FWbTKkxt88X8j7UAbulamCBHdKD/tV0bWiTw74iGI4znmuQt4dkg3D5Ox9a3dNu5LWQEHcndfSgCVYijZ4GB2q0sKzYGQpHQk/pViRIpkWaDBDDpmlQDOCOPagCSwTAKY+Yc//AFq0UXlN+35eB3zVSJQwV8j2IHWrtxHtiV06AjI60AaukyFwAccnPrz606eMCaQkDJ6c8VV0txGFIIHHcdK05Cr5KnPpigCiiiOVug7nParsDESH+6QOO4+lZ7/8fIdTtPQ8dRVxQACc5OcDHrQAl8QQckbm4PFYd1EQmdp3AcY5/wA/Sti5cBNq5JA79MVlyruG4jbkcDPegDIkPUjrj1/nWdKMHjBB/IVqTRjBJIPvVGVQRjv0weKAM+UfM3ZRz9agHy5I6gYxVyQYQ5xgY/Kq+3LHOKAKjjBznIxz9Kjf7ucY9DVp1UbsAZ9MVCULbeMDq30oArkMXJH4nFJtHIXOeuasFQxyOQOuabgEnPQnjHagCEoTjsQOe2aRUI5wMVMykAkZB460oQ5AB5x0oAIIwXUD1FFWbaM71JGDuFFAHlkhxK/1NeifDC7LQ3Nq3IGGArzuT/XN6bjXU/D258jX415xKpX60AemTAZOeVPb2qo4+Y889qvXHJySGBHAxxVFzhjtJIz060ARMCee570yWLI3AZJ4IqwDhsdicDn9KbJwRjOR1zQBVRSd2OWI4FCoR94Zz1z6VM0JXrgsvOe2PWp1j38AAZ/lQBXdMMSOPan7M8LnAH5mniMlDuAK9APShVOQ3I/hPvQBHsckAnAI9PSp4kB/h3DHftUrpjkHI7HpmliVtuTgfLwO9AFiAZKkAY7Z4/KrtsOPmGQTxg9TVONei44B7ng1owoWyMAc8cUAWVba+0dAORTLw4B3lRznOetSkHjB+U57VDcAMuFxgnBoAxLx8SrnkHse/vU6XAEZXo2OMDFLfRjyW5BYde/HpWdYzbyEJ+Yep60AWiWlRtysDyR6UgLJb5HAI+lOziMsMEDj3xRcgLCvTA6/WgDNlBOG+b0J7VTmn8sBRgt/Kn3MuGOCTmqEuN2Mc9z3oAjmLZZiTnrzVYhpSMYVR1J7VJcMI8M+QCc4zmsy5uXn+XO2IHhQaAHz3MNsWCneR0I9ay7i+dkb5BtzzTZ0ZmwcEDg5FIkW7IzwOPrQA2F1fG5Bg+laFvEhwVGQeKhSNUOMDgcgdaljYq2VOO+P6UAXkiOcKDk1dfatsFGC2cE+lVIiRGpBIZzxT2l2nZwwAz+NAAx7kYP86sCLYVbkkdR6VSDEksT247U6KZmIBxls80AWMEPgDn+lMljWQuTjAHHqajmlk3cHqDzUPmEOpbj6UAJ/ENwOc4p0qgQ7yxz0x6VBO4WUgbtpHrU1sGkiZGAycEZNAFR5m3EEYPpUfysfmwCDSXbFSAeAevrmqzPuwqkkDvmgC4ssSnGT7+1Txzw44JBrLXA6DI61JG2XIbABoA6e0lSVfKLjvtNW5FKNhxhvUdPwrl7UlGwGIPt2robS++REuAXUdG7j3oA0dOumtpCc/I/LKa24tk6qyEEHmuexnBi+ZM8HOKvWkphPB4GPpigDoLOPg4AJNaMyj7K29RvzketULG4BUE44PSprmUujAf8A66AJ7WQlFAwQR2PetHeDGRnBbr7Yrm7WTLx5yMcYx1rTnm2DKsc9Pc0AW4QTOAAMCtPyVEfI7dR+lZVkH2qxbJ9+tapfauQSVPU9QKAM+4VFHAIyMkk4zVC6cfKuGx9K07gllcHGF5AA61lzKwyGJ6H6CgDKu8eYu3B45OMc1SclCS2QRk+prTuUB6c46ZPaqJ4+Ynkcf0oApTRhpd+eo57/AIiqrxYc9OeDWkVyRgfjUc0Zy2cZboPQUAZjod2ORz271EV+Td2zV2UfMRng1XwTkEEDvQBXHynaoznoRSMmCDklR2qwY+cqOB60xlJf1GaAGlAxAxz/ADpUTtyFzxipOp4A2npUqKNw4+b60ASW0eHT60VPbKCynbxnrmigDxqT/WMO+41reFn8nXrJh2fFZTj94/UDcatabIIb6CQnAVwfpQB7SWDRKcjPeqMoBJAJyB/nNPspfOt1bjBHBqO4G0g85UcUAIhOMbQAOfxp5YKQzYz3qIEAkEEgnj2qQjOcAdPrQBPncDtwDjgev+NKoAYE8g8fQ1EONhXkqMeuB6VPEA6jj5SvBz0NABs8xNoHJY8H1pqozBmkCqwOOPT/ABqT7smVPKnkA9ankGHMqgYbtQBCUDYJHIGM1IsfzHnIHc9qa4Ug/N8ueM06JjwChwBjg0ATRJ3A+bOa07dfmGT94HnFVLUA4AwGbjgdB3q/ABwAcDj/APVQArIQWBY54GcYqo+7JXOVHcd/etIhR80jLgj1pksVsEd/M9/vDAoAw5lJYKORjOcdazbu1MAEkeB6+1a17f2MQxvU45xnmsW+1yIpiNA3bLcUAJNdlYkWRgCxGQasXM263IYZHTmuO1K+kuHRBtHz54HStO2ud0OGbPH50AE8vzkf5/GoJD1YcDqRn+VNu5QB3IPQ5pqyF4hxzjH+TQBTuDuPJ69jVNgvPartwoGc4wOlU5u4YdPxoArPGMkEn8acUULjKgsPrRz5WQCcdKhcxoQHPzEZwDQBLsAYA/ialCF+hAOfzqvFcKMAhSB1NaEM4KnaoB6g4zQBagjbyVSXBI6D0FRzhCp2gggU8S7wMMd4PPPWo3kDA4GcnAoAjR16NgqOCakCbSWPQ81BcRhQTjaMU6xkJyCeD0yOlAFj5X+Y9OvFZ+oHaqBBznrmryhd/LYGM1larMsTBQctgmgCUEuimQ4bsc1agZYlTHI9a54XBk2Fgc+g7VKl60ZCjOOmM5/CgC5qhE1wSpwvp6/SoAgHXOcelS+cjqu4E4PAp0O0gHIAz1zQBD5bEeiimoMueQAD+dWzE3b5u/NMVTuxt2Y7kUALDuEwBJ57VqQEFcZz6VQiVRk5GT7datwcADIGTQBqWsjR8g5Xoa0IpRuPPyk/d96z04AI5PcVYhwGUZycfjQBtWsxjfIxtyB161rwSZU4P3h1rl45Od2Ofc0Tam9qQQc+2etAG+lwFYDAxzx7+taFmgmbLkKvHBrj9Pv1uJVEkmxTxz0rs7FFSNSrZyMZ7fhQBppCU5QfIByKsxSbjgLk+9QxqzQEAnnrjv7VJBDKoOQVUjBGf60AFwmSd/Tt7H0+lZkw4IJGTzWhMS7lduCOnNULhQuOhJ70AZtwhyM9z1NUpVO47uGPGK0bgZXaNx54yOlVpAoPygHoOaAKzIEjA29eTUE6Zw2DyMjmrknyg8ZxyeagZCRnoDznPagCgyNtCsSG7n29KayBgFxjjg+tWZceYGVeew7VCOjOWwRnj/CgCtNlTsyRTCmGz7Y4NW9udvrj8vaoI0yeVwzcfSgAIBA2g8VOiseCoIxwaXaSMZGcVLF8vOCPQZoAdAp3qcegx/OinxAF1wDjIooA8Wk4d+MfMaQ8A8YIFLLkyuR1yaQIWOB3OBQB6t4QkMukx78nArSu1JzgAADIFZfgvP2JkHG0gfpWtMSQ2VX0GaAKyH5N3QngGpABtYk5OajlB6dh+nvUqLxzgr6560AOXGNoOR2461YThdxGWz27VEnDYA7dTU0OSu5jxnjNAEwQjkAZPepI1DxOF6ryP/rURttULzt9ODUq4EeB9M9xQBUdCHGwAg0gQqFI+UYPerDKxZT0yetQ8BmD9skgdj7UAW4D5ecdQOp/lVnz2IGMDrWcmQ6qp6YGR/OrDuVVskZFAGZ4g1b7LGzZAAHWvO73Vbu4m3+cypnhAf51oeLr0zX/AJOTsTk/WudY9+tAGzBqIlQLN8pHGQOtLcXEez5XHHYViZ5xyKViMdyaALTXGZQw4wfTOauW+pqrFWU/WsiNwSQeRUhAJ9+ufWgDbe4WQqCBj39KuCT90AuP8RWBaPl/n/h7GtiNi0SYOBjk+9AEN4+CON2aq7gdwI5x1qW8bMgxgD9eOtVxyOfyoArXUsknyjgjgelVVty6YfJPQGrzBdoYZbBz/wDWpG5IGQB1z60AVEHlYVjmrlvKCACQFHXJqu2OuM8UyRtqDHJNAG5CPl4wQBUwgBIJHzHmqllJtijx8zHrWtJ8yKOA2M470AUmCsQXP4elR7ljOEHbt3qS5HzLj7x5qlLMdrBhz0zmgB13MiwmXPQZ47Vy9/dGaUtgD0q5qkxIZfbkA1kNkYGcgUAaVm5AycZOPrUk0LeaF2ggeneq9q443HJIq+JHijXA+Y8cdxQBWnYoow3HpVZpyDjPy1NdDecjkdPoKgeMKuDkk9qALdvNITgNxjmrkN033dwx71m2owm0jHuamjAV8np2HrQBrJMCOg+vpVyHG3nIz0z2FZMb4X5e36+1dF4L0a48T+IdN0mzZVnvJRGGbOE9WP0AJ/CgCW3bcoyMhSKndlVQWOPr1rp9TtfB+meJ7/QmXW3jsZXtJdT86MKZkYq2Lfy8lAwIz5me4B6UieBrtvCGn+Ib7WNC03T76KV4lv7zyZCUJymCvzMcHAXPvigDj7q8CKcZ3dqzZpmlOSTgV1nh/wAGTeLJPK0HWdMvNSFt9o+wBbiOUrgEqGeIRswzyA56cE1P4Q8EtdDw3q+uXNna6RqmoxWtvDO0vm3o3gOIxGpIGMjcxUe/Q0Acnb3Hl4zjite11ia2A+zzFT1K10HizwRnxt4xj0kW2l+H9ClHm3Ny8jRQKQu0EgO7MSTgAEmuc8WeF73w1JYG7ltri21C2W7tLm2YmOaNuhG4BgfUEAigDZtfG1xbMvmQxy4HVTg102m+J/txVwwA7gD+lc78PvDmk+I77StPTTPEOo3k8qi+mspEihsY2cqGOY33cDcclR7+mRqyW/h3xdqdjp18t9ZWly8C3C9HAPtxweOPQ0AenvIksTFcJnv1qpc8OoJGCKo6dcB4VZSScZFTysXDAdxnnsaAKlw24nBxk9OhqvlWYlT6jP8ASnSdW5yD39KiQbdpJ656UAOYKQFHTrTJECpwBnn5fT6U9egbocnC+tI4bflunY4oAqOm1wO55BphXIIH8PQVadMFt/Pv6VCEUANyMcDHegCuqEnLHB6jtxTGbG7aeDxkip5GwuT1wTioFXauScj1NACxqc5qRT8vJyTx9KQYZSW4GefcU7HzE4NADo/ldd397HFFIvLqo6Z6YooA8alP718+pqSzUNMuf4eTUcuBI2cdas6cCbjjkgcZoA9F8ID/AEdyBnnNbUhCqQx6fhWZ4SQi0ZhjB61tPDvznp0NAGe6/Pyp9etTxAYZecD+dSSJyAQevGPSmkbVUE4UdfcUAOUDb8+Dt4Oe9P3DGc9COvT8KhJVmYbjip964wRkAZ/GgCaPJfBHykfd+lTuyk5VunpVWMuUwWG8+nQelSA7ihzweCcdKAJnChgAdynoPSoZgNy9QSDz60oLZYDkdMY/Wn7SYsjDEc9enrQAwIFIcdCOmf1pJ32WzNg7utOchU+Xn6mq9/kWZJ/ukCgDzHU3Et9OxOQXOOaTSdLvdZ1S203SreS5vrhwkMSDlj/T3J4ABJpkw3Sv9T/Ouw+DniWx8IfEXSdY1YN9iiLxyOq7igdGXcAOTjPOOcZxQBWvPAcllfX2nf8ACR+H5tXso3eexSeXepQZdA5jERcYPyhycisQeGtdayF6mjao1m8DXKz/AGWTyzCv3pN2MbBkZboK9Qs9F8F2qeL5fEd54Zv4TDcXOlX0Gqt9pmmcsY0aBZsjGRkGMc9SRVP4keLCfhv8PdH0XxC6R/2ZPFqdpY3pGAfLAWdEbpguNrds+9AHnt14T8R2OnG/u/D+r29ltDm5kspEjweQdxGMVo+AvBWreLtXsYILW+j0y4nWCXUUtHlhhJOMsRgdxwSK9m8Lt4H8Jar4gg0PUfD66Pd+HZUXUZ9YVrq7nYL+7eHzAqdTwYw2eh6is3Rda0W/X4OXcGu6TZWGiAx39rcXiQtDP8uZDGxBYMd3zAYGTkigDym98L6hB4x1bQdHt7zVbiwupbYm2tmZnEblS+xdxA4z3qKWC6sLmaz1G2ntbmMgPFPGY3U+6nkV6xH4h8P3+l/E/SYZ9Cn1DUddlvLY6hdtDa30Cy5C+ekiDjDEAuFJYdcmuA+KHiG71jWtKn1G60Ke6h06OCRNGdpY4lV32o0pkkEjgYJIY9QMnFAEul+DJdbudLtU1vR7fUtTBa1sppJTK4yQN2yNlTJBxvZc4rldatLjSb690+7j2XdrK9vMmQdjqcEZHXkda9L+GJTw14o0TV08QeFk0qTbPfvdzWq3NuoU7o1WT98GwSAYuvGe4Hnviq40y58T6xc6J5z6XNeSyW7TszPIhYkMS3zEnr83PPNAGIsm6IdcjqB3qKa4YEKgGehyegpLleGdGwemOmaoMZHkx055zQBeSZehJOO+KniHmuMngjtVKND/ABZzVpHEargjA6g8UAalkqBwkhIatN7lSw2fdBxgDvXPS3a8ASf7xxz+FPjuj5gAbOaANuaRS5yCAeMVl3se3oxxngDmpWucRjBJHbPaqc13wRgH2oAzbhFdyrN9aozxKhAHPHXNXZSB0JPc5qoF80460AJCBuUd+nWtseXHCoJ3Fh+X1rFRNkuN3Ga27JRLAFxz1B96AKUyeWMngk5x3qIoXUMQT6Yq/cxhCd4yB+n0qqUOPlJGe3rQBXAxyc4qZR2556471GwZQPQfpTEOG685/OgDQhDFyB9OK6LwXrtz4Z8SWGr2Sq0tjKJAj9HHQg+xBIrnrZt4Gcbjx+FW1A3DBwDQB7ZofxO0TRfEGt6vpsPiUrqyTySaSWjNqlzM4Z5RJ5oz0OMxZ5xnFcd4o8VW2p/Dvwd4djhuhfaR55uZ5AnlsXOQFO4sT65ArkIm2oSMgDp7U+Kwv7mwub+CyuZbK2IE9xHCxjhJOF3MBhSe2fWgD2jQfjDoOja9o16kPiC006z04Ws2j2MMItXnI5mz5qlyQAPmXIxnPXPIaP480ZvDPgKz1201Rb7wtc+YhtFjZJ4y6sQSzqVYbV6Bs4PTOR5w5yvvTQ3A4oA9gtvivanWPHJWPWbLTPEMyzQ3NnIsV7asigBhh8HOMEbxx35rhfFusQ6u1h5N94h1J7ZHWS61u5LuxYqQETzZAijH94kn8AObV8n61LnHbNAHX+HdS8KaddaFqN5Hrseo6dKJpktIoZEuHVyykM8qmM4wpwrdM1m+M/EL+KvFera29qtoL2bzFt1bd5ahVUAnAyTtyfcmsqXTr+LTY9RksrpbCRzGl0Ym8p35+UPjBYYPGe1QRn5eRz+tAHd+ELnzrHDk7oztroXJXOR2zgVxXgqUrcyxk9cGuzl/hXPJ4x7UAUwGJY9R1GPSkVvmAGWzjnNTbMgnBAx0z2pIlAcnk4747+lAEiIWGTgcYJx0pGClhkDPt2qXAGWJ4z+RqGSIhgSMEjPPX60AV34jZVPXjHc1BINq8cn+EVZUrwFwSe+envUE6grz8r9SSeDQBWfnBYHHqKUAhSduB1Ix0NO5TBJ59Pemk5xuyuOeO/tQA0Rk8leR2pCRgAEg+9TR7sMvU9eP5Co24JIGCO9ADU4YAHvyBRTWOGXGeDk+pooA8cl/1zAep7VbscLMpPQ8VUY5mfv8xrT0mASz5IyF5/HtQB6V4fTy7JFA5xk10CrlWOF6dR2rC0Ri9urE4I6jsK3nfgdh6+pxQBSuB8zMQfm5xVQn5zubPbjtU87bumQR39KgYc9MfzzQAqdT3OcjjpTs5G5s+2P5VGNwABbJPA/xqQnap/ibOc+lAE0Jy6nglf4c1PGVZHL8g8DjtVZOhbjpT9zBVXney4APYUATbnwA56cipoDkFuRg8e/+elVUdQp54HYdq6S10S0j8GDxFqF/cRwm/FiIbe2EjlioIbJdR3746daAMTAzhfukZWoNSTNnJlfl6gV6DN4Dni1nVrE3L3EWm2a32bW3Mk88bbtvlxZGWJVhjPUVl2PhWfWLy9to4tSt4rK0+13CXFgwuEGWHlrErNvkO3IVWPUDOaAPAZlKzSA9mPT61Wnxk5/I17HL8H7ifxD4Yga9urOz8QtME+22JhuLV40LFZId5644Ibpz6Z5g/D8z+CfEWvxaizPpOprpq2ot+ZyZFjDbt3y8vnGD9aAPO1Jyf8aCQ2ckZPYV9AeAPh7o/h3x3q+h65NDrGsQaBLdXFrJYI9tbOdhXbIzEs4BHIQD5utcDpHw5hk0fwrPr+uHTrrxRL5emww2nn8ZCh5W3rsUsyDgMfm6cHAB5qzc5PSnK2B7/WvRG+Fs+mWfim/8Val/Z2naBdLZyvbW/wBpkuJmxtEaFkGMMpyzDhh749WuPCWnT/FPwxYaPpugW8U3hNLuRLzSVnikfc2XaJXTMhAHzbjj3oA+bEYqqnIGOOKmXnJPU/lXpOt6Vpn/AAof4f3zWkUN1ealPFdXlvao1xJGHkGOqlyAOFLAcAZHWoNY+Gb2ngK58VQz6xBY2ksUc8OqaV9klaORlVZIgJXWQZcfxCgDg5srDnI45HvVaRgYcljx1r1n4weGfCnh/W/D1jpB1S2N7plrcyRQ2gn3h2kBly9xnedo/dgbePvc1keIvhq1h4FHikXOrwadFdJBcQ6npP2SdUcgCSNfNZZB8w/iH1oA80nyRlXyB05qDzBgrnk9TX0H4k8EeGNI+NfhTRfDkawzXcUMrWmoWBu7NgySZdy0+5iSo+QAAdd3auG1f4fQpb+JvEviHU49L0e21ybTYRp9gHaaUSNkRwmRQkYAJGXOApHOOQDzVZtnckY6mq7Ts27B5J7+levQ/BK7Hi/WNCvdchhis9GbW7e8jtjItzDkAfKWBXJznrjb3rkfFfgWLRfA3h3xZpmqvfadq7yRbJrYQSwyoSCpAdwR8rc59OOaAORQM4Oc5AzzUtqW3jJIOODmlgIKB5Pveg70p+f5gAD2NAF4XOVIYYwdrVBcSbC5TBJ7GiMFfmyMY5NRyZI5HPUn1oARU8w5J5x+VNaBkXd078UCYxBlwM0i3JkXZtAoAiJOVAGGPNa2mOVUgnA7cd6rwQgxFj1HStGzQCHcQNwz9aAKt7NjCsdynsag80n7uD2zSXh8yYgdvfrVViBgE9KAJGLSsMfKB19Kelu2RyefSoomZpflHBGDV+NlVT27fjQA+CMxr6gfxV6/8OvC/hzXvCSrBc6DL4vmvRClnrd5Nbx+URwIliZWeQnHcj29fHw4C5bgY6eldHovjDWtIjt49PvIYhbtmF3s4JmhOScxtIjFDk5ypHNAHoF34UsPDfgfxP4h1fR4rnUbPVhpUGmyXUjQW5+Ul3eMqz8NwMr29af4ant734GfEuWytFsLd7mwCQ+c0gT95GD8x5xnJ56A4yetefWni/XdMGoC21KWT+0XMl4t0iXSXLZzudJVZWOe5HFRv4t1+bSdU05tSY2OptE15EsESiTytojAwvyBdigBcDigD1/X/B3gLwx4mPhjWrm3TdYII7qOO/mvzdP91wkaGDYTwF5b3rA17TvCvh74X+D9Tm8MPfavrlnc7pW1GWBYpFKhZGUBslSwwo2jrnPGOPi8feKUhtUXVyXtY/Kt5pbWCWeFMY2pM6GRRj0YVlanr2qalpWkaXfXjS2GkxtFZwmNFEQbBbkKGbO0dSaAPaIPAPhqL4k6V4Cl0xpRd6V9pl1gXEgn84ozbo1DeXsGwjBQnnrxzmeFPBfh/WvDdja6Fc+HtR8UvPNHeWuqX00ExVCwAtkjYAkqu7c24Dv3FefJ498UJZraw6zPEiW5tUlWGL7RHD/zzScp5qr7BgKi0nxdrukW9vHpl+lsbePy4JRaQPNChBGElZC6cE/dYdaAO81XRdPi+FnhaXWXvLGN/E8lpdqLyWVLaIeaHKx7jHvUA/MFycH1p3xE8HadaeH9S1nwpB4dvfD9tLFEl5p+pTS3MG4oM3CsxTcxbAVQuNwzXnK+KNdi0vTtMTUZvsNhdm+t4yiFlnO7MhcruJ+Zupxz0qXUfE2tarpg0+7vlXTjKJ2tra2htklkGMNJ5SKZCMA5bPPNAFjwicag3XlQa7uVd5Vc/KMHj1rhvCCMbxyB0xkV3042t06jgkd6AKzvhV2gjtxRt2OC4JBHAFOYrtwVJRf50fd+c857elADwwCgDAA5+tVrhmJIPAUfrUrPtA3MctznH8qgkfdnI7kD1xQBBkF2O3CYwSKR2BIIXOBgN3oaTYvQgZ/U03cSenI4ye4oAjlGzrggDg9zSuMgdR9f5U3cQwwBu/lU6hW+bgfjnFAEabgSFAzjnFQyDdwwyD3Hepn+VSvHJwaRYyuQc4J5oArzZyMDn37D60VLKhZOnGc/SigDxyNC8xVBlmYgCun0q0FvCM4zjk+pqHTNP2MzMuXJ5P8ASt+CzJiAwp5JoA1/D75gZW6NyPStpuIwD0BzyKy9MtjFEvPT0raWLK8jBx3PegDNfJYHaST6imoG/iHzdMDua0xZnapIwc1A0B3D5SR3OcYoAqbVAxgk9jjrTyCVO0nODx6/WpnQbjnIJ59KZIAq7lByRgetAFcr+7wD16jHWkkbaWwxDMPWpGK4DHlevTB+lQXD4yo2ll6MOOtAAkmApJx6+mfWu7XW9Gg+E1pY30kN3etrYlTT0vVt5pFEf3vuu2zPUhfxFeeTZ4YdQOgPOfSltZiHz1brj0FAHbT+JdR1XxBqWs39qyXdwkcEEenajJataQRq+ESYISSS5LNt7nAFaV1421e8vdQutVs7SXTrzTl0p9N895N9v8+4tOQGMh3n5gox6HrXIWco3ow+hwetaMgDxOy52+9AHNweI7Twf4j0XVvD/hexspLGd5XZrrz5JwyFChYRRhVAJxhSc8nPAqDUPiNCfCHiHQtJ0J7JNW1JNS8+TUfOaBlkSQgARLuGU46EZ5Jqv4mty8Dgc47+9cQQdvHT1oA9RHxnhXxbqPiWTwsraxqGmnT7qRdQKRscKN6p5ZK8KMglugwRznB0n4lRR6V4Wt9e0JdTufDEhk02eK8NuAMhgsq+W29QyoRgoflxnk1wEi9cD8qrvnn2oA9Ef4p3Op6X4r0/xPpialba/drfH7PcG3a2mXbtKEq+V2oq4IyQOtbkfxuMfjrS/ESeG0VbHRf7HW1W+OGGSd+4xkjr93B6da8aON1Ln5uKAPStC+KM2j+HPBWlw6TDJJ4bvnvfOknyJ95Y7Nm35cBuGyeRnFT+I/ina3/hjxhpNpoFxBL4kvY72e5uNU+0NEySq+1R5K5XCbQM8A9TjFeXsxC8fjUchLDI6+tAHrDfGGOXxF4X8QTeH92uaJaxWZlN4PIniTf1i8vKv+8OGD4B5welVPEnxNtdR8HeI9Cs9Dubc63qK6lLdXOp/aXRwynaB5S5Hy4HOQO5ry1wQPQgU0SjbhvwoA9auvi7bXfjPw14ruvD0x1vSIooJCmoBYblEVxnYYiUYlwc7iOOnOazp/idDqGja5o3iHRHvdF1LVpNXhit7zyJrWZ3JIEhjYMuCV5QdSRjt5nuyKUEugHGRQB7BF8bruTxXreuXmjQyJeaM2h21pFcFFtYc5U7irFyDknpnPauR1jxudT+GHh7weNP8v8Asq5luPtfnbvN8xmO3Zt4xu67j0rjY1BOM4p4R0k5GR6igC3GqeV179KtwQrI44+VRk5qmoJ2Fc8dRWh5vlQjcOfQdqAG3DCJVAI+lUJHJGeRzSzTb3II+lRv0BGcZoAYzDPy4P171JbJyV7moXU8kDmr1l9zbjk9aAHpuViu4dulXvO2QMAeMcYqNLctwy4XHFF4QSUQYx2oAy3yc9Sev0p20nJbrT5RhsIctjBp5AVR/Ex9e1AEEcjAgqOcd6lDN5QGec5pjFQSBnHoKfDzg/dUd80AOjYqSG5z1yasiQdR9fpVNiAeeB0HNKHGQoLAZ70AXFmDudp6d6kRuw65/DFU4yACE6jsD1qxF0znt60AWxgDqeKQHJB6ZpgPyn270KeR70ASvgL3yD+VIDkDPAphOTjNJng4PagCQHLAj6e1WYeB7e9Vo16e1WR046+1AHYeB4WLO+3q35Yrrrkgn72QOmKxvCMP2a0TcDkrk/U1uEck/wAOMkD+lAECwlU3M2B1xj+lMlbHUgJnGTzz64pLidY42IXB7AGs2Wc4zjGB07kelAFiWbb90bnHeomcqGc52ZBJNQJKWcbMBeG+lTsAxUYBBGc55zQBG7DJHDYO4Uh4PXjH6UwyMM5AOODkdqEJzjOFzwMc0AKcZJbg5wD3p4fbgkdeMetJIAeR+naol5JUAEjqaALR4IIBA6470/buIYDOBu/+tUcZy4yePf1qZQHIA5ycDH86AK1ydkRbJzxz/SilvEyoAJOeeBRQBy8EOGK7ehzW1YQDbl+MnvXO/wBqFZCF+TB5xzVm21A/3s5460AdlbeUqjD89KuwTR7gRnPTOOlcraXm/Ht0FasUpZQQDjHJxQBt+bHk4OM9sU50DjK8hqxBM6jPYHuelSR3ZTDbyOcDFAFuWHrk/rVOWMqT1464q292jIA5w2cHHFMdQwJBJXsc0AZkiA5K5wR+NUJgc8HJ646ZFassbB8cjt/k1Uliy5LBVfBwB0NAFPzHbORjP6e9QkEd+f5irDKWYD15GeoqJ1KEo4HsxoAt2k/c8N1PNb1rJ5luUAxngjr1rkQ5WT3HA71u6RclyBnJAznpmgCtqih1ZHADDj615/qERguXQnjt2r0nV49szbR8vXI964vX7ZTiQDr1x60ActOcMck/41Uc47n3q3djBJz7VRkYEUANbJzSlsc5xioQxzwOKV2+vFADnbn0pqyEccc0yRjwPSmE4IoAs4yvHb1qs4wSPepQ9Mk5H1oAiNICRSkU2gCzHKN24gA1J5gOdx49BVPtmjPAoA0rd4/Nwx+UCr1xGtwpKEge/HFYUb4cVeSdvLCgkLngnvQA82zeao35I54NOaN8jjPbii3kO7Iz6ZqVW3Luz747UAVRExYA8Dvmr1vCqHcSSRVOUlgBkA/zqxbkFU5z60AXzM0agHnNZ6zMWPbvVqUB4zk5296z923hjQASNycdT3zR5hKk5HPakZ9wbHSmNnORQA7IXp39KZuO7k9TUgBKYHUdajYhTk0ADHLdOe/FLuwQR+dN3EDAIpjS8jA+YfzoAsLnzVIHSrnIJPYiq1udxBJAB61YdslQCaAJkYeX/OlV+zHt2NV0PUHoPenhgc54oAnY8Hrz60sfXPvUDPgdM+tSwsAB2oAsx/e9+ua0NOi8+8jjxxnPSqMC/L15zXT+FbTfIZmGcnAoA7jRodluGOPlBOD+lLfzrChkkYE46DrVhQYLFMjBfls+nauY1e7MsoUZz0PrQA2a8Ly5I3eoPQVXEhYhjggHOTwKrOSpII4p0RLBefl9D6UAaFs4UMFIPHLH39KldhtIHLEcH2FUwwWXYoPPU+v0qzGpkkUhjvH93t70AIAGwGbg9B3H41KgAJ5BJ7U5EAIKjaMZ65zVqGAkDCjOM5P9KAK+Pl3Hr2HXFRuuFwc9skdq0/sxx8o24AHHPNKtmzBRgcfzoAy4h8mccdcVbhJAPc4/KrBtGIBGMjrjrSJZsoUFc468cmgCoVy4UgksOntRVwwFHBbJxRQB5WqEytuPOT0q9ZKsZG1Qee9ZkDnzGAxjJHStW2+YAcAd/b3oA27SXbyoJxxwK2rW4+Tj8TXNwttXJOD1PvWtbvuVTuzuP0FAGyZVYN8ikc4461BLFG3GGVvamRP8o68HOKduxk84J6UAQSxyJ0JYD061El0yPgHlTxVsMevOeOar3Nt52Sh2yevrQBbW4ScHeMMenNMnjA54AHJzxj396x1kKn58gr1q59rlYLkkccmgBH+Vj8pA7Edqz5yWYgjgHqO9aP2hWUiUAlh+n9KgkETrhiM54HrQBnyxsR8uMcYq7pcjJKAehHftTkSNtyhW98VcgsyzBkPPb6UAXtSAks0kGTkY/wAK5O7TeHWQHvxXYlGOlujclSQPwrlb+IiUnHB64oA4rVLco3TisVwRu9q7TU7cOhJGcjtXIXalXPFAFPI59Kap5zn2pWqInBoAc+Rx2plJnmkoAk/hoJO3g80iGg4oATqMUYFAznrUgHpyKAIc9RRT25yelNoAfBtMg3VcJ2hiRnI4qpCAHBNWyx257GgAR1KHjH0qRSfLIHX1qMxNnH3T3FLjYMDJIoADkryeauWsalVYn5iO9UtxK/OPpVqKQIo44A/KgCS4JjTIPBPTHSqQ+8T/ADp9xJkkjgGoFcZAIBoAlcFAcHGeKE4HQ5AFLkE9etNKkGgBwk2HPcnvUbneScHg5NOY4BJIPpmm7vlxnGfSgCMqc4B6fpSoNrA8E96RnKtwODUsfzDGKALEC4QkjnNNdwC2Dye9PdtqBVJquwJPUUATxSALkjmpgcqcE/UVTDFcVPC27HHPagCQHDADIHpU0bn+9zURAJyDxU8CHf7DtQBo2wJZVX7xr0Pw5beXCqAYyK5HQLPzJgxXgV6JpCrGoY8Ac/WgBNeuWihWJOG6AelcjJIXduSW6gn+VX9eunkuCFz8p4A7mslH2hyBgt79DQA45yw69Dz61YtY/wB4Nw567Qe3vSW6GQrjg9Se4q5BGSxMYx2LMefyoAQKBkKMknk5/wA8Vo2cZ8tWU8n8KiCpu4y3Y4GPrV5H2gmQgcde/wBaAHxRpuxs+YHuauRRqACCAnT5uMVmfbccooQDv1JNRyXe8daANwTwo5wN/YnOAKT7Um7d5a+mKwt7uwCgnn61MrOS25W5oA2FuMncAOM8etPW4QhsqCcdqyPNdVJKMT7GojdlM54I9qANO5YNyvJbt3orAa7d2VwxPPeigDzO3Yrcf7OSR3rZtG4wpBZiKxY1IkY46MQK07TGCBgcZP0oA2IiQQAM8ce1X7c9M/3hg54qhF/eBHTpV6LgKpz85PXvQBpRN+7YjHPQelDMfu554z6H2qKM4GTwBxj2FPGVVumBxyKAJ2fLMc4HcDrT4uVJYnHp7VTL8hcZwOetTrJkKcfhQA6/st8QmjUF1Gce1UUGAu7r1PateKRtwOcH3qnqcAjJlibh+o6UAUJB1ByVPOR0qu2VQZY4znFSk8YU4z2qGXjLEnPfvigB8bnPQ9hwcfjWlazNC6EkAAZ5781jKT90c5GQe341pwYdfmGcKBQB1FuBIsqkfeXOf61y2rRfM69h05rotIfKqCScrgGsTVk/esOh56cUAc7IvmIyEDI6CuT1u38uXeo+U11sqlCGPYflWZqUAnjdQc/zoA4eXhiKhNXr6BonIbqP1qiaAEoxSigCgBB1p4AJptCmgB2OeKVMjk9qTHQ0vUe9AAwBGQaYOTT+xpYvvZx0oAlSPADE1Yj/AHRye3amI+4ZwOKVeGHegCyzq+0qADnn3poVOeTj6d6ZsO49v6U4BgpPT2oAbgKOOeKY0hB46dqa24rjrUZzjA6UALJIORUYGfrThH9OlI55wOlADkkw2atI4YbT0Pb0qkFz7fWpB8oJoAmlQfwnIqDBBx3604Sfr+tNDfMTnjPSgBRGc881NkADFRbs9+vWkyAepx/WgCRiM+hprNgHOKYzHGc9aiJ560ASBzu5/GrMJOQfyqkmc8Vetx+JoAnYjd8uOa1tJheWVUVQSaoW0O5s9q7Tw7ZLDF5m35iKANrSrT7PCqjlh1PrXQp+4sXfA7L1rJswxYL36Z+la+pArbJGXClgCfagDlJ4jLKrZ5JJzmiKzLY38k5yVGKvTxpGAzt82MAGqss/OEwAMDjqaAHLCsZO8qFXkKD/ADqWKWGPduZtufT9az2fcflPA745oTPVseuD1FAGubhE+6AWHQ1A07SZYkbs9P61QdvkwMbTx061ftbfb+8mHOOAOooAkht3cZbCD39KuQxQx4yu455J5NNViOTxn+dK3XPB7E0AW0OcHp61GzEqp3EH1J5JFR7zglun3uPUdaZK+N5YZ9z2NAD3k+Tr1/CqVxKejHINE02Aw65GaydRvfKUnOSKAFvLhBhehBxwaK56S4ZpQWbqc5/z0ooAzoQNxyDkN1/GtSzUpsIGeeOOtMgRPNI2rj6VpWaJui+Vfu+n1oAkjX5wp52j9auCNo1GMsSSoxzyalsEUgZUfd9K04UXevyj8qAM8ngJGWODj6+tSE4MhB4HAz9etWJEQOCFXOB296lmRdjfKvLelAFDO3C9xycHt71LGPmA6cZznpmnuoyOByDSRKCeQD+FAFiIkg/Lkk460pYS+YmfYGrESr5i/KOnp9aWNF3fdHUdvegDnnQRyMCTknGTUcmCMMfmHp1NaN8i/bPur+VNVEMSkqpOfT2oAzVXBwxPTnFXbc4ChfXP1p7IuCdq547VbslXyIjtGd3pQBo6ZuA3AZ96qa8Asr46Vr2aqFICjHpj6VX1xFJbKj7vpQBxMoATOR/tA/zrPuFVsHsTjJ61tX6Lv+6vLHPFUURCDlV6HtQBzmq2SzxF1H7wcj3rlJUIZgRg+lek3CJtHyr19K5PUYoxeTfIv3vSgDnsYGKPpWk0aZ+4v5U3y0/uL+VAFDGaTFaXlp/cX8qQxptHyL+VAFBetKQOa0BGn9xenpR5af3F/KgCht+XOacqfLgDvWj5aY+4v5VKsabR8i/lQBnD5OcU9SWBPQ1fMabB8i/lTBGmc7Fzn0oAjVS3/wBantCxAzya0rdE8sfKv5VMEXH3V6HtQBi+ScZJOKikiCtzxXQeWm0fIvbtVK4jTcBsXHPb3oAyCBjA6/ypgTrzz3rSZEyflX8qBGnzfIvT0oAzyABgCmkcjArTMaY+4vT0pBGnHyL+VAGXsyOMUFO3f1rWaNP7i/lTfLTP3F6elAGYEyT9KQKQeSOOma0gif3V/KkaNNw+RfyoAy2HfNCrkdM1ovGmPuL19KFjTafkX8qAKEack1dtVOQAdpNSBE/ur19Kt28aZPyL09KANjRrMysrMB5a9jXWQYAHYKAee/4VW0dE+yJ8q/c9K1Aq5Hyjp6UAXdJjLzIBxuq3qMgMrsxGEz2yf/11PoiL5+Nox9PajVFURS4Uct6UAcneTMx3EEn3qmcp0GSR19K2Z0TkbVxgdqrlF8snauSPT2oApRDGfu4I/GgEkHPTse9W4kXax2jr6VLbRoc5RTz6UALp1tuTzZFwv8Iq6ThzkD885q3Iqhkwo/Km7F2H5R09KAIVwFIJIPpQrYP3MDHSrSouM7R19KYEQryq9fSgCqGwgKjoMn1qrLIfTGD61oqBufgdDVFlXb90fdPb3oAyp5yZGAOep/8ArVhXD726/nW/Mil+VH5VlSouU+VfvelAGQTmUdTggc96K0ERCxBVcbh2ooA//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bilateral sacroiliitis grade 3 with widening and sclerosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Xenofon Baraliakos, Rheumazentrum Ruhrgebiet, Herne, Germany.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_34_35362=[""].join("\n");
var outline_f34_34_35362=null;
var title_f34_34_35363="Patient information: Lung cancer (The Basics)";
var content_f34_34_35363=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15416\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/17/41237\">",
"         Normal lungs",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?36/16/37121\">",
"         Patient information: What are clinical trials? (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?27/34/28195\">",
"         Patient information: Chronic cough in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?32/14/32993\">",
"         Patient information: Flexible bronchoscopy (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?5/28/5570\">",
"         Patient information: Lung cancer prevention and screening (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?1/3/1076\">",
"         Patient information: Lung cancer risks, symptoms, and diagnosis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?40/22/41314\">",
"         Patient information: Non-small cell lung cancer treatment; stage I to III cancer (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?16/63/17396\">",
"         Patient information: Non-small cell lung cancer treatment; stage IV cancer (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?19/13/19670\">",
"         Patient information: Quitting smoking (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?22/8/22659\">",
"         Patient information: Small cell lung cancer treatment (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Lung cancer (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/lung-cancer-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H455976196\">",
"      <span class=\"h1\">",
"       What is lung cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Lung cancer happens when normal cells in the lungs change into abnormal cells and grow out of control (",
"      <a class=\"graphic graphic_figure graphicRef67527 \" href=\"mobipreview.htm?40/17/41237\">",
"       figure 1",
"      </a>",
"      ). There are different types of lung cancer. Some types grow much faster than others.",
"     </p>",
"     <p>",
"      In the United States, lung cancer is the biggest cause of deaths from cancer in men and women.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H455976203\">",
"      <span class=\"h1\">",
"       What are the symptoms of lung cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Common symptoms of lung cancer can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Cough",
"       </li>",
"       <li>",
"        Trouble breathing, or wheezing",
"       </li>",
"       <li>",
"        Spitting or coughing up blood",
"       </li>",
"       <li>",
"        Chest pain that can be dull, sharp, or stabbing",
"       </li>",
"       <li>",
"        Hoarse voice",
"       </li>",
"       <li>",
"        Headache and swelling of the face, arms, or neck",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If the cancer is growing in the top part of the lungs, it can also cause:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Pain in the arm, shoulder, or neck",
"       </li>",
"       <li>",
"        Droopy eyelid or blurred vision",
"       </li>",
"       <li>",
"        Weakness of the hand muscles",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      All of these symptoms can also be caused by conditions that are not lung cancer. But if you have these symptoms, you should let your doctor or nurse know.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H455976210\">",
"      <span class=\"h1\">",
"       Is there a test for lung cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If your doctor suspects that you have lung cancer, she or she will do an exam and a chest X-ray. If the chest X-ray shows a spot that looks like it could be cancer, he or she will probably follow up with other tests. These can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        CT scan &mdash; This test creates images of the inside of your body and can show abnormal growths.",
"       </li>",
"       <li>",
"        Biopsy &ndash; A doctor will remove a small sample of tissue from the lung. He or she will look at the sample under a microscope to see if it has cancer.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H455976217\">",
"      <span class=\"h1\">",
"       What is lung cancer staging?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Cancer staging is a way in which doctors find out how far a cancer has spread.",
"     </p>",
"     <p>",
"      The right treatment for you will depend, in part, on the stage of your lung cancer. Your treatment will also depend on the type of lung cancer you have, your age, and your other health problems.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H455976224\">",
"      <span class=\"h1\">",
"       How is lung cancer treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most people with lung cancer have one or more of the following treatments:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Surgery",
"        </strong>",
"        &mdash; Lung cancer can sometimes be treated with surgery to remove the cancer.",
"       </li>",
"       <li>",
"        <strong>",
"         Radiation therapy",
"        </strong>",
"        &mdash; Radiation kills cancer cells.",
"       </li>",
"       <li>",
"        <strong>",
"         Chemotherapy",
"        </strong>",
"        &mdash; Chemotherapy is the term doctors use to describe a group of medicines that kills cancer cells.",
"       </li>",
"       <li>",
"        <strong>",
"         Targeted therapy",
"        </strong>",
"        &mdash; Some medicines work only for cancers that have certain characteristics. Your doctor might test you to see if you have a kind of lung cancer that would respond to these medicines.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      People with lung cancer also receive treatment for any symptoms they have. For example, if you have trouble breathing because fluid has collected around your lungs, your doctor can drain the fluid to help you breathe more easily.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H455976231\">",
"      <span class=\"h1\">",
"       What happens after treatment?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After treatment, you will be checked every so often to see if the lung cancer comes back. Follow up tests usually include exams, chest X-rays, or CT scans. You should also watch for the symptoms listed above, because having those symptoms could mean the cancer has come back. Tell your doctor or nurse if you have any symptoms.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H455976238\">",
"      <span class=\"h1\">",
"       What happens if the lung cancer comes back?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If the lung cancer comes back, you might have more chemotherapy, radiation, or surgery.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H455976245\">",
"      <span class=\"h1\">",
"       Can lung cancer be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Maybe. The best way to avoid getting lung cancer is to not smoke. People who smoke have a much higher chance than those who don&rsquo;t smoke of getting lung cancer. If you smoke, you can reduce your chance of getting lung cancer by quitting smoking.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H455976252\">",
"      <span class=\"h1\">",
"       What else should I do?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It is important to follow all your doctors&rsquo; instructions about visits and tests. It&rsquo;s also important to talk to your doctor about any side effects or problems you have during treatment.",
"     </p>",
"     <p>",
"      Getting treated for lung cancer involves making many choices, such as what treatment to have and when.",
"     </p>",
"     <p>",
"      Always let your doctors and nurses know how you feel about a treatment. Any time you are offered a treatment, ask:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        What are the benefits of this treatment? Is it likely to help me live longer? Will it reduce or prevent symptoms?",
"       </li>",
"       <li>",
"        What are the downsides to this treatment?",
"       </li>",
"       <li>",
"        Are there other options besides this treatment?",
"       </li>",
"       <li>",
"        What happens if I do not have this treatment?",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H455976259\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/16/37121?source=see_link\">",
"       Patient information: What are clinical trials? (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/3/1076?source=see_link\">",
"       Patient information: Lung cancer risks, symptoms, and diagnosis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/34/28195?source=see_link\">",
"       Patient information: Chronic cough in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?32/14/32993?source=see_link\">",
"       Patient information: Flexible bronchoscopy (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?40/22/41314?source=see_link\">",
"       Patient information: Non-small cell lung cancer treatment; stage I to III cancer (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?16/63/17396?source=see_link\">",
"       Patient information: Non-small cell lung cancer treatment; stage IV cancer (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?22/8/22659?source=see_link\">",
"       Patient information: Small cell lung cancer treatment (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?5/28/5570?source=see_link\">",
"       Patient information: Lung cancer prevention and screening (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/13/19670?source=see_link\">",
"       Patient information: Quitting smoking (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?34/34/35363?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15416 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-2345798AF2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_34_35363=[""].join("\n");
var outline_f34_34_35363=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H455976196\">",
"      What is lung cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H455976203\">",
"      What are the symptoms of lung cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H455976210\">",
"      Is there a test for lung cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H455976217\">",
"      What is lung cancer staging?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H455976224\">",
"      How is lung cancer treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H455976231\">",
"      What happens after treatment?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H455976238\">",
"      What happens if the lung cancer comes back?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H455976245\">",
"      Can lung cancer be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H455976252\">",
"      What else should I do?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H455976259\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15416\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/17/41237\">",
"      Normal lungs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/34/28195?source=related_link\">",
"      Patient information: Chronic cough in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?32/14/32993?source=related_link\">",
"      Patient information: Flexible bronchoscopy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?5/28/5570?source=related_link\">",
"      Patient information: Lung cancer prevention and screening (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/3/1076?source=related_link\">",
"      Patient information: Lung cancer risks, symptoms, and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?40/22/41314?source=related_link\">",
"      Patient information: Non-small cell lung cancer treatment; stage I to III cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?16/63/17396?source=related_link\">",
"      Patient information: Non-small cell lung cancer treatment; stage IV cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/13/19670?source=related_link\">",
"      Patient information: Quitting smoking (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?22/8/22659?source=related_link\">",
"      Patient information: Small cell lung cancer treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/16/37121?source=related_link\">",
"      Patient information: What are clinical trials? (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_34_35364="Sites of acute osteomyelitis in children";
var content_f34_34_35364=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F61415&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F61415&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 561px\">",
"   <div class=\"ttl\">",
"    Sites of involvement in acute hematogenous osteomyelitis in children",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 541px; height: 551px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Tubular bones are affected more frequently than nontubular (flat) bones or spine.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_34_35364=[""].join("\n");
var outline_f34_34_35364=null;
var title_f34_34_35365="Ciclesonide (oral inhalation): Patient drug information";
var content_f34_34_35365=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ciclesonide (oral inhalation): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/5/34902?source=see_link\">",
"     see \"Ciclesonide (oral inhalation): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/26/22949?source=see_link\">",
"     see \"Ciclesonide (oral inhalation): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8002707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Alvesco&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8002711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Alvesco&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10030309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700842",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       When changing from an oral steroid to a breathed in one, there may be very bad and sometimes deadly side effects. Signs like weakness, feeling tired, dizziness, upset stomach, throwing up, not thinking clearly, or low blood sugar may happen. Call your doctor right away if you have any of these signs. If you have a bad injury, have surgery, or any type of infection, you may need extra doses of oral steroids. These extra steroids will help your body deal with these stresses. Carry a warning card saying that there may be times when you may need extra steroids.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10030311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691735",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat asthma.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10030310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701801",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ciclesonide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701052",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are having a breathing attack.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701378",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a bad infection.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10030315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696945",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use this drug to treat an asthma attack.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696653",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid being near anyone with chickenpox or measles.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697224",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma or cataracts, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have soft, brittle bones (osteoporosis), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697345",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have TB (tuberculosis), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10030316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nose stuffiness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698350",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sore throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698238",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mouth infection.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697932",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cataracts or glaucoma with long-term use.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10030318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698659",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired, weak, or touchy; trembling; having a fast heartbeat, confusion, sweating, or dizziness if you missed a dose or recently stopped this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699035",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad mouth irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698964",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor right away if your normal dose does not work as well or if you need to use your inhaler more often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698962",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       More asthma attacks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10030313\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694896",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For breathing in only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3696742",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Prime puffer (inhaler) before first use or if not used for more than 1 week by spraying it 3 times.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695599",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Rinse out mouth after each use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694373",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A spacer may be used with the puffer (inhaler) for easy use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695184",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are using a puffer (inhaler), wait 10 minutes before using this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694584",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check your spray use with your doctor at each visit. Read and follow the facts on how to use the spray. Make sure you use the spray the right way.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10030314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10030319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10030320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11578 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-D3C9B8B2AC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_34_35365=[""].join("\n");
var outline_f34_34_35365=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8002707\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8002711\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030309\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030311\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030310\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030315\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030316\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030318\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030313\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030314\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030319\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030320\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?34/25/35220?source=related_link\">",
"      Ciclesonide (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?26/37/27221?source=related_link\">",
"      Ciclesonide (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?3/33/3604?source=related_link\">",
"      Ciclesonide (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?34/5/34902?source=related_link\">",
"      Ciclesonide (oral inhalation): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/26/22949?source=related_link\">",
"      Ciclesonide (oral inhalation): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_34_35366="Histology case 5 with answer";
var content_f34_34_35366=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F68860&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F68860&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 521px\">",
"   <div class=\"ttl\">",
"    Histology case 5 with answer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 501px; height: 241px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The cause of the nephrotic syndrome in this patient is",
"    <strong>",
"     collapsing glomerulopathy",
"    </strong>",
"    , most likely due to HIV infection. Light microscopy (panel A) reveals collapse of the glomerular tuft, segmental sclerosis, and few open loops. The electron micrograph in panel B shows numerous intraendothelial tubuloreticular structures (arrow). These structures are suggestive of HIV infection and are not seen in the idiopathic form of collapsing glomerulopathy. The short duration of diabetes indicated that the nephrosis was not due to diabetic nephropathy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_34_35366=[""].join("\n");
var outline_f34_34_35366=null;
var title_f34_34_35367="Chemoprevention of bladder cancer";
var content_f34_34_35367=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chemoprevention of bladder cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/34/35367/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/34/35367/contributors\">",
"     Juan Antonio Jimenez, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/34/35367/contributors\">",
"     Steven C Campbell, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/34/35367/contributors\">",
"     J Stephen Jones, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/34/35367/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/34/35367/contributors\">",
"     Jerome P Richie, MD, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/34/35367/contributors\">",
"     Seth P Lerner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/34/35367/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/34/35367/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/34/35367/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bladder cancer, the most common malignancy of the urinary tract, is diagnosed in more than 60,000 persons each year in the United States. Thus, it is the fourth most common malignancy in men and the ninth most common malignancy in women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35367/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The majority of cases of bladder cancer can be attributed to smoking and occupational and environmental carcinogen exposures, which cause diffuse changes in the urothelium and eventually result in bladder cancer. The identification of these risk factors provides an opportunity to minimize the incidence of bladder cancer by smoking cessation programs and decreasing exposure to workplace carcinogens. Other potentially useful approaches include increasing fluid intake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35367/abstract/3\">",
"     3",
"    </a>",
"    ] and decreasing dietary fat and cholesterol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35367/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/61/26586?source=see_link&amp;anchor=H6#H6\">",
"     \"Epidemiology and etiology of urothelial (transitional cell) carcinoma of the bladder\", section on 'Etiology and risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chemoprevention is the use of various systemic agents to prevent or reverse these changes. Primary chemoprevention seeks to block the formation of de novo bladder cancers in healthy individuals, while secondary chemoprevention focuses on avoiding formation of additional tumors in patients who have already been treated for bladder cancer.",
"   </p>",
"   <p>",
"    The chemoprevention of bladder cancer with systemic agents is reviewed here, with the focus primarily on agents for which epidemiologic or clinical trial data are available. The use of intravesical agents to prevent the recurrence of non-muscle-invasive bladder cancer is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/11/40122?source=see_link&amp;anchor=H18#H18\">",
"     \"Treatment of non-muscle-invasive bladder cancer\", section on 'Intravesical therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RATIONALE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Field carcinogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bladder cancer is thought to be initiated by chemical carcinogens that damage DNA in the transitional cell epithelium. These carcinogens are excreted in the urine and temporarily stored in the bladder, where they have an extended opportunity to interact with the urothelium. The gradual accumulation of chromosomal damage in the transitional cells eventually results in phenotypic expression and transformation into overt neoplasm.",
"   </p>",
"   <p>",
"    The premalignant and malignant changes in the urothelium can develop throughout the area of epithelium that is chronically exposed to environmental carcinogens, a process referred to as \"field carcinogenesis\". Within this area, cancer can develop from multiple clones. Effective chemopreventive agents can potentially act by preventing the initial damage, enhancing repair, or blocking specific neoplastic processes such as angiogenesis and invasion that are involved in the transformation into invasive bladder cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Molecular pathways",
"    </span>",
"    &nbsp;&mdash;&nbsp;The carcinogens that are associated with bladder cancer form highly reactive electrophilic species that bind nucleic acid and induce structural mutations. The observed changes include allelic deletions or loss of heterozygosity, inactivation of tumor suppressor genes, or activation of protooncogenes, and may vary in different cells. The molecular mechanisms and pathways associated with the development of bladder cancer are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/61/26586?source=see_link\">",
"     \"Epidemiology and etiology of urothelial (transitional cell) carcinoma of the bladder\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Target population",
"    </span>",
"    &nbsp;&mdash;&nbsp;Effective bladder cancer chemoprevention is facilitated by the identification of appropriate target populations. The identification of risk factors for bladder cancer (eg, tobacco use, exposure to chemical carcinogens) identifies populations for whom primary chemoprevention may be of special utility. The known high rate of relapse after the diagnosis and treatment of early stage bladder cancer allows the identification of a separate population for whom secondary chemoprevention may be valuable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CHEMOPREVENTIVE AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemopreventive agents can work either by blocking the effects of carcinogens or by suppressing the neoplastic process following its initiation. The agents that have been most widely considered for chemoprevention of bladder cancer include vitamins, micronutrients, and various synthetic compounds. None of these agents currently has an established role in either primary or secondary chemoprevention, although some data are suggestive.",
"   </p>",
"   <p>",
"    The rationale and available data for the most widely evaluated agents will be reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Retinoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retinoids (vitamin A compounds) are known modulators of differentiation and proliferation in epithelial cells and can serve as potent inhibitors of neoplastic transformation. Laboratory studies demonstrated that rats deficient in vitamin A are more susceptible to environmentally induced bladder carcinogenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35367/abstract/6\">",
"     6",
"    </a>",
"    ] and that retinoid supplements could prevent carcinogen-induced bladder cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35367/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. Despite these laboratory data, epidemiologic and clinical trial data have not established a role for retinoids for either primary or secondary chemoprevention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Primary chemoprevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of retinoids in the primary prevention of bladder cancer has been investigated in epidemiologic studies and a large clinical trial. The conflicting results of these studies are illustrated by the following studies.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One case-control series of 1592 persons with bladder cancer and an equal number of controls found that a high dietary intake of vitamin A and vitamin C was associated with a significant decrease in the incidence of bladder cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/34/35367/abstract/10\">",
"       10",
"      </a>",
"      ]. Subset analysis revealed that this benefit was restricted to smokers. Similarly, another case-control study in 569 bladder cancer patients and 1025 matched controls found that lower levels of vitamin A consumption were associated with an increased risk of bladder cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/34/35367/abstract/11\">",
"       11",
"      </a>",
"      ]. Despite these findings, a meta-analysis that included six case control studies could not confirm these observations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/34/35367/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Two studies evaluated plasma levels of carotenoids in bladder cancer patients and matched controls. The smaller of these (84 cases, 173 controls) suggested that higher circulating carotenoid levels were associated with a decreased risk of bladder cancer, a finding that was more pronounced in smokers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/34/35367/abstract/12\">",
"       12",
"      </a>",
"      ]. The second study (386 cases, 389 controls) found a protective effect with higher vitamin A (retinol) and vitamin E (alpha-tocopherol) levels and that the magnitude of this effect appeared to be directly correlated to vitamin levels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/34/35367/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An analysis of dietary intake of vitamin A and other vitamins by subjects in the Alpha-Tocopherol,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/50/21283?source=see_link\">",
"       Beta-Carotene",
"      </a>",
"      Study (ATBC Study) found no relationship between the intake of retinoids and subsequent development of bladder cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/34/35367/abstract/14\">",
"       14",
"      </a>",
"      ]. Similarly, a cohort study of over 120,000 persons in the Netherlands could not identify an association between the risk of bladder cancer and dietary intake of various vitamins, including vitamin A.",
"     </li>",
"     <li>",
"      The use of a vitamin A precursor (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/50/21283?source=see_link\">",
"       beta-carotene",
"      </a>",
"      ) for primary chemoprevention was directly evaluated in the ATBC Study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/34/35367/abstract/15\">",
"       15",
"      </a>",
"      ]. In this trial more than 29,000 male smokers in Finland were randomly assigned to receive either beta-carotene, alpha-tocopherol (a vitamin E precursor), both, or placebo. At a median follow-up of 6.1 years, there were no statistically significant differences in the number of new cases of bladder cancer in the four treatment groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Secondary chemoprevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of various retinoids for secondary chemoprevention has been assessed in several small trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35367/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. In the largest trial, 137 patients with resected superficial bladder cancer were randomly assigned to fenretinide or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35367/abstract/16\">",
"     16",
"    </a>",
"    ]. The risk of recurrence at one year did not differ significantly between the two treatment arms (32 percent in both groups). Two smaller trials, evaluating etretinate and fenretinide, also failed to demonstrate a benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35367/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Pyridoxine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pyridoxine (vitamin B6) has been recommended as a means to counteract abnormalities in tryptophan metabolism that are observed in patients with bladder cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35367/abstract/19\">",
"     19",
"    </a>",
"    ]. Despite this rationale, two randomized clinical trials investigating the use of pyridoxine for secondary bladder cancer chemoprevention have not provided evidence of a useful chemopreventive effect.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an initial trial conducted by the Veteran's Administration, 121 patients with stage I bladder cancer were randomly assigned to oral pyridoxine, placebo, or intravesical",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35414?source=see_link\">",
"       thiotepa",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/34/35367/abstract/20\">",
"       20",
"      </a>",
"      ]. The percentage of patients with recurrence was not significantly different among the three arms, although pyridoxine was better than placebo if recurrences during the first 10 months were excluded from the analysis.",
"     </li>",
"     <li>",
"      Based upon these suggestive results, the European Organization for Research and Treatment of Cancer (EORTC) organized a larger trial, in which 291 men with previously treated superficial bladder cancer were randomly assigned to pyridoxine or placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/34/35367/abstract/21\">",
"       21",
"      </a>",
"      ]. The use of pyridoxine had no significant effect on the time to first recurrence or the overall recurrence rate, even after adjusting for urinary levels of tryptophan metabolites.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Vitamin C",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin C (ascorbic acid) is a reducing agent that acts as a free radical scavenger; in particular, vitamin C decreases the formation of N-nitroso chemicals that are associated with bladder cancer carcinogenesis. Despite this, high levels of sodium ascorbate have increased the incidence of bladder cancer in rats [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35367/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The epidemiologic data assessing the relationship between bladder cancer and vitamin C intake are conflicting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a cohort of 11,580 cancer-free elderly subjects followed over an eight year period, an inverse association was observed between the use of vitamin C supplements and the incidence of bladder cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/34/35367/abstract/23\">",
"       23",
"      </a>",
"      ]. Two case control series also suggested that vitamin C might offer some protection against bladder cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/34/35367/abstract/24,25\">",
"       24,25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, the prospective Cancer Prevention Study II failed to identify any benefit from the use of vitamin C in a cohort of over 990,000 people followed for up to 16 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/34/35367/abstract/26\">",
"       26",
"      </a>",
"      ]. The use of vitamin C supplements &ge;15 times per month was not associated with a decrease in bladder cancer mortality. Similarly, a dietary analysis of patients enrolled in the ATBC study failed to identify any protective effect associated with increased levels of vitamin C intake [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/34/35367/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Alpha tocopherol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alpha tocopherol (vitamin E) is an antioxidant and inhibits N-nitroso formation in vitro. These observations provide a rationale for alpha tocopherol's use in preventing urothelial transformation.",
"   </p>",
"   <p>",
"    Epidemiologic data suggest that diets high in alpha tocopherol are associated with a lower risk of bladder cancer, but clinical trials have not confirmed a benefit for dietary supplements with this agent.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A study of 386 bladder cancer cases compared plasma levels of vitamin A and vitamin E with 389 controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/34/35367/abstract/13\">",
"       13",
"      </a>",
"      ]. A potential protective effect was seen for patients with higher vitamin A and higher vitamin E levels separately. Furthermore, the strength of this effect increased with increasing plasma levels of the vitamins, suggesting a dose-dependent relationship might be at work. However, all levels were collected after cancer diagnosis and smoking as well as unknown dietary confounders may have influenced the results.",
"     </li>",
"     <li>",
"      The Health Professionals Follow-up Study, a prospective cohort of 51,529 men, analyzed the relationship between intakes of various macro- and micronutrients and the risk of bladder cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/34/35367/abstract/27\">",
"       27",
"      </a>",
"      ]. Total vitamin E intake and vitamin E supplements were inversely associated with risk. In addition, a dose-response relation was observed for duration of vitamin E supplement use.",
"     </li>",
"     <li>",
"      In the Cancer Prevention Study II, regular vitamin E supplementation for more than ten years was associated with a reduced risk of bladder cancer mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/34/35367/abstract/26\">",
"       26",
"      </a>",
"      ]. This finding was more pronounced in ex-smokers and current smokers than in nonsmokers, suggesting some protection from carcinogens associated with smoking. Use for shorter periods of time was not associated with a reduction in disease-specific mortality.",
"     </li>",
"     <li>",
"      In contrast to these epidemiologic studies, the ATBC trial did not demonstrate a reduction in bladder cancer risk with vitamin E supplementation. In this trial, over 29,000 male smokers were randomly assigned to alpha tocopherol,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/50/21283?source=see_link\">",
"       beta-carotene",
"      </a>",
"      , both, or placebo. There were no statistically significant differences in the incidence of bladder cancer between the groups [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/34/35367/abstract/15\">",
"       15",
"      </a>",
"      ]. However, the dose of alpha tocopherol used in this trial was lower than that of typical daily supplements (50 versus 200 to 1000 international units). Although this trial did not demonstrate any benefit from vitamin E supplements, it remains possible that higher doses would be beneficial.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Multivitamins",
"    </span>",
"    &nbsp;&mdash;&nbsp;The theoretical benefits of vitamin supplementation for cancer prevention led to the idea that a combination of vitamins might prove more powerful than any single nutrient. A possible role for multivitamins in primary bladder cancer chemoprevention was suggested by a case control study that included 262 patients and 405 controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35367/abstract/25\">",
"     25",
"    </a>",
"    ]. The daily use of multivitamin supplements for more than ten years was associated with a decrease in the risk of bladder cancer (OR 0.39, 95% CI 0.24 - 0.63).",
"   </p>",
"   <p>",
"    In contrast, the Health Professionals Follow-up Study did not identify an association between bladder cancer risk and the intake of various micronutrients including water soluble vitamins, other than vitamin E&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35367/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Alpha tocopherol'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A possible role of multivitamins in secondary chemoprevention was suggested by a prospective trial in which 65 patients treated for non-invasive bladder cancer were treated with intravesical BCG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35367/abstract/28\">",
"     28",
"    </a>",
"    ]. Patients were randomly assigned to a recommended daily allowance (RDA) multi-vitamin or to a megadose vitamin with augmented levels of vitamins A, B6, C, E, and zinc. Although there was no difference between the two regimens in the first year, patients receiving the megadose vitamin had a statistically significant lower rate of recurrence at five years (41 versus 91 percent with the RDA supplement).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Difluoromethylornithine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polyamine synthesis is associated with the induction of urothelial (transitional cell) cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35367/abstract/29\">",
"     29",
"    </a>",
"    ]. Difluoromethylornithine (DFMO) irreversibly inhibits ornithine decarboxylase, an enzyme that is required for polyamine synthesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35367/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    DFMO was evaluated as a chemopreventive agent in a randomized trial in which 454 patients with newly diagnosed or recurrent superficial bladder cancer were randomly assigned to treatment with DFMO or placebo for one year following resection of their bladder cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35367/abstract/30\">",
"     30",
"    </a>",
"    ]. At a median follow-up of 42 months, DFMO did not decrease the incidence of tumor recurrence (46 versus 43 percent with placebo), nor were any benefits observed in terms of the number of patients with progression to TIS or grade 3 disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Nonsteroidal antiinflammatory drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cyclooxygenases catalyze the synthesis of prostaglandins from arachidonic acid. The effects of prostaglandin synthesis may include increased angiogenesis, inhibition of apoptosis, and decreased immune surveillance, all of which may contribute to carcinogenesis. Cyclooxygenase-2 (COX-2) is typically upregulated in cancer and most inflammatory conditions.",
"   </p>",
"   <p>",
"    COX-2 overexpression may increase the activation of many carcinogens, including aromatic amines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35367/abstract/31\">",
"     31",
"    </a>",
"    ]. COX-2 is expressed in a high percentage of carcinoma in situ and T1 tumors, suggesting that its upregulation is an early event in tumorigenesis in the bladder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35367/abstract/32\">",
"     32",
"    </a>",
"    ]. The degree of COX-2 expression appears to be increased with higher stage and grade [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35367/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Laboratory studies of bladder cancer cell lines treated with COX-2 inhibitors have demonstrated dose-dependent growth inhibition as well as apoptosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35367/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Animal studies also indicate that COX-2 inhibition may deter bladder cancer growth, specifically when used in combination with intravesical chemotherapy such as Bacillus Calmette-Guerin therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35367/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potential role of cyclooxygenase inhibition in humans was illustrated by a population-based case control study of 1514 bladder cancer patients and an equal number of matched controls, who were surveyed regarding their use of nonsteroidal antiinflammatory drugs (NSAIDs). Regular NSAID users had a 20 percent lower incidence of bladder cancer when compared to irregular users or non-users [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35367/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/11/40120?source=see_link\">",
"     Celecoxib",
"    </a>",
"    , a selective COX-2 inhibitor, significantly decreases the number of bladder cancers that develop in rats in response to known carcinogens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35367/abstract/38\">",
"     38",
"    </a>",
"    ]. Furthermore, celecoxib retained its ability to inhibit carcinogenesis even when it was administered after the carcinogen. Based upon this rationale, celecoxib is being assessed in a phase",
"    <span class=\"nowrap\">",
"     IIB/III",
"    </span>",
"    trial in patients with urothelial cancer of the bladder, to see whether treatment with this agent can delay or prevent recurrences.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Selenium",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/37/13907?source=see_link\">",
"     Selenium",
"    </a>",
"    is required for the activity of a glutathione peroxidase, which converts lipid hydroperoxides into nontoxic alcohols and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    into water and oxygen. Glutathione peroxidase may also provide a direct protective effect against carcinogens in the bladder by neutralizing their oxidative potential.",
"   </p>",
"   <p>",
"    Several large studies correlating the incidence of bladder cancer and serum",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    levels (or toenail concentrations, a surrogate measure of selenium intake during the previous 12 months) have yielded conflicting results. A large cohort study from the Netherlands reported an inverse correlation between toenail concentrations of selenium and the risk of bladder cancer, with the effect being more pronounced in those with invasive bladder cancer and in ex-smokers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35367/abstract/39\">",
"     39",
"    </a>",
"    ]. A Belgian case-control study of 178 cases and 362 controls examining serum selenium levels supported these findings. Patients were divided into tertiles by selenium levels, and the middle and highest groups demonstrated significantly decreased risk of bladder cancer compared to the lowest group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35367/abstract/40\">",
"     40",
"    </a>",
"    ]. A Turkish case-control study of serum selenium levels showed that those with grades 2 to 3 bladder cancer had lower levels than those with grade 1 cancers or normal controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35367/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, the Nurses' Health Study reported that women who developed bladder cancer actually had higher levels of toenail",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    than the control population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35367/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Isoflavones",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isoflavones are natural substances derived from soy protein that are excreted in the urine. A reduced risk of breast, colon, and prostate cancers has been observed in populations with higher levels of soy consumption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35367/abstract/43\">",
"     43",
"    </a>",
"    ]. In addition, animal experiments indicate that soy protein diets have a protective effect against bladder carcinogenesis, and cell cycle studies show that these agents can induce apoptosis in immortalized bladder cancer cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35367/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The limited available evidence does not support a chemoprotective effect from soy protein or isoflavone supplementation on bladder cancer in men. An epidemiologic study from China reported a higher risk of bladder cancer with increased dietary soy intake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35367/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Polyphenols",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polyphenols are powerful antioxidant compounds that are found in green tea. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/13/40154?source=see_link&amp;anchor=H10#H10\">",
"     \"Complementary and alternative therapies for cancer\", section on 'Green tea'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Animal studies have shown that green tea leaves inhibit carcinogen-induced bladder tumor growth in a dose-dependent manner. Epidemiologic studies for a variety of human cancers suggest that high levels of green tea consumption may reduce the risk for bladder cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35367/abstract/46\">",
"     46",
"    </a>",
"    ]. These preclinical and epidemiological data have provided the rationale for the evaluation of a green tea extract in an ongoing randomized phase II trial in patients with resected superficial urothelial cancer of the bladder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     EGFR inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The epidermal growth factor receptor (EGFR) pathway is upregulated in several types of cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35367/abstract/47\">",
"     47",
"    </a>",
"    ], and EGFR is overexpressed in advanced stage urothelial cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35367/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The development of specific inhibitors of the EGFR tyrosine kinase, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/12/19654?source=see_link\">",
"     gefitinib",
"    </a>",
"    , has led to the evaluation of these agents for the chemoprevention of bladder cancer. A phase II placebo-controlled trial is underway assessing the role of erlotinib in former smokers with resected superficial urothelial cancer of the bladder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Oltipraz",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oltipraz is an antischistosomal agent that induces the cytochrome P450 pathway, thus potentially detoxifying carcinogens that could affect the bladder epithelium. Animal model data support a possible role for this approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35367/abstract/49,50\">",
"     49,50",
"    </a>",
"    ], but there are no clinical data in man.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Etiologic risk factors for bladder cancer include smoking and various environmental and occupational carcinogens. These substances are concentrated in the urine, where the urothelial lining is exposed to their carcinogenic effects. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Rationale'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A number of substances have been assessed for their ability to prevent de novo bladder cancer (primary chemoprevention) or recurrence after an earlier diagnosis (secondary chemoprevention). Several of these agents have been extensively evaluated including the retinoids (vitamin A derivatives), pyridoxine (vitamin B6), alpha tocopherol (vitamin E), ascorbic acid, and difluoromethylornithine. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Chemopreventive agents'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Although some of the data supporting these agents is suggestive, no role has been established for any of these agents in either primary or secondary chemoprevention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35367/abstract/51\">",
"     51",
"    </a>",
"    ]. Additional studies continue with these and other agents.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35367/abstract/1\">",
"      Sporn MB, Dunlop NM, Newton DL, Smith JM. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc 1976; 35:1332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35367/abstract/2\">",
"      Chan AT, Giovannucci EL, Meyerhardt JA, et al. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA 2005; 294:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35367/abstract/3\">",
"      Michaud DS, Spiegelman D, Clinton SK, et al. Fluid intake and the risk of bladder cancer in men. N Engl J Med 1999; 340:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35367/abstract/4\">",
"      Steinmaus CM, Nu&ntilde;ez S, Smith AH. Diet and bladder cancer: a meta-analysis of six dietary variables. Am J Epidemiol 2000; 151:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35367/abstract/5\">",
"      Steineck G, Hagman U, Gerhardsson M, Norell SE. Vitamin A supplements, fried foods, fat and urothelial cancer. A case-referent study in Stockholm in 1985-87. Int J Cancer 1990; 45:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35367/abstract/6\">",
"      Cohen SM, Wittenberg JF, Bryan GT. Effect of avitaminosis A and hypervitaminosis A on urinary bladder carcinogenicity of N-(4-(5-Nitro-2-furyl)-2-thiazolyl)formamide. Cancer Res 1976; 36:2334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35367/abstract/7\">",
"      Sporn MB, Squire RA, Brown CC, et al. 13-cis-retinoic acid: inhibition of bladder carcinogenesis in the rat. Science 1977; 195:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35367/abstract/8\">",
"      Becci PJ, Thompson HJ, Grubbs CJ, et al. Inhibitory effect of 13-cis-retinoic acid on urinary bladder carcinogenesis induced in C57BL/6 mice by N-butyl-N-(4-hydroxybutyl)-nitrosamine. Cancer Res 1978; 38:4463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35367/abstract/9\">",
"      Mathews-Roth MM, Lausen N, Drouin G, et al. Effects of carotenoid administration on bladder cancer prevention. Oncology 1991; 48:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35367/abstract/10\">",
"      Castelao JE, Yuan JM, Gago-Dominguez M, et al. Carotenoids/vitamin C and smoking-related bladder cancer. Int J Cancer 2004; 110:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35367/abstract/11\">",
"      Mettlin C, Graham S. Dietary risk factors in human bladder cancer. Am J Epidemiol 1979; 110:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35367/abstract/12\">",
"      Hung RJ, Zhang ZF, Rao JY, et al. Protective effects of plasma carotenoids on the risk of bladder cancer. J Urol 2006; 176:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35367/abstract/13\">",
"      Liang D, Lin J, Grossman HB, et al. Plasma vitamins E and A and risk of bladder cancer: a case-control analysis. Cancer Causes Control 2008; 19:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35367/abstract/14\">",
"      Michaud DS, Pietinen P, Taylor PR, et al. Intakes of fruits and vegetables, carotenoids and vitamins A, E, C in relation to the risk of bladder cancer in the ATBC cohort study. Br J Cancer 2002; 87:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35367/abstract/15\">",
"      Virtamo J, Edwards BK, Virtanen M, et al. Effects of supplemental alpha-tocopherol and beta-carotene on urinary tract cancer: incidence and mortality in a controlled trial (Finland). Cancer Causes Control 2000; 11:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35367/abstract/16\">",
"      Sabichi AL, Lerner SP, Atkinson EN, et al. Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer. Clin Cancer Res 2008; 14:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35367/abstract/17\">",
"      Studer UE, Jenzer S, Biedermann C, et al. Adjuvant treatment with a vitamin A analogue (etretinate) after transurethral resection of superficial bladder tumors. Final analysis of a prospective, randomized multicenter trial in Switzerland. Eur Urol 1995; 28:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35367/abstract/18\">",
"      Decensi A, Torrisi R, Bruno S, et al. Randomized trial of fenretinide in superficial bladder cancer using DNA flow cytometry as an intermediate end point. Cancer Epidemiol Biomarkers Prev 2000; 9:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35367/abstract/19\">",
"      Yoshida O, Brown RR, Bryan GT. Relationship between tryptophan metabolism and heterotopic recurrences of human urinary bladder tumors. Cancer 1970; 25:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35367/abstract/20\">",
"      Byar D, Blackard C. Comparisons of placebo, pyridoxine, and topical thiotepa in preventing recurrence of stage I bladder cancer. Urology 1977; 10:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35367/abstract/21\">",
"      Newling DW, Robinson MR, Smith PH, et al. Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective, randomised phase III study performed by the EORTC GU Group. EORTC Genito-Urinary Tract Cancer Cooperative Group. Eur Urol 1995; 27:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35367/abstract/22\">",
"      Fukushima S, Imaida K, Sakata T, et al. Promoting effects of sodium L-ascorbate on two-stage urinary bladder carcinogenesis in rats. Cancer Res 1983; 43:4454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35367/abstract/23\">",
"      Shibata A, Paganini-Hill A, Ross RK, Henderson BE. Intake of vegetables, fruits, beta-carotene, vitamin C and vitamin supplements and cancer incidence among the elderly: a prospective study. Br J Cancer 1992; 66:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35367/abstract/24\">",
"      Nomura AM, Kolonel LN, Hankin JH, Yoshizawa CN. Dietary factors in cancer of the lower urinary tract. Int J Cancer 1991; 48:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35367/abstract/25\">",
"      Bruemmer B, White E, Vaughan TL, Cheney CL. Nutrient intake in relation to bladder cancer among middle-aged men and women. Am J Epidemiol 1996; 144:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35367/abstract/26\">",
"      Jacobs EJ, Henion AK, Briggs PJ, et al. Vitamin C and vitamin E supplement use and bladder cancer mortality in a large cohort of US men and women. Am J Epidemiol 2002; 156:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35367/abstract/27\">",
"      Michaud DS, Spiegelman D, Clinton SK, et al. Prospective study of dietary supplements, macronutrients, micronutrients, and risk of bladder cancer in US men. Am J Epidemiol 2000; 152:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35367/abstract/28\">",
"      Lamm DL, Riggs DR, Shriver JS, et al. Megadose vitamins in bladder cancer: a double-blind clinical trial. J Urol 1994; 151:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35367/abstract/29\">",
"      Messing EM, Hanson P, Reznikoff CA. Normal and malignant human urothelium: in vitro response to blockade of polyamine synthesis and interconversion. Cancer Res 1988; 48:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35367/abstract/30\">",
"      Messing E, Kim KM, Sharkey F, et al. Randomized prospective phase III trial of difluoromethylornithine vs placebo in preventing recurrence of completely resected low risk superficial bladder cancer. J Urol 2006; 176:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35367/abstract/31\">",
"      Patton SE, Hall MC, Ozen H. Bladder cancer. Curr Opin Oncol 2002; 14:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35367/abstract/32\">",
"      Shariat SF, Kim JH, Ayala GE, et al. Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder. J Urol 2003; 169:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35367/abstract/33\">",
"      Wadhwa P, Goswami AK, Joshi K, Sharma SK. Cyclooxygenase-2 expression increases with the stage and grade in transitional cell carcinoma of the urinary bladder. Int Urol Nephrol 2005; 37:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35367/abstract/34\">",
"      Gee J, Lee IL, Jendiroba D, et al. Selective cyclooxygenase-2 inhibitors inhibit growth and induce apoptosis of bladder cancer. Oncol Rep 2006; 15:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35367/abstract/35\">",
"      Mohammed SI, Dhawan D, Abraham S, et al. Cyclooxygenase inhibitors in urinary bladder cancer: in vitro and in vivo effects. Mol Cancer Ther 2006; 5:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35367/abstract/36\">",
"      Dovedi SJ, Kirby JA, Davies BR, et al. Celecoxib has potent antitumour effects as a single agent and in combination with BCG immunotherapy in a model of urothelial cell carcinoma. Eur Urol 2008; 54:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35367/abstract/37\">",
"      Castelao JE, Yuan JM, Gago-Dominguez M, et al. Non-steroidal anti-inflammatory drugs and bladder cancer prevention. Br J Cancer 2000; 82:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35367/abstract/38\">",
"      Grubbs CJ, Lubet RA, Koki AT, et al. Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res 2000; 60:5599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35367/abstract/39\">",
"      Zeegers MP, Goldbohm RA, Bode P, van den Brandt PA. Prediagnostic toenail selenium and risk of bladder cancer. Cancer Epidemiol Biomarkers Prev 2002; 11:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35367/abstract/40\">",
"      Kellen E, Zeegers M, Buntinx F. Selenium is inversely associated with bladder cancer risk: a report from the Belgian case-control study on bladder cancer. Int J Urol 2006; 13:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35367/abstract/41\">",
"      Yal&ccedil;in O, Karata�� F, Erula�� FA, Ozdemir E. The levels of glutathione peroxidase, vitamin A, E, C and lipid peroxidation in patients with transitional cell carcinoma of the bladder. BJU Int 2004; 93:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35367/abstract/42\">",
"      Garland M, Morris JS, Stampfer MJ, et al. Prospective study of toenail selenium levels and cancer among women. J Natl Cancer Inst 1995; 87:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35367/abstract/43\">",
"      Messina M, Barnes S. The role of soy products in reducing risk of cancer. J Natl Cancer Inst 1991; 83:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35367/abstract/44\">",
"      Theodorescu D, Laderoute KR, Calaoagan JM, Guilding KM. Inhibition of human bladder cancer cell motility by genistein is dependent on epidermal growth factor receptor but not p21ras gene expression. Int J Cancer 1998; 78:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35367/abstract/45\">",
"      Sun CL, Yuan JM, Wang XL, et al. Dietary soy and increased risk of bladder cancer: a prospective cohort study of men in Shanghai, China. Int J Cancer 2004; 112:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35367/abstract/46\">",
"      Bianchi GD, Cerhan JR, Parker AS, et al. Tea consumption and risk of bladder and kidney cancers in a population-based case-control study. Am J Epidemiol 2000; 151:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35367/abstract/47\">",
"      Dannenberg AJ, Lippman SM, Mann JR, et al. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol 2005; 23:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35367/abstract/48\">",
"      Popov Z, Gil-Diez-De-Medina S, Ravery V, et al. Prognostic value of EGF receptor and tumor cell proliferation in bladder cancer: therapeutic implications. Urol Oncol 2004; 22:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35367/abstract/49\">",
"      Moon RC, Kelloff GJ, Detrisac CJ, et al. Chemoprevention of OH-BBN-induced bladder cancer in mice by oltipraz, alone and in combination with 4-HPR and DFMO. Anticancer Res 1994; 14:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35367/abstract/50\">",
"      Iida K, Itoh K, Kumagai Y, et al. Nrf2 is essential for the chemopreventive efficacy of oltipraz against urinary bladder carcinogenesis. Cancer Res 2004; 64:6424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35367/abstract/51\">",
"      Busby JE, Kamat AM. Chemoprevention for bladder cancer. J Urol 2006; 176:1914.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2971 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-F708DC0240-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_34_35367=[""].join("\n");
var outline_f34_34_35367=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RATIONALE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Field carcinogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Molecular pathways",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Target population",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CHEMOPREVENTIVE AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Retinoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Primary chemoprevention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Secondary chemoprevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Pyridoxine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Vitamin C",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Alpha tocopherol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Multivitamins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Difluoromethylornithine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Nonsteroidal antiinflammatory drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Selenium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Isoflavones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Polyphenols",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      EGFR inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Oltipraz",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/13/40154?source=related_link\">",
"      Complementary and alternative therapies for cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/61/26586?source=related_link\">",
"      Epidemiology and etiology of urothelial (transitional cell) carcinoma of the bladder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/11/40122?source=related_link\">",
"      Treatment of non-muscle-invasive bladder cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_34_35368="Guttate psoriasis 1";
var content_f34_34_35368=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F55141%7EDERM%2F64836&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F55141%7EDERM%2F64836&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Guttate psoriasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Numerous erythematous, scaly papules are present in this patient with guttate psoriasis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Guttate psoriasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple erythematous papules with scale are typically present in guttate psoriasis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_34_35368=[""].join("\n");
var outline_f34_34_35368=null;
var title_f34_34_35369="Dermatitis herpetiformis";
var content_f34_34_35369=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Dermatitis herpetiformis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/34/35369/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/34/35369/contributors\">",
"     Christopher Hull, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/34/35369/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/34/35369/contributors\">",
"     John J Zone, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/34/35369/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/34/35369/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/34/35369/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H23341158\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dermatitis herpetiformis (DH) is an uncommon autoimmune cutaneous eruption associated with gluten sensitivity. Affected patients typically develop intensely pruritic inflammatory papules and vesicles on the forearms, knees, scalp, or buttocks (",
"    <a class=\"graphic graphic_picture graphicRef86749 graphicRef86750 graphicRef86751 graphicRef86752 graphicRef86768 graphicRef78315 graphicRef86769 \" href=\"mobipreview.htm?41/61/42970\">",
"     picture 1A-G",
"    </a>",
"    ). The vast majority of patients with DH also have an associated gluten-sensitive enteropathy (celiac disease). In most of these patients, the enteropathy is asymptomatic.",
"   </p>",
"   <p>",
"    DH usually responds well to treatment.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     Dapsone",
"    </a>",
"    and a gluten-free diet are the primary interventions for the management of this disease.",
"   </p>",
"   <p>",
"    The pathogenesis, diagnosis, and treatment of DH will be discussed here. Celiac disease is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/44/40650?source=see_link\">",
"     \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/2/14377?source=see_link\">",
"     \"Diagnosis of celiac disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/3/37946?source=see_link\">",
"     \"Clinical manifestations and diagnosis of celiac disease in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23341172\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;DH is an uncommon disorder that most frequently occurs in individuals of northern European heritage. Epidemiological studies from northern Europe have found incidence rates between 0.4 and 3.5 per 100,000 people per year and prevalence rates between 1.2 and 75.3 per 100,000 people [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/1-8\">",
"     1-8",
"    </a>",
"    ]. A Finnish study that compared the incidence of DH in three successive decades, beginning in 1970, found that the incidence of DH decreased over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/3\">",
"     3",
"    </a>",
"    ]. The estimated annual incidence for each decade was 5.2, 2.9, and 2.7 per 100,000 people, respectively. The authors postulated that the fall in incidence may have been related to societal changes in gluten consumption due to increased awareness of subclinical celiac disease.",
"   </p>",
"   <p>",
"    A population-based study in Utah, a location with a relatively high proportion of individuals with northern European ancestry, found incidence and prevalence rates similar to those reported in Europe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/9\">",
"     9",
"    </a>",
"    ]. Between 1978 and 1987, the incidence of DH was 0.98 per 100,000 people per year, and the prevalence of DH in 1987 was 11.2 per 100,000 people.",
"   </p>",
"   <p>",
"    Epidemiologic studies have found that males are more likely to develop DH than females; reported male to female ratios have ranged from 1.1:1 to 1.9:1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/3\">",
"     3",
"    </a>",
"    ]. The reason for a male predominance in DH is unknown. &nbsp;",
"   </p>",
"   <p>",
"    Although the mean age of disease onset is often reported to be in the fourth or fifth decade [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/3\">",
"     3",
"    </a>",
"    ], individuals of all ages may be affected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/3,10\">",
"     3,10",
"    </a>",
"    ]. DH is uncommon in children. In the Finnish study mentioned above, only 18 of 477 patients with DH were children (4 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23341179\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of DH appears to be complex, involving both intrinsic and extrinsic factors. Like celiac disease, DH is considered a manifestation of gluten-sensitivity that is most likely to occur in genetically susceptible individuals. The importance of gluten in the pathogenesis of these disorders is supported by the observation that the elimination of dietary gluten results in the remission of both diseases. (See",
"    <a class=\"local\" href=\"#H2261977249\">",
"     'Gluten-free diet'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/38/4714?source=see_link\">",
"     \"Management of celiac disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/47/7929?source=see_link\">",
"     \"Management of celiac disease in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Histological examination of skin biopsy specimens supports an important role for the immune system in DH. Subepidermal deposition of IgA and neutrophilic dermal infiltrates in the superficial dermis are characteristic findings of this disease. (See",
"    <a class=\"local\" href=\"#H23341348\">",
"     'Histopathology'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2016766306\">",
"    <span class=\"h2\">",
"     Genetic predisposition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain human leukocyte antigen (HLA) genes predispose to the development of DH. Virtually all patients with DH carry the HLA DQ2 or HLA DQ8 haplotype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/11\">",
"     11",
"    </a>",
"    ]. This concept was evident in a comparative study of 50 subjects with DH and 290 healthy controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/12\">",
"     12",
"    </a>",
"    ]. The study found that genes encoding HLA DQ2 were carried by 86 percent of the patients with DH, compared with only 25 percent of the healthy controls. In addition, six of the seven patients with DH who were negative for HLA DQ2 were positive for HLA DQ8. The importance of HLA DQ2 and HLA DQ8 is likely related to their role in the promotion of an immune response against gliadin peptides (see",
"    <a class=\"local\" href=\"#H2016766164\">",
"     'Gluten sensitivity'",
"    </a>",
"    below). Non-HLA genetic factors may also influence the risk of developing DH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A genetic contribution to DH is supported further by familial studies that demonstrate that first-degree relatives of patients with DH have an increased risk for both DH and celiac disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. In a Finnish cohort of over 1000 patients with DH, 4 percent reported that they had a first-degree relative with DH, and 6 percent reported that they had a first-degree relative with celiac disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2016766164\">",
"    <span class=\"h2\">",
"     Gluten sensitivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The strong epidemiologic link between DH and celiac disease strongly supports a shared pathogenesis involving gluten-sensitivity. More than 90 percent of patients with DH exhibit small bowel biopsy findings consistent with some degree of gluten-sensitive enteropathy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/44/40650?source=see_link\">",
"     \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/3/37946?source=see_link\">",
"     \"Clinical manifestations and diagnosis of celiac disease in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Both the adaptive and innate immune systems may contribute to the development of the clinical manifestations of gluten-sensitivity. Gliadin peptides (peptides derived from the digestion of gluten) and tissue transglutaminase (a calcium-dependent enzyme that catalyzes crosslinks between glutamine and lysine protein residues and forms covalent bonds with gliadin) are key antigens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/17\">",
"     17",
"    </a>",
"    ]. Antibodies against tissue transglutaminase are present in serum from affected patients and are used to support the diagnosis of DH and celiac disease. (See",
"    <a class=\"local\" href=\"#H23341214\">",
"     'Serology'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A potential pathway through which exposure to dietary gluten could lead to DH is as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/18-21\">",
"     18-21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Following the ingestion and digestion of gluten-containing food, gliadin is absorbed into the intestinal mucosa",
"     </li>",
"     <li>",
"      Gliadin is deaminated by tissue transglutaminase in the intestinal mucosa and covalent crosslinks are formed between gliadin and tissue transglutaminase",
"     </li>",
"     <li>",
"      Deaminated gliadin peptides bind to HLA DQ2 or HLA DQ8 molecules on antigen presenting cells, where they are recognized by helper T cells",
"     </li>",
"     <li>",
"      The activated T cells then produce proinflammatory cytokines and matrix metalloproteinases that stimulate damage to the gut mucosa and the production of antibodies against tissue transglutaminase by B cells",
"     </li>",
"     <li>",
"      Over time, epitope spreading (the development of an immune response against an endogenous antigen or multiple endogenous antigens due to exposure of an endogenous antigen during tissue damage) may occur and contribute to the production of antibodies that are capable of binding to epidermal transglutaminase.",
"     </li>",
"     <li>",
"      The IgA anti-epidermal transglutaminase antibodies travel through the bloodstream, and upon reaching the skin, complex with epidermal transglutaminase in the dermis",
"     </li>",
"     <li>",
"      The deposition of immune complexes in the dermis stimulates neutrophil chemotaxis and proteolytic cleavage within the lamina lucida, leading to blistering",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2261977824\">",
"    <span class=\"h2\">",
"     Other factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to genetic predisposition and dietary gluten exposure, other environmental factors may play a role in the development of DH. This concept is supported by a study that identified six patients with DH who had a monozygotic twin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/22\">",
"     22",
"    </a>",
"    ]. Although the presence of a manifestation of gluten sensitivity (celiac disease, DH, or both disorders) was concordant in five of six twin sets, DH was present in both twins in only three twin sets. Additional study is necessary to confirm the pathogenic mechanisms of DH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1643384077\">",
"    <span class=\"h1\">",
"     CLINICAL FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with DH may experience cutaneous, oral, and gastrointestinal manifestations related to gluten-sensitivity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1643388780\">",
"    <span class=\"h2\">",
"     Cutaneous manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classic clinical finding in DH is the development of multiple intensely pruritic papules and vesicles that occur in grouped (&ldquo;herpetiform&rdquo;) arrangements. The elbows, dorsal forearms, knees, scalp, back, and buttocks are among the most common sites for lesion development (",
"    <a class=\"graphic graphic_picture graphicRef86749 graphicRef86750 graphicRef86751 graphicRef86752 graphicRef86768 graphicRef78315 \" href=\"mobipreview.htm?40/39/41594\">",
"     picture 1A-F",
"    </a>",
"    ). The face and groin are less frequent sites of involvement.",
"   </p>",
"   <p>",
"    Due to the associated pruritus, very few intact papules or vesicles are usually seen on clinical examination. Erosions and excoriations tend to be the most abundant clinical findings (",
"    <a class=\"graphic graphic_picture graphicRef86769 \" href=\"mobipreview.htm?28/46/29408\">",
"     picture 1G",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The extent of cutaneous involvement varies widely. Patients with mild disease present with involvement limited to a few localized areas, such as the knees or dorsal forearms, while patients with severe disease present with widely distributed lesions on the trunk and extremities. The skin lesions usually heal without scarring. However, postinflammatory pigmentary changes may develop [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Petechiae or purpuric macules on the fingers or palms are uncommon clinical features of DH. These lesions are more likely to occur in children, but may also appear in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/23-26\">",
"     23-26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1643388809\">",
"    <span class=\"h2\">",
"     Oral manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Involvement of the oral mucosa is rare. Since most reports that document oral involvement in DH have not confirmed the diagnosis through direct immunofluorescence microscopy, there is some uncertainty regarding whether some cases have actually represented aphthous stomatitis or other disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/17\">",
"     17",
"    </a>",
"    ]. Oral mucosal involvement may manifest as vesicles, erosions, or erythematous macules on the oral mucosa or tongue. Discomfort may or may not be present.",
"   </p>",
"   <p>",
"    As with celiac disease, tooth enamel defects may occur in patients with DH. Patients may present with horizontal grooves, pits, or discoloration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/17\">",
"     17",
"    </a>",
"    ]. In a series of 30 adults with DH, 53 percent had enamel defects compared with only 2 percent of 66 healthy controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/27\">",
"     27",
"    </a>",
"    ]. A series of 10 children with DH and no clinical symptoms of celiac disease also found an elevated rate of tooth abnormalities among patients with DH; 80 percent had bilateral enamel defects, whereas similar defects were seen in only 13 percent of healthy children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1643388787\">",
"    <span class=\"h2\">",
"     Gastrointestinal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vast majority of patients with DH (75 to 90 percent) have associated subclinical or clinical small bowel disease related to gluten-sensitivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/10,29\">",
"     10,29",
"    </a>",
"    ]. Findings on small bowel biopsy may demonstrate the villous atrophy and crypt hyperplasia classically associated with celiac disease; other cases may demonstrate only mild findings such as increase in intraepithelial lymphocytes in intestinal microvilli [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/2/14377?source=see_link&amp;anchor=H6#H6\">",
"     \"Diagnosis of celiac disease\", section on 'Small bowel biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite the common presence of histological abnormalities in the gut, only a minority of DH patients develop gastrointestinal symptoms. Symptomatic patients may present with abdominal bloating, cramping, pain, diarrhea, or constipation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/44/40650?source=see_link&amp;anchor=H15#H15\">",
"     \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/3/37946?source=see_link&amp;anchor=H14#H14\">",
"     \"Clinical manifestations and diagnosis of celiac disease in children\", section on 'Symptoms'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21110852\">",
"    <span class=\"h2\">",
"     Clinical course",
"    </span>",
"    &nbsp;&mdash;&nbsp;DH is usually a life-long condition. However, the clinical course of skin disease is variable. While some patients experience intermittent eruptions that last only a few days and are separated by long asymptomatic periods, others develop continuous symptoms that wax and wane in severity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/31\">",
"     31",
"    </a>",
"    ]. Occasionally, spontaneous remissions occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2261977532\">",
"     'Prognosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23341200\">",
"    <span class=\"h1\">",
"     ASSOCIATED DISEASES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to celiac disease, other diseases may occur at increased frequencies in patients with DH. The most common associated condition is autoimmune thyroid disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/30\">",
"     30",
"    </a>",
"    ]. As an example, in a retrospective study of 264 adults with DH, thyroid disease was documented in 11 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/30\">",
"     30",
"    </a>",
"    ]. Hypothyroidism is more likely to occur than hyperthyroidism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/30,33,34\">",
"     30,33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Type I diabetes mellitus and pernicious anemia also may be more likely to develop in patients with DH. The prevalence of type 1 diabetes mellitus in patients with DH is estimated to be between 2 and 5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/17\">",
"     17",
"    </a>",
"    ]. Between 1 and 3 percent of patients with DH may have pernicious anemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/30\">",
"     30",
"    </a>",
"    ]. Other diseases that may occur with increased frequency in patients with DH include vitiligo, Addison&rsquo;s disease, alopecia areata, and several other autoimmune diseases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/30,34\">",
"     30,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Celiac disease has been associated with an increased risk for non-Hodgkin lymphoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/35\">",
"     35",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/44/40650?source=see_link&amp;anchor=H25#H25\">",
"     \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\", section on 'Risk of malignancy and mortality'",
"    </a>",
"    ). An increased risk for lymphoma may also occur in association with DH, though estimates of this risk have varied [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/36-42\">",
"     36-42",
"    </a>",
"    ]. As an example, a Swedish population-based study that included 1354 patients with DH found a slightly increased overall risk for cancer (standard incidence ratio [SIR] 1.2, 95% CI 1.0-1.4), which primarily appeared due to an increase in lymphoma and leukemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/36\">",
"     36",
"    </a>",
"    ]. In addition, a cohort study in the United Kingdom that included 84 patients with DH who were followed for a mean of 22 years found that the risk for non-Hodgkin lymphoma was increased in comparison to the general population (SIR 5.14, 95% CI 1.05-15.0) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/37\">",
"     37",
"    </a>",
"    ]. In this study, the overall risk for malignancy was not increased (SIR 0.99, 95% CI 0.65-1.44).",
"   </p>",
"   <p>",
"    The impact of a gluten-free diet on the risk for malignancy in patients with DH is uncertain. One retrospective study suggested a reduced risk for lymphoma among patients with a history of long-term adherence to a gluten-free diet [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/43\">",
"     43",
"    </a>",
"    ]. However, additional studies are necessary to explore the impact of a gluten-free diet on the risk for malignancy. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1643388880\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the recognition of consistent clinical findings, obtaining laboratory studies, including tissue pathology, direct immunofluorescence microscopy (DIF), and serology can aid in the diagnosis of DH. DIF is considered the gold standard test for diagnosis.",
"   </p>",
"   <p>",
"    Our initial approach to the diagnosis of DH in patients who present with suggestive clinical findings involves obtaining a lesional skin biopsy for routine hematoxylin and eosin (H&amp;E) staining and a perilesional skin biopsy for DIF. We use serological studies as adjunctive tests to support the diagnosis. Serology can also be useful for assessing adherence to dietary therapy. (See",
"    <a class=\"local\" href=\"#H23341214\">",
"     'Serology'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23341348\">",
"    <span class=\"h2\">",
"     Histopathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 4 mm punch biopsy is usually sufficient for obtaining a tissue specimen for routine histological examination. The biopsy specimen ideally should be taken from the site of a small, intact vesicle. If no intact vesicles are present, the biopsy should be taken from an area of intact, inflamed skin. Biopsies of excoriated lesions may yield nonspecific findings. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/20/40264?source=see_link&amp;anchor=H12#H12\">",
"     \"Skin biopsy techniques\", section on 'Punch biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The histological findings vary based upon the age of the lesion. The earliest lesions may demonstrate only collections of neutrophils (with or without eosinophils) and fibrin at the tips of the dermal papillae (papillary microabscesses) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/44\">",
"     44",
"    </a>",
"    ]. Lesions older than 48 hours begin to demonstrate subepidermal vesiculation at the papillary tips, which eventually connect to form larger subepidermal blisters that contain neutrophils, eosinophils, and fibrin (",
"    <a class=\"graphic graphic_picture graphicRef86748 \" href=\"mobipreview.htm?34/23/35193\">",
"     picture 2",
"    </a>",
"    ). A perivascular lymphohistiocytic infiltrate with varying numbers of neutrophils and eosinophils is usually found in the dermis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The histological findings in DH may resemble other subepithelial blistering disorders. In particular, DH can be difficult to distinguish from linear IgA bullous dermatosis and bullous systemic lupus erythematosus. Bullous pemphigoid may also resemble DH histologically, but typically is characterized by a greater abundance of eosinophils [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1643388910\">",
"    <span class=\"h2\">",
"     Direct immunofluorescence microscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;DIF is the gold standard test for the diagnosis of DH. A 4 mm punch biopsy is typically utilized to obtain the tissue specimen. The biopsy should be taken from perilesional skin (normal-appearing skin adjacent to a lesion) because biopsies taken from lesional skin are more likely to yield falsely negative findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/45\">",
"     45",
"    </a>",
"    ]. Michel&rsquo;s medium may be used to transport the specimen. Tissue for DIF should not be placed in formalin. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/20/40264?source=see_link&amp;anchor=H12#H12\">",
"     \"Skin biopsy techniques\", section on 'Punch biopsy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/54/14186?source=see_link&amp;anchor=H4714358#H4714358\">",
"     \"Approach to the patient with cutaneous blisters\", section on 'Direct immunofluorescence'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The characteristic finding on DIF is the presence of granular deposits of IgA within the dermal papillae (",
"    <a class=\"graphic graphic_picture graphicRef86538 \" href=\"mobipreview.htm?9/59/10163\">",
"     picture 3",
"    </a>",
"    ). Deposits of IgM and C3 may also be present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/44\">",
"     44",
"    </a>",
"    ]. Infrequently, a fibrillar, rather than granular, pattern of IgA deposition is detected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Granular deposits of IgA along the basement membrane may also be seen in DH, and may lead to the misdiagnosis of DH as linear IgA bullous dermatosis (",
"    <a class=\"graphic graphic_picture graphicRef86539 \" href=\"mobipreview.htm?17/36/17985\">",
"     picture 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. Serological studies are useful for clarifying the diagnosis in ambiguous cases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/36/14922?source=see_link&amp;anchor=H829103#H829103\">",
"     \"Linear IgA bullous dermatosis\", section on 'Direct immunofluorescence'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    DIF is usually positive in DH. In a retrospective study of 264 patients with DH, DIF was positive in 244 patients (92 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/30\">",
"     30",
"    </a>",
"    ]. DIF can become negative in patients on strict gluten-free diets since adherence to the diet reduces IgA deposits in the dermis. In a retrospective series, 10 of 41 patients with DH who were on strict gluten-free diets no longer had detectable IgA deposits in the skin after an average of 13 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/50\">",
"     50",
"    </a>",
"    ]. IgA deposition is not affected by pharmacological therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23341214\">",
"    <span class=\"h2\">",
"     Serology",
"    </span>",
"    &nbsp;&mdash;&nbsp;We obtain serological studies to confirm the diagnosis of DH in patients with consistent clinical, histological, and DIF findings and to aid in the diagnosis of DH in cases in which DIF is negative or equivocal. Elevated levels of IgA tissue transglutaminase antibodies, IgA epidermal transglutaminase antibodies, and IgA endomysial antibodies are often present in patient serum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/30,52-56\">",
"     30,52-56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serology is also useful for clinical follow-up. Serum levels of these antibodies fall with gluten restriction and may be useful for monitoring the adherence and response to a gluten-free diet. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/38/4714?source=see_link&amp;anchor=H11#H11\">",
"     \"Management of celiac disease in adults\", section on 'Monitoring the response to a gluten-free diet'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The serological tests utilized in DH are generally sensitive and specific. The sensitivity of enzyme-linked immunosorbent assay (ELISA) for IgA tissue transglutaminase antibodies ranges between 47 and 95 percent, and the specificity for this test is reported to be greater than 90 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/48\">",
"     48",
"    </a>",
"    ]. The sensitivity of ELISA for IgA epidermal transglutaminase antibodies ranges between 60 and 81 percent, and the specificity for this test is between 93 and 100 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Endomysium is the connective tissue found in smooth muscle of the esophagus, stomach, and small intestine. The test for endomysial antibodies is performed via indirect immunofluorescence on monkey esophagus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/51\">",
"     51",
"    </a>",
"    ]. The sensitivity of this test for celiac disease and DH ranges from 52 to 100 percent and the specificity of the test approximates 100 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/54/14186?source=see_link&amp;anchor=H4714372#H4714372\">",
"     \"Approach to the patient with cutaneous blisters\", section on 'Indirect immunofluorescence'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Our typical serological work-up for patients with suspected DH includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Enzyme-linked immunosorbent assay (ELISA) for IgA tissue transglutaminase antibodies",
"     </li>",
"     <li>",
"      ELISA for IgA epidermal transglutaminase antibodies (when available)",
"     </li>",
"     <li>",
"      Indirect immunofluorescence for IgA endomysial antibodies",
"     </li>",
"     <li>",
"      Total IgA level",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The total IgA level is necessary because selective IgA deficiency, which decreases the likelihood of detecting DH IgA autoantibodies, occurs at an increased frequency in patients with celiac disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/51\">",
"     51",
"    </a>",
"    ]. The assessment of IgG antibodies against tissue transglutaminase and endomysium may be useful in this setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21111880\">",
"    <span class=\"h1\">",
"     ADDITIONAL TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since DH is considered a cutaneous manifestation of celiac disease and the treatment for both disorders is similar (a gluten-free diet), performance of a small bowel biopsy to confirm bowel pathology is not indicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/51,57\">",
"     51,57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/2/14377?source=see_link\">",
"     \"Diagnosis of celiac disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/3/37946?source=see_link\">",
"     \"Clinical manifestations and diagnosis of celiac disease in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Due to the association of DH with thyroid disease, we typically obtain thyroid function tests and anti-thyroid peroxidase antibody titers in patients with DH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/51\">",
"     51",
"    </a>",
"    ]. We also screen patients for diabetes. Additional tests may be ordered based upon clinical suspicion for other autoimmune diseases. (See",
"    <a class=\"local\" href=\"#H23341200\">",
"     'Associated diseases'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23341221\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical features of DH can resemble the clinical findings of other dermatologic disorders. Intensely pruritic conditions that present with excoriations and inflammatory papules, such as atopic dermatitis, scabies, and arthropod bites should be considered. Other subepidermal blistering diseases such as bullous pemphigoid (",
"    <a class=\"graphic graphic_picture graphicRef72866 \" href=\"mobipreview.htm?26/16/26885\">",
"     picture 5",
"    </a>",
"    ), linear IgA bullous dermatosis (",
"    <a class=\"graphic graphic_picture graphicRef51248 graphicRef56434 \" href=\"mobipreview.htm?32/2/32809\">",
"     picture 6A-B",
"    </a>",
"    ), and bullous systemic lupus erythematosus are also included in the differential diagnosis. Blistering tends to be more prominent in these conditions than in DH. However, in the prodromal phase of bullous pemphigoid, blistering may be minimal or absent (",
"    <a class=\"graphic graphic_picture graphicRef80385 \" href=\"mobipreview.htm?41/50/42788\">",
"     picture 7",
"    </a>",
"    ). The careful assessment of the patient history as well as the clinical, histopathological, immunopathological, and serological findings usually successfully distinguishes DH from other disorders. (See",
"    <a class=\"local\" href=\"#H1643388880\">",
"     'Diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1643384165\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two most important therapeutic interventions for DH include a strict gluten-free diet and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/58-60\">",
"     58-60",
"    </a>",
"    ]. A gluten-free diet is effective for both DH and the often associated gluten-sensitive enteropathy. However, several months to a few years may be required to achieve complete remission of DH with a gluten-free diet as monotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/10,58\">",
"     10,58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to a gluten-free diet,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    is rapidly effective for DH, resulting in the resolution of active skin lesions within days of the start of therapy. Disadvantages of dapsone therapy include the potential for drug-related adverse events and its lack of effect on the gastrointestinal manifestations of gluten-sensitivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/58\">",
"     58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/44/40650?source=see_link\">",
"     \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Our preferred approach to the treatment of DH consists of a combination regimen that allows patients to benefit from the favorable features of both interventions. At the start of treatment, we prescribe",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    to induce rapid clearance of symptoms and simultaneously strongly encourage patients to eliminate gluten in their diets. We then slowly taper dapsone as tolerated, with a goal of eventually maintaining clinical improvement only on dietary therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21111917\">",
"    <span class=\"h2\">",
"     Indications for referral",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients are usually managed by a dermatologist (for the management of DH) and a nutritionist (for dietary counseling) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/29\">",
"     29",
"    </a>",
"    ]. Additional specialists are added as needed based upon patient comorbidities (eg, thyroid disease, diabetes).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2261977181\">",
"    <span class=\"h2\">",
"     First-line therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;First-line therapy for DH consists of both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    and the elimination of gluten from the diet.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1643384272\">",
"    <span class=\"h3\">",
"     Dapsone",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    in DH is well-accepted based upon extensive clinical experience and the clear correlation with rapid clinical improvement immediately after the initiation of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/10,51,57,58,60,61\">",
"     10,51,57,58,60,61",
"    </a>",
"    ]. Pruritus usually improves within 72 hours, and the skin manifestations typically resolve within days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/17\">",
"     17",
"    </a>",
"    ]. No randomized trials have evaluated the efficacy of dapsone in DH.",
"   </p>",
"   <p>",
"    In adults with DH, treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    is typically begun at 25 to 50 mg per day. The dose is slowly titrated upward (eg, 25 mg per week up to a dose of 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) based upon patient tolerance and the response to therapy. Our experience suggests that most adult patients on unrestricted diets respond fully to doses between 50 and 150 mg per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/62\">",
"     62",
"    </a>",
"    ]. Mild eruptions (eg, one to two new lesions per week) are expected at optimum dosing and are not an indication for increasing the dose of dapsone. Symptoms from these mild outbreaks can be treated with application of a potent topical corticosteroid. (See",
"    <a class=\"local\" href=\"#H2261977229\">",
"     'Corticosteroids'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     Dapsone",
"    </a>",
"    therapy is associated with a variety of potential adverse effects (",
"    <a class=\"graphic graphic_table graphicRef86540 \" href=\"mobipreview.htm?34/23/35195\">",
"     table 1",
"    </a>",
"    ). Some degree of hemolysis occurs in essentially all patients. Although this is tolerated by most patients, individuals with glucose-6-phosphate (G6PD) deficiency are at increased risk for severe hemolytic anemia. Examples of additional side effects include methemoglobinemia, agranulocytosis, and a dapsone hypersensitivity reaction. When it occurs, agranulocytosis usually appears 2 to 12 weeks after the initiation of dapsone therapy. Dapsone-associated hypersensitivity syndrome classically presents with flu-like symptoms, a morbilliform cutaneous eruption, fever, lymphadenopathy, hepatitis, and eosinophilia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/25/4505?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical manifestations of glucose-6-phosphate dehydrogenase deficiency\", section on 'Acute hemolytic anemia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/57/43929?source=see_link\">",
"     \"Drug reaction with eosinophilia and systemic symptoms (DRESS)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Careful laboratory monitoring is necessary during",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    therapy. We typically obtain a complete blood count (CBC), liver function tests, and renal function tests prior to the start of therapy. A G6PD screen is also recommended since dapsone therapy is contraindicated in patients with G6PD deficiency. We repeat a CBC every one to two weeks for one month, and every one to three months during the first six months of therapy. Subsequently, we obtain a CBC and liver function tests every three to six months provided the dose of dapsone is not increased. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/50/39719?source=see_link&amp;anchor=H2#H2\">",
"     \"Diagnosis and treatment of glucose-6-phosphate dehydrogenase deficiency\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Slow, progressive tapering of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    can be attempted after the patient has been on a gluten-free diet for two to three months (see",
"    <a class=\"local\" href=\"#H2261977249\">",
"     'Gluten-free diet'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/63\">",
"     63",
"    </a>",
"    ]. Tapering too rapidly can result in disease flares. The best regimen for reducing the dose of dapsone has not been determined. We usually attempt to taper the drug by 12.5 mg every two to four weeks. In one study, tapering of dapsone to treatment cessation required an average of two years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2261977249\">",
"    <span class=\"h3\">",
"     Gluten-free diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;The designation of a gluten-free diet as a first-line treatment for DH is based upon uncontrolled studies and extensive clinical experience that support its benefit in DH and the dual efficacy of the diet for the cutaneous and gastrointestinal manifestations of gluten-sensitivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/50,58,64-67\">",
"     50,58,64-67",
"    </a>",
"    ]. Although",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    is highly effective for inducing clinical remissions of DH, a gluten-free diet is our preferred option for long-term therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/38/4714?source=see_link\">",
"     \"Management of celiac disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/47/7929?source=see_link\">",
"     \"Management of celiac disease in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who adhere to a gluten-free diet are usually able to reduce the requirement for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    and eventually may be able to discontinue dapsone therapy. As an example, in a 36-month study of 81 patients with DH who were on a gluten-free diet for 6 to 36 months and 49 patients with DH who maintained a normal diet, reductions in the dose of dapsone were achieved in 93 versus 16 percent of patients, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/64\">",
"     64",
"    </a>",
"    ]. After one year, the average reduction in the dose of dapsone in patients on a gluten-free diet was 60 percent; the percentage reduction increased to 80 percent after three years. During the study period, 28 percent of patients on the gluten-free diet were able to discontinue dapsone completely. Among these patients, the mean amount of time required to discontinue dapsone was two years.",
"   </p>",
"   <p>",
"    Strict adherence to a gluten-free diet is challenging. Counseling with a dietician is recommended to help patients to identify and eliminate both obvious and hidden sources of dietary gluten and to assist patients with finding alternatives to gluten-containing foods. Multiple resources that provide information on gluten-free diets are available. Examples include the Celiac Disease Foundation (",
"    <a class=\"external\" href=\"file://www.celiac.org/\">",
"     www.celiac.org",
"    </a>",
"    ) and the Gluten Intolerance Group (",
"    <a class=\"external\" href=\"file://www.gluten.net/\">",
"     www.gluten.net",
"    </a>",
"    ). Whether a gluten-free diet reduces the risk for autoimmune diseases and malignancy in patients with DH is not clear. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/38/4714?source=see_link&amp;anchor=H7#H7\">",
"     \"Management of celiac disease in adults\", section on 'Is strict gluten avoidance necessary?'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If a relapse of DH occurs in a patient on a strict gluten-free diet, the possibility of exposure to hidden sources of gluten should be considered. Close review of the diet with a dietician may identify unintentional sources of gluten intake. For severe recurrences,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    can be reinstituted with the same regimen used for initial therapy. (See",
"    <a class=\"local\" href=\"#H1643384272\">",
"     'Dapsone'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2261977207\">",
"    <span class=\"h2\">",
"     Other therapies",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87246548\">",
"    <span class=\"h3\">",
"     Other sulfa-based drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who cannot tolerate treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    , other sulfonamide drugs are options for pharmacotherapy. However, there is much less experience with the use of these therapies.",
"   </p>",
"   <p>",
"    Case reports document successful treatment of DH with sulfapyridine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/68,69\">",
"     68,69",
"    </a>",
"    ] and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/70-72\">",
"     70-72",
"    </a>",
"    ]. Although sulfasalazine is metabolized to sulfapyridine in the intestine, the absorption of sulfapyridine (the active drug) is more predictable when sulfapyridine is administered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/70,73\">",
"     70,73",
"    </a>",
"    ]. Thus, our preference is to use sulfapyridine. Sulfapyridine may be given to adults at a starting dose of 0.5 g three times per day, which may be increased to up to 6 g per day if necessary to control patient symptoms. Sulfasalazine has been reported to be effective in doses between 1 and 2 g per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Of these two agents, only",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    is commercially available in the United States. Sulfapyridine may be obtained through compounding pharmacies.",
"   </p>",
"   <p>",
"    Although sulfapyridine and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    do not cause the hemolysis seen with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    therapy, agranulocytosis and hypersensitivity reactions are potential adverse effects. In addition, adequate fluid intake is recommended during treatment with these drugs to reduce the risk for drug-induced nephrolithiasis. As with dapsone, laboratory monitoring should be performed periodically. We typically follow a CBC, liver function panel, and urinalysis.",
"   </p>",
"   <p>",
"    Sulfamethoxypyridazine has also been reported to be effective for DH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. This agent is not available in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2261977229\">",
"    <span class=\"h3\">",
"     Corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical superpotent corticosteroids may help alleviate pruritus (",
"    <a class=\"graphic graphic_table graphicRef62402 \" href=\"mobipreview.htm?38/56/39809\">",
"     table 2",
"    </a>",
"    ). These agents are not sufficient for the management of DH, and should be used in conjunction with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    and a gluten-free diet. Systemic glucocorticoids are usually ineffective for DH. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21110581\">",
"    <span class=\"h2\">",
"     Treatment of children",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with adults, the treatment of children with DH typically consists of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    and a gluten-free diet. Dapsone is usually initiated at a low dose (&lt;0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) and titrated upward as tolerated; the therapeutic dose is typically between 0.5 and 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/76\">",
"     76",
"    </a>",
"    ]. As the gluten-free diet begins to take effect, dapsone is tapered as tolerated.",
"   </p>",
"   <p>",
"    The duration of time to improvement without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    therapy was evaluated in a study in which 41 children with DH were treated with only a gluten-free diet [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/10\">",
"     10",
"    </a>",
"    ]. The study found that 33 of 41 children (80 percent) treated with a gluten-free diet alone had resolution of their symptoms within one to six months. However, since the relief attained with dapsone is almost immediate, we typically use combination therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2261977532\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most often, DH is a life-long condition that requires continued treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a gluten-free diet to maintain remission. Symptoms can recur within two days after the discontinuation of dapsone, and within three months after the resumption of gluten intake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/57,61\">",
"     57,61",
"    </a>",
"    ]. However, 10 to 15 percent of patients may develop remissions that persist despite the discontinuation of both pharmacological and dietary therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/32,50\">",
"     32,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ln contrast to celiac disease, which may be associated with an increased risk for mortality compared with the general population, patients with DH may have a reduced mortality rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/42,77\">",
"     42,77",
"    </a>",
"    ]. A Finnish cohort study of 476 patients with DH found a lower than expected mortality rate despite a transient increase in the risk for death due to lymphoproliferative malignancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35369/abstract/77\">",
"     77",
"    </a>",
"    ]. Further studies are necessary to clarify the factors that may contribute to a reduction in mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2261977592\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dermatitis herpetiformis is an uncommon cutaneous disorder that occurs as a manifestation of gluten sensitivity. DH is usually accompanied by a gluten-sensitive enteropathy (celiac disease). (See",
"      <a class=\"local\" href=\"#H23341158\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/44/40650?source=see_link\">",
"       \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/3/37946?source=see_link\">",
"       \"Clinical manifestations and diagnosis of celiac disease in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      DH most frequently occurs in individuals of northern European ancestry. Both children and adults may be affected. (See",
"      <a class=\"local\" href=\"#H23341172\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Genetic predisposition and gluten-sensitivity are key factors in the pathogenesis of DH. Virtually all patients with DH carry the HLA DQ2 or HLA DQ8 haplotype. Antibodies against epidermal transglutaminase produced in association with an immune response to ingested gluten play a key role in the disease pathogenesis. (See",
"      <a class=\"local\" href=\"#H23341179\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      DH classically presents as an intensely pruritic skin eruption characterized by the development of inflammatory papules and vesicles (",
"      <a class=\"graphic graphic_picture graphicRef86749 graphicRef86750 graphicRef86751 graphicRef86752 graphicRef86768 graphicRef78315 graphicRef86769 \" href=\"mobipreview.htm?41/61/42970\">",
"       picture 1A-G",
"      </a>",
"      ). Due to the pruritus, excoriations and erosions are often the most prominent clinical manifestations. The elbows, forearms, knees, buttocks, back, and scalp are common sites for lesion development. (See",
"      <a class=\"local\" href=\"#H1643384077\">",
"       'Clinical findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with DH may have an increased risk for the development of other autoimmune diseases. Thyroid disease is the most common autoimmune disorder associated with DH. Patients with DH may also have an increased risk for lymphoma. (See",
"      <a class=\"local\" href=\"#H23341200\">",
"       'Associated diseases'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of DH is made based on both the clinical findings and laboratory studies. The gold standard test for diagnosis is direct immunofluorescence (DIF). DIF classically demonstrates granular deposits of IgA within the papillary dermis (",
"      <a class=\"graphic graphic_picture graphicRef86538 \" href=\"mobipreview.htm?9/59/10163\">",
"       picture 3",
"      </a>",
"      ). Serological studies that identify circulating IgA antibodies against tissue transglutaminase, epidermal transglutaminase, and endomysium are useful for confirming the diagnosis. (See",
"      <a class=\"local\" href=\"#H1643388880\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Our preferred approach to the treatment of DH consists of both pharmacotherapy and dietary therapy. For children and adults with DH, we suggest treatment with both",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"       dapsone",
"      </a>",
"      and a gluten-free diet as initial therapy (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). Subsequently, dapsone may be slowly tapered with the goal of sustaining remission with dietary therapy. (See",
"      <a class=\"local\" href=\"#H1643384165\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      DH is usually a life-long condition that requires continued treatment. Spontaneous remission may occur in a minority of patients. (See",
"      <a class=\"local\" href=\"#H2261977532\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/1\">",
"      Reunala T, Lokki J. Dermatitis herpetiformis in Finland. Acta Derm Venereol 1978; 58:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/2\">",
"      Mobacken H, Kastrup W, Nilsson LA. Incidence and prevalence of dermatitis herpetiformis in western Sweden. Acta Derm Venereol 1984; 64:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/3\">",
"      Salmi TT, Hervonen K, Kautiainen H, et al. Prevalence and incidence of dermatitis herpetiformis: a 40-year prospective study from Finland. Br J Dermatol 2011; 165:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/4\">",
"      Christensen OB, Hinds&eacute;n M, Svensson A. Natural history of dermatitis herpetiformis in southern Sweden. Dermatologica 1986; 173:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/5\">",
"      Burrows D. The prevalence of dermatitis herpetiformis. Br J Dermatol 1972; 86:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/6\">",
"      Buckley DB, English J, Molloy W, et al. Dermatitis herpetiformis: a review of 119 cases. Clin Exp Dermatol 1983; 8:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/7\">",
"      Gawkrodger DJ, Blackwell JN, Gilmour HM, et al. Dermatitis herpetiformis: diagnosis, diet and demography. Gut 1984; 25:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/8\">",
"      Moi H. Incidence and prevalence of dermatitis herpetiformis in a country in central Sweden, with comments on the course of the disease and IgA deposits as diagnostic criterion. Acta Derm Venereol 1984; 64:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/9\">",
"      Smith JB, Tulloch JE, Meyer LJ, Zone JJ. The incidence and prevalence of dermatitis herpetiformis in Utah. Arch Dermatol 1992; 128:1608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/10\">",
"      Ermacora E, Prampolini L, Tribbia G, et al. Long-term follow-up of dermatitis herpetiformis in children. J Am Acad Dermatol 1986; 15:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/11\">",
"      Bonciani D, Verdelli A, Bonciolini V, et al. Dermatitis herpetiformis: from the genetics to the development of skin lesions. Clin Dev Immunol 2012; 2012:239691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/12\">",
"      Spurkland A, Ingvarsson G, Falk ES, et al. Dermatitis herpetiformis and celiac disease are both primarily associated with the HLA-DQ (alpha 1*0501, beta 1*02) or the HLA-DQ (alpha 1*03, beta 1*0302) heterodimers. Tissue Antigens 1997; 49:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/13\">",
"      Forabosco P, Neuhausen SL, Greco L, et al. Meta-analysis of genome-wide linkage studies in celiac disease. Hum Hered 2009; 68:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/14\">",
"      Hervonen K, Hakanen M, Kaukinen K, et al. First-degree relatives are frequently affected in coeliac disease and dermatitis herpetiformis. Scand J Gastroenterol 2002; 37:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/15\">",
"      Meyer LJ, Zone JJ. Familial incidence of dermatitis herpetiformis. J Am Acad Dermatol 1987; 17:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/16\">",
"      Reunala T. Incidence of familial dermatitis herpetiformis. Br J Dermatol 1996; 134:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/17\">",
"      Bolotin D, Petronic-Rosic V. Dermatitis herpetiformis. Part I. Epidemiology, pathogenesis, and clinical presentation. J Am Acad Dermatol 2011; 64:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/18\">",
"      Marsh MN. Transglutaminase, gluten and celiac disease: food for thought. Transglutaminase is identified as the autoantigen of celiac disease. Nat Med 1997; 3:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/19\">",
"      Caputo I, Barone MV, Martucciello S, et al. Tissue transglutaminase in celiac disease: role of autoantibodies. Amino Acids 2009; 36:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/20\">",
"      Molberg O, Mcadam SN, K&ouml;rner R, et al. Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease. Nat Med 1998; 4:713.",
"     </a>",
"    </li>",
"    <li>",
"     Hull CM, Zone JJ. Dermatitis herpetiformis and linear IgA bullous dermatosis. In: Dermatology, 3rd ed, Bolognia JL, Jorizzo JL, Schaffer JV, et al.  (Eds), Elsevier Limited, 2012. Vol 1, p.491.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/22\">",
"      Hervonen K, Karell K, Holopainen P, et al. Concordance of dermatitis herpetiformis and celiac disease in monozygous twins. J Invest Dermatol 2000; 115:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/23\">",
"      McCleskey PE, Erickson QL, David-Bajar KM, Elston DM. Palmar petechiae in dermatitis herpetiformis: a case report and clinical review. Cutis 2002; 70:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/24\">",
"      Flann S, Degiovanni C, Derrick EK, Munn SE. Two cases of palmar petechiae as a presentation of dermatitis herpetiformis. Clin Exp Dermatol 2010; 35:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/25\">",
"      Heinlin J, Knoppke B, Kohl E, et al. Dermatitis herpetiformis presenting as digital petechiae. Pediatr Dermatol 2012; 29:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/26\">",
"      Hofmann SC, Nashan D, Bruckner-Tuderman L. Petechiae on the fingertips as presenting symptom of dermatitis herpetiformis Duhring. J Eur Acad Dermatol Venereol 2009; 23:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/27\">",
"      Aine L, M&auml;ki M, Reunala T. Coeliac-type dental enamel defects in patients with dermatitis herpetiformis. Acta Derm Venereol 1992; 72:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/28\">",
"      Aine L, Reunala T, M&auml;ki M. Dental enamel defects in children with dermatitis herpetiformis. J Pediatr 1991; 118:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/29\">",
"      K&aacute;rp&aacute;ti S. An exception within the group of autoimmune blistering diseases: dermatitis herpetiformis, the gluten-sensitive dermopathy. Dermatol Clin 2011; 29:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/30\">",
"      Alonso-Llamazares J, Gibson LE, Rogers RS 3rd. Clinical, pathologic, and immunopathologic features of dermatitis herpetiformis: review of the Mayo Clinic experience. Int J Dermatol 2007; 46:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/31\">",
"      K&aacute;rp&aacute;ti S. Dermatitis herpetiformis. Clin Dermatol 2012; 30:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/32\">",
"      Paek SY, Steinberg SM, Katz SI. Remission in dermatitis herpetiformis: a cohort study. Arch Dermatol 2011; 147:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/33\">",
"      Gaspari AA, Huang CM, Davey RJ, et al. Prevalence of thyroid abnormalities in patients with dermatitis herpetiformis and in control subjects with HLA-B8/-DR3. Am J Med 1990; 88:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/34\">",
"      Kaplan RP, Callen JP. Dermatitis herpetiformis: autoimmune disease associations. Clin Dermatol 1991; 9:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/35\">",
"      Tio M, Cox MR, Eslick GD. Meta-analysis: coeliac disease and the risk of all-cause mortality, any malignancy and lymphoid malignancy. Aliment Pharmacol Ther 2012; 35:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/36\">",
"      Askling J, Linet M, Gridley G, et al. Cancer incidence in a population-based cohort of individuals hospitalized with celiac disease or dermatitis herpetiformis. Gastroenterology 2002; 123:1428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/37\">",
"      Grainge MJ, West J, Solaymani-Dodaran M, et al. The long-term risk of malignancy following a diagnosis of coeliac disease or dermatitis herpetiformis: a cohort study. Aliment Pharmacol Ther 2012; 35:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/38\">",
"      Hervonen K, Vornanen M, Kautiainen H, et al. Lymphoma in patients with dermatitis herpetiformis and their first-degree relatives. Br J Dermatol 2005; 152:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/39\">",
"      Collin P, Pukkala E, Reunala T. Malignancy and survival in dermatitis herpetiformis: a comparison with coeliac disease. Gut 1996; 38:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/40\">",
"      Sigurgeirsson B, Agnarsson BA, Lindel&ouml;f B. Risk of lymphoma in patients with dermatitis herpetiformis. BMJ 1994; 308:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/41\">",
"      Leonard JN, Tucker WF, Fry JS, et al. Increased incidence of malignancy in dermatitis herpetiformis. Br Med J (Clin Res Ed) 1983; 286:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/42\">",
"      Viljamaa M, Kaukinen K, Pukkala E, et al. Malignancies and mortality in patients with coeliac disease and dermatitis herpetiformis: 30-year population-based study. Dig Liver Dis 2006; 38:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/43\">",
"      Lewis HM, Renaula TL, Garioch JJ, et al. Protective effect of gluten-free diet against development of lymphoma in dermatitis herpetiformis. Br J Dermatol 1996; 135:363.",
"     </a>",
"    </li>",
"    <li>",
"     Weedon D. The vesicobullous reaction pattern. In: Weedon's Skin Pathology, 3rd ed, Elsevier Limited, 2010. p.123.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/45\">",
"      Zone JJ, Meyer LJ, Petersen MJ. Deposition of granular IgA relative to clinical lesions in dermatitis herpetiformis. Arch Dermatol 1996; 132:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/46\">",
"      Ko CJ, Colegio OR, Moss JE, McNiff JM. Fibrillar IgA deposition in dermatitis herpetiformis--an underreported pattern with potential clinical significance. J Cutan Pathol 2010; 37:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/47\">",
"      Kawana S, Segawa A. Confocal laser scanning microscopic and immunoelectron microscopic studies of the anatomical distribution of fibrillar IgA deposits in dermatitis herpetiformis. Arch Dermatol 1993; 129:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/48\">",
"      Bonciolini V, Bonciani D, Verdelli A, et al. Newly described clinical and immunopathological feature of dermatitis herpetiformis. Clin Dev Immunol 2012; 2012:967974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/49\">",
"      Van L, Browning JC, Krishnan RS, et al. Dermatitis herpetiformis: potential for confusion with linear IgA bullous dermatosis on direct immunofluorescence. Dermatol Online J 2008; 14:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/50\">",
"      Garioch JJ, Lewis HM, Sargent SA, et al. 25 years' experience of a gluten-free diet in the treatment of dermatitis herpetiformis. Br J Dermatol 1994; 131:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/51\">",
"      Bolotin D, Petronic-Rosic V. Dermatitis herpetiformis. Part II. Diagnosis, management, and prognosis. J Am Acad Dermatol 2011; 64:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/52\">",
"      S&aacute;rdy M, K&aacute;rp&aacute;ti S, Merkl B, et al. Epidermal transglutaminase (TGase 3) is the autoantigen of dermatitis herpetiformis. J Exp Med 2002; 195:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/53\">",
"      Hull CM, Liddle M, Hansen N, et al. Elevation of IgA anti-epidermal transglutaminase antibodies in dermatitis herpetiformis. Br J Dermatol 2008; 159:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/54\">",
"      Dieterich W, Laag E, Bruckner-Tuderman L, et al. Antibodies to tissue transglutaminase as serologic markers in patients with dermatitis herpetiformis. J Invest Dermatol 1999; 113:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/55\">",
"      Borroni G, Biagi F, Ciocca O, et al. IgA anti-epidermal transglutaminase autoantibodies: a sensible and sensitive marker for diagnosis of dermatitis herpetiformis in adult patients. J Eur Acad Dermatol Venereol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/56\">",
"      Rose C, Armbruster FP, Ruppert J, et al. Autoantibodies against epidermal transglutaminase are a sensitive diagnostic marker in patients with dermatitis herpetiformis on a normal or gluten-free diet. J Am Acad Dermatol 2009; 61:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/57\">",
"      Caproni M, Antiga E, Melani L, et al. Guidelines for the diagnosis and treatment of dermatitis herpetiformis. J Eur Acad Dermatol Venereol 2009; 23:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/58\">",
"      Fry L, Leonard JN, Swain F, et al. Long term follow-up of dermatitis herpetiformis with and without dietary gluten withdrawal. Br J Dermatol 1982; 107:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/59\">",
"      Zone JJ, Meyer LJ. Dermatitis herpetiformis. Immunol Ser 1989; 46:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/60\">",
"      Egan CA, O'Loughlin S, Gormally S, Powell FC. Dermatitis Herpetiformis: a review of fifty-four patients. Ir J Med Sci 1997; 166:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/61\">",
"      Cardones AR, Hall RP 3rd. Management of dermatitis herpetiformis. Immunol Allergy Clin North Am 2012; 32:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/62\">",
"      Sanders SW, Zone JJ. The relationship between dapsone dose, serum concentration and disease severity in dermatitis herpetiformis. Arzneimittelforschung 1986; 36:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/63\">",
"      Collin P, Reunala T. Recognition and management of the cutaneous manifestations of celiac disease: a guide for dermatologists. Am J Clin Dermatol 2003; 4:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/64\">",
"      Reunala T, Blomqvist K, Tarpila S, et al. Gluten-free diet in dermatitis herpetiformis. I. Clinical response of skin lesions in 81 patients. Br J Dermatol 1977; 97:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/65\">",
"      Nino M, Ciacci C, Delfino M. A long-term gluten-free diet as an alternative treatment in severe forms of dermatitis herpetiformis. J Dermatolog Treat 2007; 18:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/66\">",
"      Heading RC, Paterson WD, McClelland DB, et al. Clinical response of dermatitis herpetiformis skin lesions to a gluten-free diet. Br J Dermatol 1976; 94:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/67\">",
"      Fr&ouml;din T, Gotthard R, Hed J, et al. Gluten-free diet for dermatitis herpetiformis: the long-term effect on cutaneous, immunological and jejunal manifestations. Acta Derm Venereol 1981; 61:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/68\">",
"      COOPER MM. Sulfapyridine in dermatitis herpetiformis; report of case under 11 years of continuous treatment. U S Armed Forces Med J 1958; 9:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/69\">",
"      COSTELLO MJ. Sulfapyridine in the treatment of dermatitis herpetiformis. Arch Derm Syphilol 1947; 56:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/70\">",
"      Willsteed E, Lee M, Wong LC, Cooper A. Sulfasalazine and dermatitis herpetiformis. Australas J Dermatol 2005; 46:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/71\">",
"      Goldstein BG, Smith JG Jr. Sulfasalazine in dermatitis herpetiformis. J Am Acad Dermatol 1990; 22:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/72\">",
"      Lowney ED. Use of sulfasalazine in dermatitis herpetiformis in young people. Arch Dermatol 1978; 114:1553.",
"     </a>",
"    </li>",
"    <li>",
"     Hall R. Dapsone. In: Comprehensive Dermatologic Therapy, Wolverton S (Ed), WB Saunders Co, Philadelphia 2001. p.230.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/74\">",
"      McFadden JP, Leonard JN, Powles AV, et al. Sulphamethoxypyridazine for dermatitis herpetiformis, linear IgA disease and cicatricial pemphigoid. Br J Dermatol 1989; 121:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/75\">",
"      PERRY HO, WINKELMANN RK. Adverse reactions to sulfamethoxypyridazine (kynex); its use in the treatment of dermatitis herpetiformis. J Am Med Assoc 1959; 169:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/76\">",
"      Lara-Corrales I, Pope E. Autoimmune blistering diseases in children. Semin Cutan Med Surg 2010; 29:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35369/abstract/77\">",
"      Hervonen K, Alakoski A, Salmi TT, et al. Reduced mortality in dermatitis herpetiformis: a population-based study of 476 patients. Br J Dermatol 2012; 167:1331.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15307 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-77399545CD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_34_35369=[""].join("\n");
var outline_f34_34_35369=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2261977592\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23341158\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23341172\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23341179\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2016766306\">",
"      Genetic predisposition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2016766164\">",
"      Gluten sensitivity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2261977824\">",
"      Other factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1643384077\">",
"      CLINICAL FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1643388780\">",
"      Cutaneous manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1643388809\">",
"      Oral manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1643388787\">",
"      Gastrointestinal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21110852\">",
"      Clinical course",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23341200\">",
"      ASSOCIATED DISEASES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1643388880\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23341348\">",
"      Histopathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1643388910\">",
"      Direct immunofluorescence microscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23341214\">",
"      Serology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21111880\">",
"      ADDITIONAL TESTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23341221\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1643384165\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21111917\">",
"      Indications for referral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2261977181\">",
"      First-line therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1643384272\">",
"      - Dapsone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2261977249\">",
"      - Gluten-free diet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2261977207\">",
"      Other therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H87246548\">",
"      - Other sulfa-based drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2261977229\">",
"      - Corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21110581\">",
"      Treatment of children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2261977532\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2261977592\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/15307\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/15307|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?34/21/35155\" title=\"picture 1A\">",
"      Dermatitis herpetiformis knee",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/27/26032\" title=\"picture 1B\">",
"      Dermatitis herpetiformis buttocks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?36/32/37377\" title=\"picture 1C\">",
"      Dermatitis herpetiformis knees",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?31/24/32128\" title=\"picture 1D\">",
"      Dermatitis herpetiformis vesicles on elbow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?41/3/42032\" title=\"picture 1E\">",
"      Dermatitis herpetiformis papules and vesicles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?23/38/24163\" title=\"picture 1F\">",
"      Dermatitis herpetiformis elbows",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?28/46/29408\" title=\"picture 1G\">",
"      Dermatitis herpetiformis excoriated papules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?34/23/35193\" title=\"picture 2\">",
"      Dermatitis herpetiformis histopathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?9/59/10163\" title=\"picture 3\">",
"      Dermatitis herpetiformis direct immunofluorescence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?17/36/17985\" title=\"picture 4\">",
"      Dermatitis herpetiformis direct immunofluorescence linear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?26/16/26885\" title=\"picture 5\">",
"      Bullous pemphigoid multiple lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?7/49/7954\" title=\"picture 6A\">",
"      Linear IgA bullous dermatosis on extremity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/62/16359\" title=\"picture 6B\">",
"      Linear IgA bullous dermatosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?41/50/42788\" title=\"picture 7\">",
"      Bullous pemphigoid eczematous",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/15307|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/23/35195\" title=\"table 1\">",
"      Adverse effects of dapsone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/56/39809\" title=\"table 2\">",
"      Topical corticosteroids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/54/14186?source=related_link\">",
"      Approach to the patient with cutaneous blisters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/3/37946?source=related_link\">",
"      Clinical manifestations and diagnosis of celiac disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/25/4505?source=related_link\">",
"      Clinical manifestations of glucose-6-phosphate dehydrogenase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/50/39719?source=related_link\">",
"      Diagnosis and treatment of glucose-6-phosphate dehydrogenase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/2/14377?source=related_link\">",
"      Diagnosis of celiac disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/57/43929?source=related_link\">",
"      Drug reaction with eosinophilia and systemic symptoms (DRESS)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/36/14922?source=related_link\">",
"      Linear IgA bullous dermatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/38/4714?source=related_link\">",
"      Management of celiac disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/47/7929?source=related_link\">",
"      Management of celiac disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/44/40650?source=related_link\">",
"      Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/20/40264?source=related_link\">",
"      Skin biopsy techniques",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_34_35370="Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis";
var content_f34_34_35370=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/34/35370/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/34/35370/contributors\">",
"     Daniel L Hamilos, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/34/35370/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/34/35370/contributors\">",
"     Jonathan Corren, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/34/35370/contributors\">",
"     Daniel G Deschler, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/34/35370/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/34/35370/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/34/35370/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 31, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H368890043\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic rhinosinusitis (CRS) may be broadly defined as an inflammatory disorder of the paranasal sinuses and linings of the nasal passages that lasts 12 weeks or longer. More precisely, it is a heterogeneous group of related disorders that share certain clinical and pathologic features. In the past, CRS lacked a clear definition and was approached differently by various specialties. However, multidisciplinary expert panels have now been established to determine how these disorders should be defined, evaluated, and managed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/1-5\">",
"     1-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The definition, epidemiology, clinical manifestations, pathologic features, evaluation, and diagnosis of chronic rhinosinusitis will be discussed here. Treatment is presented separately. The complex role of microbes and antimicrobial therapy in CRS is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/4/30794?source=see_link\">",
"     \"Management of chronic rhinosinusitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/58/26537?source=see_link\">",
"     \"Microbiology and antibiotic management of chronic rhinosinusitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic rhinosinusitis is defined as an inflammatory condition involving the paranasal sinuses and linings of the nasal passages that lasts 12 weeks or longer. The diagnosis requires objective evidence of mucosal inflammation.",
"   </p>",
"   <p>",
"    In some iterations of the definition, the phrase &ldquo;despite attempts at medical management&rdquo; is included to eliminate the possibility that chronic rhinosinusitis simply represents untreated acute rhinosinusitis. However it is problematic to include this phrase, since there is no definitive standard of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/2-6\">",
"     2-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Current definitions differ from earlier definitions of \"chronic sinusitis\" by adopting the term \"rhinosinusitis\" to emphasize the involvement of both the nasal passages and the paranasal sinuses, and by requiring objective evidence of sinus mucosal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/1,6,7\">",
"     1,6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1858543\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estimates of the prevalence of CRS worldwide vary significantly, in part because of differences in the diagnostic criteria used (eg, symptom-based diagnosis versus inclusion of objective rhinoscopy or imaging findings). In the United States, estimates ranged from 2 percent (based on ICD-9 diagnosis code) to 16 percent (based on the National Health Interview Survey) of the population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/8,9\">",
"     8,9",
"    </a>",
"    ], while in various European countries, the prevalence based on a postal survey ranges from 7 to 27 percent with an average of 10.9 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/10\">",
"     10",
"    </a>",
"    ]. Other estimates from South America and the Caribbean are in a similar range [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CRS occurs in both children and adults, although it is typically diagnosed in young or middle-aged adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/13\">",
"     13",
"    </a>",
"    ]. In several studies of adults, the mean age at diagnosis was 39 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/8,12\">",
"     8,12",
"    </a>",
"    ]. Women were disproportionately affected in some studies, although this finding is not consistent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/8,12\">",
"     8,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3250712\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;CRS may begin abruptly, beginning as a nonspecific upper respiratory infection or acute sinusitis that fails to resolve, or develop slowly and insidiously over months or years. Occasionally, the first manifestation of CRS may be a relatively acute presentation with severe headaches or facial pain or visual changes (such as diplopia). (See",
"    <a class=\"local\" href=\"#H3255792\">",
"     'Warning signs and complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3250739\">",
"    <span class=\"h2\">",
"     Signs and symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are four cardinal",
"    <span class=\"nowrap\">",
"     signs/symptoms",
"    </span>",
"    of CRS in adults:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Anterior",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      posterior nasal mucopurulent drainage",
"     </li>",
"     <li>",
"      Nasal",
"      <span class=\"nowrap\">",
"       obstruction/nasal",
"      </span>",
"      <span class=\"nowrap\">",
"       blockage/congestion",
"      </span>",
"     </li>",
"     <li>",
"      Facial pain, pressure,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fullness",
"     </li>",
"     <li>",
"      Reduction or loss of sense of smell",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In children, the fourth cardinal",
"    <span class=\"nowrap\">",
"     sign/symptom",
"    </span>",
"    is cough (rather than",
"    <span class=\"nowrap\">",
"     reduction/loss",
"    </span>",
"    of smell) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/4\">",
"     4",
"    </a>",
"    ]. Except when noted, the material in this topic review is applicable to both adults and children.",
"   </p>",
"   <p>",
"    Several other symptoms are reported by patients with CRS, including fatigue, malaise, cough, sleep disturbance, ear pain or pressure, dizziness, halitosis, dental pain, dysphonia, or nasal or throat irritation. However, none of these is specific enough to be clinically useful in diagnosis.",
"   </p>",
"   <p>",
"    The four cardinal symptoms of CRS may be present with any subtype of disease, and do not differentiate among the subtypes of CRS. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Features of specific subtypes'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Useful observations about the four leading",
"    <span class=\"nowrap\">",
"     signs/symptoms",
"    </span>",
"    include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Anterior",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       posterior nasal mucopurulent drainage",
"      </strong>",
"      &ndash; The typical anterior",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      posterior nasal drainage of CRS is usually opaque white or light yellow. Thick yellow, green, or brown mucus can occur, although it is more characteristic of recurrent acute rhinosinusitis or allergic fungal rhinosinusitis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/48/39688?source=see_link\">",
"       \"Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Nasal",
"       <span class=\"nowrap\">",
"        obstruction/nasal",
"       </span>",
"       <span class=\"nowrap\">",
"        blockage/congestion",
"       </span>",
"      </strong>",
"      &ndash; Nasal congestion is often described by the patient as nasal blockage or stuffiness or less commonly as nasal fullness. The differential diagnosis of nasal congestion includes allergic rhinitis, chronic nonallergic (idiopathic) rhinitis, rhinitis associated with medication use, and secondary atrophic rhinitis (ie, \"empty nose syndrome\"). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/17/30999?source=see_link\">",
"       \"An overview of rhinitis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/61/12250?source=see_link\">",
"       \"Chronic nonallergic rhinitis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/5/18519?source=see_link\">",
"       \"Atrophic rhinosinusitis\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Congestion in CRS is bilateral, although patients may find congestion on one side to be more bothersome or noticeable than the other. However, truly unilateral nasal",
"      <span class=\"nowrap\">",
"       congestion/blockage",
"      </span>",
"      raises the question of a local anatomic problem or tumor, such as an antral choanal cyst. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/44/16072?source=see_link\">",
"       \"Etiologies of nasal symptoms: An overview\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Facial pain, pressure,",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       fullness",
"      </strong>",
"      &ndash; Facial pressure and headache are reported by most patients with CRS (83 percent in one series) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/14\">",
"       14",
"      </a>",
"      ]. These symptoms may be seen in all subtypes of CRS, but they are less common in CRS with nasal polyps because the mucosal thickening in this condition is generally not associated with chronic infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/15\">",
"       15",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'CRS with nasal polyposis'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      Facial symptoms are common in patients with CRS, although they are least specific of the cardinal symptoms. Facial pain can be caused by various nonrhinogenic conditions, including migraine headaches, tension headaches, cluster headaches, and other poorly understood facial pain syndromes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/16\">",
"       16",
"      </a>",
"      ]. In addition, the presence of facial pain",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pressure is less reliable for predicting the presence of objective findings of rhinosinusitis, compared to the symptoms of nasal obstruction or posterior nasal drainage [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/17\">",
"       17",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The mucosal linings of the paranasal sinuses are poorly innervated, which probably contributes to the nonspecific nature of facial pain in CRS. Most patients describe vague discomfort, fullness, or pressure in the cheeks, above or below the eyes, or across the bridge of the nose. Many patients point to an area on the face that anatomically localizes to the ostiomeatal complex on one or both sides (",
"      <a class=\"graphic graphic_figure graphicRef67454 \" href=\"mobipreview.htm?16/36/16962\">",
"       figure 1",
"      </a>",
"      ). Obstruction of the nasofrontal recess may be associated with facial pain, pressure, or headache above the eyes or in the forehead.",
"      <br/>",
"      <br/>",
"      Focal and sharp facial pain over one or more sinus area(s) is less characteristic of CRS, and is typically not associated with radiographic evidence of sinus disease. Evaluation of these sharp, localized pains usually does not identify a precise explanation, and the pains are often ultimately diagnosed as \"neurogenic\" or \"causalgic\" in nature. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/34/3624?source=see_link\">",
"       \"Headache syndromes other than migraine\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Pain in the upper teeth is suggestive of nerve irritation caused by an inflammatory process adjacent to tooth roots. In patients with CRS, this symptom is typically intermittent and associated with an increase in other symptoms, such as nasal purulence. Dental pain was reported by 50 percent of patients in the series mentioned previously [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/14\">",
"       14",
"      </a>",
"      ]. However, in our experience, a much lower percentage of patients with CRS complain of tooth pain (eg, 5 to 10 percent). Even when this is reported, an \"odontogenic\" cause for the pain is not commonly found.",
"     </li>",
"     <li>",
"      <strong>",
"       Decreased sense of smell",
"      </strong>",
"      &ndash; Disturbance in sense of smell may be perceived as a reduced or completely absent sense of smell (hyposmia or anosmia, respectively). Anosmia is usually associated with mucosal thickening or opacification in the anterior ethmoid sinuses and is much more common in CRS with nasal polyposis than without polyposis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/18\">",
"       18",
"      </a>",
"      ]. Patients with anosmia also frequently report a reduced ability to taste foods (ageusia).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3255792\">",
"    <span class=\"h2\">",
"     Warning signs and complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following symptoms and signs are suggestive of other conditions or complications that require immediate evaluation: high fever, double or reduced vision, proptosis, dramatic periorbital edema, ophthalmoplegia, other focal neurologic signs, severe headache, meningeal signs, or significant or recurrent epistaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/19\">",
"     19",
"    </a>",
"    ]. Urgent referral to an",
"    <span class=\"nowrap\">",
"     otolaryngologist/head",
"    </span>",
"    and neck surgeon is indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3250746\">",
"    <span class=\"h2\">",
"     Impact on quality of life",
"    </span>",
"    &nbsp;&mdash;&nbsp;CRS can have significant adverse effects on quality of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. One study documented that patients with CRS had significantly lower quality of life scores for social functioning, as well as physical and overall health compared to the general population, with decrements similar to chronic lung or heart illnesses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     FEATURES OF SPECIFIC SUBTYPES",
"    </span>",
"    &nbsp;&mdash;&nbsp;CRS can be divided into three distinct clinical syndromes. The characteristics of each are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef53734 \" href=\"mobipreview.htm?40/6/41067\">",
"     table 1",
"    </a>",
"    ). Subtype distinctions are clinically relevant, since risk factors, contributing disorders, and response to medical or surgical management, are substantively different among the three conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The three subtypes of CRS are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      CRS with nasal polyposis &ndash; accounting for 20 to 33 percent of cases",
"     </li>",
"     <li>",
"      Allergic fungal rhinosinusitis &ndash; 8 to 12 percent",
"     </li>",
"     <li>",
"      CRS without nasal polyposis &ndash; 60 to 65 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The pathophysiology of the different subtypes remains incompletely understood, although it is an area of intense multidisciplinary study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/1,23,24\">",
"     1,23,24",
"    </a>",
"    ]. Data on the pathophysiology of each subtype is discussed in this section.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     CRS with nasal polyposis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic rhinosinusitis with nasal polyposis (CRS with NP) is characterized by the presence of bilateral nasal polyps in the middle meatus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/1\">",
"     1",
"    </a>",
"    ]. Nasal polyps are translucent, yellowish-grey to white, glistening masses filled with gelatinous inflammatory material, which may form in the nasal cavity or paranasal sinuses (",
"    <a class=\"graphic graphic_figure graphicRef50105 \" href=\"mobipreview.htm?26/4/26688\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef53872 \" href=\"mobipreview.htm?3/43/3761\">",
"     picture 1",
"    </a>",
"    ). The grey-white color is due to the relatively avascular nature of the polyp tissue. One to four percent of the general population has nasal polyps, and most are believed to be symptomatic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/4,25,26\">",
"     4,25,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4984464\">",
"    <span class=\"h3\">",
"     Presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The characteristic presentation of CRS with NP is gradually worsening nasal",
"    <span class=\"nowrap\">",
"     congestion/obstruction,",
"    </span>",
"    sinus fullness and pressure, fatigue, posterior nasal drainage, and hyposmia or anosmia. In contrast, fever and severe facial pain are uncommon.",
"   </p>",
"   <p>",
"    On physical examination, large polyps are often visible with anterior rhinoscopy, while smaller polyps require nasal endoscopy or imaging. Nasal polyps lack sensation. Swollen nasal turbinates are sometimes mistaken for nasal polyps, but turbinates are pink in color, similar in appearance to the rest of the nasal mucosa, and very sensitive to touch (",
"    <a class=\"graphic graphic_figure graphicRef52743 \" href=\"mobipreview.htm?11/43/11967\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Nasal polyps generally begin to form around the ostiomeatal complex, although they may eventually be found throughout the nasal cavities and sinuses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/2\">",
"     2",
"    </a>",
"    ]. The initial trigger for their development is probably variable. Nasal polyposis in CRS with NP should be bilateral [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/1\">",
"     1",
"    </a>",
"    ]. Unilateral polyps are relatively uncommon; if confirmed by imaging of the sinuses, this finding should prompt consideration of other diagnoses, including inverting papilloma or nasal tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/44/16072?source=see_link\">",
"     \"Etiologies of nasal symptoms: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CRS with NP affects immunocompetent patients and is associated with asthma and adverse reactions to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and other nonsteroidal antiinflammatory drugs (NSAIDs) that inhibit cyclooxygenase-1 (COX-1). Reactions involve some combination of rhinitis, conjunctival irritation,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    asthmatic symptoms occurring within one to four hours after ingestion of a COX-1 inhibiting NSAID. The combination of asthma, CRS with NP, and aspirin sensitivity is called aspirin exacerbated respiratory disease (AERD). Other terms for this combination of disorders include \"triad asthma\" or \"Samter's syndrome.\" Among patients with CRS with NP, between 30 and 40 percent report wheezing and respiratory discomfort and about 15 percent have aspirin-associated respiratory disease (",
"    <a class=\"graphic graphic_table graphicRef53734 \" href=\"mobipreview.htm?40/6/41067\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/26,29\">",
"     26,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis and management of AERD is reviewed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/0/39944?source=see_link\">",
"     \"Aspirin exacerbated respiratory disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20818307\">",
"    <span class=\"h3\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;On imaging with computerized tomography (CT), mucosal thickening is characteristically marked and bilateral. The CT density of polyps is similar to that of thickened mucosa, although polyps are differentiated from nonpolypoid mucosal thickening by their shape and contours (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef57710 \" href=\"mobipreview.htm?38/50/39715\">",
"     image 1",
"    </a>",
"    ). Polyps appear as rounded mucosal protrusions into the nasal or sinus cavities.",
"   </p>",
"   <p>",
"    Sinus opacification in the absence of facial",
"    <span class=\"nowrap\">",
"     pain/pressure/headaches",
"    </span>",
"    is typical of patients with CRS with NP, and is unlikely to represent chronic bacterial infection. When multiple polyps are present, sinus secretions may become entrapped within the crevices between the polyps. The CT attenuation values of the secretions can increase, and the polyp tissue itself might show mixed CT attenuation values with areas of increased density, simulating focal or diffuse dystrophic calcifications. When further information is required to clarify the nature of the findings, the combination of sinus CT plus sinus MRI imaging is usually helpful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H33\">",
"     'Sinus MRI'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20818430\">",
"    <span class=\"h3\">",
"     Histologic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biopsy of mucosal tissue characteristically shows edematous tissue and a paucity of submucosal glands and stromal fibrosis. Mixed infiltrates of mononuclear cells and eosinophils are usually present, with a predominancy of eosinophils. CRS with nasal polyposis and asthma share eosinophilic histopathologic features [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/18,31,32\">",
"     18,31,32",
"    </a>",
"    ]. This probably reflects a common mucosal susceptibility to environmental exposures and allergic-type inflammation that is shared by the upper and lower airways [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/33\">",
"     33",
"    </a>",
"    ]. An increase in epithelial goblet cells may also be present, although this does not distinguish CRS with NP from CRS without NP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/1,34\">",
"     1,34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4984597\">",
"    <span class=\"h3\">",
"     Pathophysiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polyp tissue typically contains high levels of the Th2 cytokines interleukin (IL)-5 and IL-13, and high levels of histamine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is evidence for localized allergic hyperresponsiveness to colonizing Staphylococcus aureus, as evidenced by the local production of specific IgE antibodies against staphylococcal enterotoxins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. Enterotoxins act as superantigens and broadly activate T lymphocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/36\">",
"     36",
"    </a>",
"    ]. Anti-enterotoxin antibodies can be measured in sinus tissues from patients with CRS with NP, although levels in the blood may be undetectable. In contrast, patients with CRS without NP do not appear to produce IgE to staphylococcal enterotoxins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A role for eosinophilic Th2 fungal sensitization has also been suggested in CRS with NP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Allergic fungal rhinosinusitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergic fungal rhinosinusitis (AFRS) is believed to result from chronic, intense allergic inflammation directed against colonizing fungi. Patients with AFRS are immunocompetent, and show evidence of allergy to one or more fungi (",
"    <a class=\"graphic graphic_table graphicRef53734 \" href=\"mobipreview.htm?40/6/41067\">",
"     table 1",
"    </a>",
"    ). AFRS is distinguished from CRS with NP by the presence of allergic mucin that contains viable fungal hyphae (as demonstrated by fungal staining or culture) and evidence of IgE-mediated allergy to one or more fungi [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/2,39\">",
"     2,39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4984667\">",
"    <span class=\"h3\">",
"     Presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;AFRS typically presents subtly over years, with symptoms similar to CRS with NP, since these patients usually have nasal polyposis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/40\">",
"     40",
"    </a>",
"    ]. Patients may report that semi-solid nasal crusts or rubbery globs of dark-colored mucus are periodically expelled from the nose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/1\">",
"     1",
"    </a>",
"    ]. Fever is uncommon. In occasional patients, AFRS presents dramatically with complete nasal obstruction, gross facial asymmetry,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    visual changes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/41\">",
"     41",
"    </a>",
"    ]. Children may present with proptosis more commonly than adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22932127\">",
"    <span class=\"h3\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with AFRS may have elevations of total serum IgE and peripheral blood eosinophilia. However, these are not required for the diagnosis of AFRS. In one study of 99 patients with either AFRS or CRS, total IgE in patients with AFRS was significantly higher than in those with CRS (mean levels, 1146 versus 247",
"    <span class=\"nowrap\">",
"     kU/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with AFRS demonstrate IgE-mediated allergy to fungus either by skin testing or in vitro immunoassays. Both epicutaneous (ie,",
"    <span class=\"nowrap\">",
"     prick/puncture)",
"    </span>",
"    and intradermal test results are relevant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/43\">",
"     43",
"    </a>",
"    ]. Most patients with AFRS show allergy to more than one fungus, although sensitization to multiple fungi is not required for the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20818833\">",
"    <span class=\"h3\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;CT usually reveals nasal polyposis with opacification of one or more sinuses. Similar to CRS with NP, sinus opacification is typically found in the absence of facial",
"    <span class=\"nowrap\">",
"     pain/pressure/headaches.",
"    </span>",
"    These findings are typically found despite previous medical therapy, including both antibiotics and oral glucocorticoids. A characteristic CT finding in AFRS is hyperattenuated mucin within the opacified sinuses, which indicate dense accumulations of allergic mucin (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77812 \" href=\"mobipreview.htm?8/3/8241\">",
"     image 2",
"    </a>",
"    ). Hyperdensities on CT are not entirely specific for AFRS and are not required to make the diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/18\">",
"     18",
"    </a>",
"    ]. Local pressure on the bony walls of the sinus cavity may result in expansion of this sinus cavity, bony demineralization over time, and possibly mucocele formation. True bone erosion is less common, occurring in 20 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20818862\">",
"    <span class=\"h3\">",
"     Histologic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;In AFRS, the sinus cavities contain \"allergic mucin,\" or thick, inspissated mucus that ranges in color from light tan to brown to dark green (",
"    <a class=\"graphic graphic_picture graphicRef67108 \" href=\"mobipreview.htm?39/35/40510\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/43\">",
"     43",
"    </a>",
"    ]. Allergic mucin is generally identified at the time of surgery. Allergic mucin contains degranulating eosinophils and is not specific to AFRS, as it can also be seen in the other subtypes of CRS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/45\">",
"     45",
"    </a>",
"    ]. However, in AFRS, the allergic mucin contains fungal hyphae demonstrable by staining or fungal culture, which is indicative of fungal colonization. By contrast, in invasive fungal sinusitis, fungal hyphae can be shown histologically to penetrate the underlying mucosa. Documentation of fungal hyphae in mucus samples requires specific staining, such as Gomori's",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/57/3989?source=see_link\">",
"     methenamine",
"    </a>",
"    silver (GMS) stain, although the insensitivity of this stain for detection of fungi has lead to proposed modifications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/36/8775?source=see_link&amp;anchor=H4#H4\">",
"     \"Fungal rhinosinusitis\", section on 'Invasive fungal sinusitis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Biopsy of mucosal tissue characteristically shows features of CRS with NP, including an infiltration with mixed mononuclear cells and abundant eosinophils.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1858077\">",
"    <span class=\"h2\">",
"     CRS without nasal polyposis",
"    </span>",
"    &nbsp;&mdash;&nbsp;CRS without nasal polyposis (CRS without NP) is the most common form of CRS, accounting for 60 to 65 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/18\">",
"     18",
"    </a>",
"    ]. CRS without NP describes the presence of CRS",
"    <strong>",
"     without",
"    </strong>",
"    the specific findings that define the other two syndromes (eg, nasal polyposis or allergic mucin with fungal hyphae).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4984675\">",
"    <span class=\"h3\">",
"     Presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The characteristic presentation of CRS without NP is that of persistent symptoms with periodic exacerbations characterized by increased facial",
"    <span class=\"nowrap\">",
"     pain/pressure",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    increased anterior or posterior drainage. Fatigue is a frequent accompanying symptom. Fever is usually absent or low-grade. A subset of patients has recurrent acute rhinosinusitis symptoms, which respond well to antibiotic treatment. Such patients may have persistent symptoms between episodes, in which case they could be classified as CRS without NP. However, they may be completely symptom free between episodes in which case they have been described as having &ldquo;recurrent acute rhinosinusitis&rdquo; or &ldquo;chronic recurrent rhinosinusitis&rdquo; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CRS without NP is heterogeneous and may include patients with allergic and nonallergic rhinitis, structural abnormalities,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    immunodeficiency. (See",
"    <a class=\"local\" href=\"#H22932626\">",
"     'Risk factors and associated conditions'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20819199\">",
"    <span class=\"h3\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;CT imaging of CRS without NP usually shows sinus opacification or sinus ostial obstruction with nonpolypoid mucosal thickening of the associated sinus cavity (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64365 \" href=\"mobipreview.htm?27/8/27779\">",
"     image 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20819125\">",
"    <span class=\"h3\">",
"     Histology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biopsy of mucosal tissue characteristically shows an infiltration of mixed mononuclear cells and neutrophils, with an increase in submucosal glands and stromal fibrosis. Epithelial goblet cell hyperplasia may be present. Eosinophils may be present but generally represent &lt;10 percent of the infiltrating inflammatory cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/1,34\">",
"     1,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pathogenic bacteria may or may not be present in the mucus. Allergic mucin is present in some cases, however patients with CRS without NP lack one or more criteria for AFRS, such as a positive mucus stain for fungi or evidence of fungal-specific IgE by skin tests or in vitro IgE immunoassays (eg, CAP-RAST tests). Thus, these patients do not fulfill all the criteria of AFRS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4984737\">",
"    <span class=\"h3\">",
"     Pathophysiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most cases, the disease process probably starts with obstruction of a sinus ostium leading to acute bacterial rhinosinusitis. If the obstruction fails to resolve, a chronic inflammatory process ensues. Antibiotic treatment",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the host immune response may clear or reduce the evidence of infection. The contribution of chronic infection at this point is variable and controversial. (See",
"    <a class=\"local\" href=\"#H4984293\">",
"     'Role of bacterial infection'",
"    </a>",
"    below.) In some cases there is little clinical evidence of infection. However, studies have demonstrated the presence of bacterial biofilm in sinus tissue in 45 to 80 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/48-51\">",
"     48-51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Histopathologic analysis typically reveals chronic inflammation with variable numbers of mononuclear cells, neutrophils, and some eosinophils (typically much fewer than seen in CRS with nasal polyps), and bacterial colonization or biofilm may contribute to the chronic inflammatory process. This remains an active area of investigation.",
"   </p>",
"   <p>",
"    Certain risk factors have been identified for the development of CRS without NP. (See",
"    <a class=\"local\" href=\"#H22932626\">",
"     'Risk factors and associated conditions'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Fungi have also been proposed to be involved in CRS without NP as well. Although most patients do not produce a classic IgE-mediated response against fungi, eosinophilic inflammation caused by a Th2-type sensitization to colonizing fungi has been proposed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. T lymphocytes from a high percentage of CRS patients produce eosinophil-promoting cytokines, including IL-5 and IL-13, when exposed in vitro to certain fungal antigens (eg, those from Alternaria) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. This type of response is best viewed as a \"modified Th2-type response.\" The significance of these findings is under investigation and the role of fungi in CRS without NP remains controversial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22932626\">",
"    <span class=\"h1\">",
"     RISK FACTORS AND ASSOCIATED CONDITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are multiple potentially causative factors that should be considered in each patient with CRS (",
"    <a class=\"graphic graphic_table graphicRef74779 \" href=\"mobipreview.htm?8/20/8523\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Allergic rhinitis:",
"      </strong>",
"      Among CRS patients undergoing sinus surgery, the prevalence of positive skin prick tests ranges from 50 to 84 percent, of which the majority of patients (60 percent) have multiple sensitivities [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/54-56\">",
"       54-56",
"      </a>",
"      ]. By definition, all patients with allergic fungal rhinosinusitis have IgE-mediated allergy to fungi. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Features of specific subtypes'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      CRS patients are typically sensitized to perennial rather than seasonal (ie, pollen) allergens [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/57\">",
"       57",
"      </a>",
"      ]. Important perennial allergens include house dust mites, fungal spores from indoor",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      outdoor sources, animal danders, cockroaches, and sometimes feathers. Perennial allergens are generally present at higher levels for longer periods of time compared to pollen allergens. Furthermore, fungal spores can germinate in sinus mucus, thereby increasing the allergenic stimulus.",
"      <br/>",
"      <strong>",
"       Asthma:",
"      </strong>",
"      Approximately 20 percent of CRS patients have concomitant asthma. Conversely, approximately two-thirds of asthma subjects, including both children and adults, have evidence of chronic sinus mucosal thickening or sinus opacification in cross-sectional studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/33\">",
"       33",
"      </a>",
"      ]. A cross-sectional study in multiple European centers consistently found a strong association between the presence of asthma and the presence of CRS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      <strong>",
"       exacerbated respiratory disease:",
"      </strong>",
"      The combination of asthma, CRS with NP, and aspirin sensitivity is called aspirin exacerbated respiratory disease (AERD). These three disorders are believed to be linked by an underlying biochemical abnormality in airway tissues, namely overproduction of cysteinyl leukotrienes. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'CRS with nasal polyposis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/0/39944?source=see_link\">",
"       \"Aspirin exacerbated respiratory disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Smoking:",
"      </strong>",
"      Active cigarette smoking is an important risk factor for CRS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/59,60\">",
"       59,60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Irritants and pollutants:",
"      </strong>",
"      Sustained exposure to other environmental noxious or ciliostatic substances, such as formaldehyde, may also contribute to nasal and sinus mucosal inflammation and decreased mucociliary function, thereby predisposing to sinus infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/61\">",
"       61",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Studies have demonstrated associations between common air pollutants, such as carbon monoxide, nitrogen dioxide, sulfur dioxide, and particulate matter [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/62\">",
"       62",
"      </a>",
"      ], although the evidence supporting a pathogenic role for poor air quality in contributing to the development of CRS is relatively weak [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Immunodeficiency:",
"      </strong>",
"      Defective or deficient antibody production is found in some children and adults with CRS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/18,63-65\">",
"       18,63-65",
"      </a>",
"      ]. The specific disorders that are associated with CRS include various forms of hypogammaglobulinemia and selective antibody deficiency with normal immunoglobulins (SADNI) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/63\">",
"       63",
"      </a>",
"      ]. Most patients with defective or deficient antibody production have a pattern of recurrent acute episodes of purulent infection. They may also have a history of concomitant pulmonary infections or recurrent otitis media. Such patients should be evaluated for an underlying immune defect. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/48/24326?source=see_link\">",
"       \"Primary humoral immune deficiencies: An overview\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/51/17209?source=see_link\">",
"       \"Selective antibody deficiency with normal immunoglobulins\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      There are more limited data about CRS risk in patients with defects in the innate immune system. Innate immune deficiency is difficult to diagnose owing to limited testing capabilities. Mannose-binding lectin (MBL) deficiency is one of the most prevalent innate immune deficiencies, but there is little evidence for an increased prevalence of MBL deficiency in children or adults with CRS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/66\">",
"       66",
"      </a>",
"      ]. The nasal and sinus epithelium produces a variety of antimicrobial proteins, such as lactoferrin, lysozyme, defensins, collectins, and cathelicidins. Little is known about functional defects in production of these proteins in chronic rhinosinusitis, although this is an area of active research [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/67-69\">",
"       67-69",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Defects in mucociliary clearance",
"      </strong>",
"      : Defects in mucociliary clearance, such as those found in cystic fibrosis and primary ciliary dyskinesia, dramatically increase the risk of developing CRS. All children diagnosed with nasal polyposis should be evaluated for cystic fibrosis. In comparison, these rare syndromes combined account for less than 1 percent of all adult CRS cases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/70\">",
"       70",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/49/28442?source=see_link\">",
"       \"Cystic fibrosis: Clinical manifestations and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/37/9817?source=see_link\">",
"       \"Primary ciliary dyskinesia (immotile-cilia syndrome)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Viral infections:",
"      </strong>",
"      In a small number of cases, patients appear to develop CRS after a period of repeated exposure to viral upper respiratory infections. This is characteristically seen in patients exposed to health care settings, day-care centers, schools, or homes with small children. However, data clearly implicating viral agents in the pathogenesis of CRS are scarce [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/71\">",
"       71",
"      </a>",
"      ], and the role of viral infection in CRS is controversial.",
"     </li>",
"     <li>",
"      <strong>",
"       Systemic diseases",
"      </strong>",
"      : CRS may be the presenting feature of an underlying systemic illness, such as granulomatosis with polyangiitis (Wegener&rsquo;s) or Churg-Strauss vasculitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/72,73\">",
"       72,73",
"      </a>",
"      ]. Nasal polyps are associated with Churg-Strauss vasculitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/2\">",
"       2",
"      </a>",
"      ]. Rarely, sarcoidosis may present with CRS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/74\">",
"       74",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Signs and symptoms that suggest the presence of these conditions include fever, other signs of vasculitis, visual or other neurologic symptoms, severe headaches, or signs of meningeal inflammation. Sinonasal findings that should raise suspicion include unilateral sinus disease, persistently bloody nasal discharge, nonhealing nasal lesions, nasal septal perforation with bleeding and crusting, and collapse of the nasal bridge. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/62/17386?source=see_link\">",
"       \"Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/56/21383?source=see_link\">",
"       \"Epidemiology, pathogenesis, and pathology of Churg-Strauss syndrome (allergic granulomatosis and angiitis)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/25/21914?source=see_link\">",
"       \"Clinical manifestations and diagnosis of sarcoidosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Dental infections",
"      </strong>",
"      : The relationship between dental infections and sinusitis is well-known but often difficult to establish. Both disorders are common and only occasionally related. &ldquo;Odontogenic sinusitis&rdquo; should be considered in patients with maxillary sinusitis who have had dental infections, dentoalveolar surgery, periodontal surgery or who have recurrent or chronic maxillary sinusitis refractory to standard treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/75\">",
"       75",
"      </a>",
"      ]. Sinus CT reports will occasionally note the presence of an oroantral fistula, apical (also known as &ldquo;periapical&rdquo;) abscess, periodontal disease, or a projecting tooth root into the maxillary antrum. Of these, oroantral fistula or apical abscess are the most likely to be associated with maxillary sinusitis, and they merit further evaluation. Dental abscesses can be overlooked or missed on routine sinus CT images unless the image extends to beyond the floor of the maxillary sinus and includes the maxillary teeth [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/76,77\">",
"       76,77",
"      </a>",
"      ]. Early stages of bony loss due to a periapical abscess can also be missed on conventional dental x-rays but may be detected on sinus CT scans [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/76\">",
"       76",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Anatomic abnormalities",
"      </strong>",
"      : Certain anatomic variants, such as septal deviation, concha bullosa, or a displaced uncinate process, have been suggested to predispose to obstruction of the ostiomeatal unit. However, there is currently little evidence that these play a role in most cases of chronic sinusitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/78-82\">",
"       78-82",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/44/16072?source=see_link\">",
"       \"Etiologies of nasal symptoms: An overview\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Repeated sinus surgeries occasionally result in anatomic abnormalities or replacement of normal sinus mucosal tissue with scar tissue that may impair normal mucociliary clearance (ie, secondary atrophic rhinitis). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/5/18519?source=see_link\">",
"       \"Atrophic rhinosinusitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Indoor dampness and mold exposure",
"      </strong>",
"      : Whereas some studies have suggested a possible relationship between indoor dampness or mold exposure and rhinosinusitis, an Institute of Medicine report in 2004 concluded that there was no convincing epidemiologic evidence of such an association [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/83\">",
"       83",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4984293\">",
"    <span class=\"h2\">",
"     Role of bacterial infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over the past decade, it has become clear that CRS is a complex inflammatory disorder, rather than a simple infectious process or anatomic problem. Bacterial infection or colonization may contribute to CRS in several ways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute bacterial rhinosinusitis may fail to resolve, leading to a chronic infection in one or more sinuses. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/58/26537?source=see_link&amp;anchor=H2#H2\">",
"       \"Microbiology and antibiotic management of chronic rhinosinusitis\", section on 'Microbiology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bacteria may form biofilms on the sinus epithelium. Sequestration of bacteria within biofilms allows them to resist antibiotic treatment and persist as a low-grade infection within the sinus mucosa [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/19,48-51,84\">",
"       19,48-51,84",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Bacterial colonization with enterotoxin-producing Staphylococcus aureus is found with increased prevalence in CRS with NP and is associated with local production of enterotoxin-specific IgE antibodies, as reviewed previously [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/36\">",
"       36",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'CRS with nasal polyposis'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Enterotoxin-specific IgE antibodies (SAE IgE) are typically only detectable in the serum of patients with severe concomitant asthma. In these cases, the presence of serum SAE IgE is strongly associated with the presence of an elevated total serum IgE independent of allergic sensitization to common airborne allergens, suggesting that the elevation may be attributable to SAE IgE [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/85\">",
"       85",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Drug-resistant infection may occur with gram-negative bacteria or methicillin-resistant Staphylococcus aureus (MRSA) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/86\">",
"       86",
"      </a>",
"      ]. Infection with drug-resistant bacteria should be considered in patients with nosocomial infections, and in individuals who work in health care settings.",
"     </li>",
"     <li>",
"      Acute bacterial infection may lead to osteitis of the underlying bone and persistent infection in some cases, although actual invasion of the bone has not been conclusively demonstrated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/87\">",
"       87",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The microbiology and antimicrobial therapy of CRS are reviewed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/58/26537?source=see_link\">",
"     \"Microbiology and antibiotic management of chronic rhinosinusitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of chronic rhinosinusitis (CRS) involves a clinical history, objective documentation of mucosal disease, allergy evaluation, and consideration of immunologic defects and infectious complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial history should include information about the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Presence of the four cardinal symptoms (see",
"      <a class=\"local\" href=\"#H3250712\">",
"       'Clinical manifestations'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Duration of symptoms",
"     </li>",
"     <li>",
"      Presence of",
"      <span class=\"nowrap\">",
"       causative/contributing",
"      </span>",
"      conditions and factors, as discussed in the preceding section (",
"      <a class=\"graphic graphic_table graphicRef74779 \" href=\"mobipreview.htm?8/20/8523\">",
"       table 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Previous treatment",
"     </li>",
"     <li>",
"      Previous imaging",
"     </li>",
"     <li>",
"      Previous surgical interventions",
"     </li>",
"     <li>",
"      Potential exposure to indoor allergens at home, school, or work",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Demonstration of mucosal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of CRS requires objective documentation of mucosal inflammation, as evidenced by one or more of the following findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Purulent (not clear) mucus or edema in the middle meatus or ethmoid regions",
"     </li>",
"     <li>",
"      Polyps in the nasal cavity or the middle meatus",
"     </li>",
"     <li>",
"      Radiographic imaging demonstrating mucosal thickening, or partial or complete opacification of the paranasal sinuses",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinicians with training in anterior rhinoscopy (with decongestion) or nasal endoscopy can directly visualize the nasal cavities and sinuses, which has the advantage of limiting the patient&rsquo;s radiation exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/88\">",
"     88",
"    </a>",
"    ]. Clinicians without such training most often obtain sinus CT scans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23061096\">",
"    <span class=\"h3\">",
"     Rhinoscopy and endoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anterior rhinoscopy can be performed with a nasal speculum or otoscope, but apart from assessing the state of the nasal mucosa or documenting polyps that protrude into the nasal cavity, this technique provides limited visualization of key structures and therefore limited capacity to document CRS. The nasal cavities are first sprayed with a solution of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/54/33632?source=see_link\">",
"     oxymetazoline",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/36/39488?source=see_link\">",
"     phenylephrine",
"    </a>",
"    to shrink the turbinate tissue.",
"   </p>",
"   <p>",
"    In contrast to rhinoscopy, nasal endoscopy, which requires a nasal endoscope and appropriate training, can directly visualize the nasal cavities, assess the patency of the major ostia, and document purulent drainage from the ostia, facilitate obtaining bacterial or fungal cultures from the sinuses, or identify polyps within the sinuses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/89\">",
"     89",
"    </a>",
"    ]. The endoscope can only enter the maxillary, ethmoid, frontal, and sphenoid sinuses if the patient has had prior sinus surgery. Otherwise, sinus imaging is required to evaluate these areas. However, in a nonsurgical patient, the nasal endoscope provides excellent visualization of the sphenoethmoidal recess, sphenoid and posterior ethmoid ostia, and middle meatus and can facilitate obtaining bacterial or fungal cultures from these areas.",
"   </p>",
"   <p>",
"    Features consistent with CRS include mucopus (purulent mucus) emanating from the middle meatus (",
"    <a class=\"graphic graphic_picture graphicRef59556 \" href=\"mobipreview.htm?34/63/35838\">",
"     picture 3",
"    </a>",
"    ), edematous hyperemic mucosa, polypoid mucosal changes, or frank polyposis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef57710 \" href=\"mobipreview.htm?38/50/39715\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3255902\">",
"    <span class=\"h3\">",
"     Sinus imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Either sinus CT (most common) or magnetic resonance imaging (MRI) can be used to demonstrate mucosal disease. Other forms of imaging are not considered adequate:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Standard radiographs (plain films) of the nasal cavity and paranasal sinuses are not adequate to diagnose CRS because abnormalities detected on plain films are neither sensitive nor specific for sinusitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Transillumination and ultrasound imaging of the sinuses are considered outmoded and have not been recommended for diagnostic purposes by consensus groups due to lack of sensitivity and specificity for rhinosinusitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/1,7\">",
"       1,7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h4\">",
"     Sinus CT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiplanar sinus CT scan is the preferred imaging modality for evaluating CRS (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77069 \" href=\"mobipreview.htm?34/31/35313\">",
"     image 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/90\">",
"     90",
"    </a>",
"    ]. However, the number of scans performed on an individual patient with sinus disease over time should be minimized, as there is growing recognition that the cumulative radiation exposure from repeat CTs can be clinically significant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/91\">",
"     91",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/17/21785?source=see_link&amp;anchor=H6024332#H6024332\">",
"     \"Radiation-related risks of imaging studies\", section on 'CT examinations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The anterior ethmoid air cells, in particular, are a common focus of persistent infection or inflammation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/92\">",
"     92",
"    </a>",
"    ]. Coronal sinus CT images provide excellent visualization of the ethmoid sinuses but may occasionally be difficult to interpret because of the small size of ethmoid air cells and the existence of ethmoid septae that orient in the coronal plane. Multiplanar images in the coronal, axial, and sagittal planes facilitate a more detailed examination of questionable ethmoid opacification.",
"   </p>",
"   <p>",
"    The most common findings in CRS are sinus mucosal thickening, sinus ostial obstruction, polyps, and sinus opacification:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Mucosal thickening",
"      </strong>",
"      : Mucosal thickening is suggestive of infection",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      obstruction of a sinus ostium (the distinct bony opening through which each sinus drains).",
"     </li>",
"     <li>",
"      <strong>",
"       Obstruction of the ostiomeatal complex",
"      </strong>",
"      : Variable degrees of sinus ostial obstruction are common in CRS. The ostiomeatal complex (or ostiomeatal unit) is an area where several structures interface, through which the anterior ethmoid and maxillary sinuses drain (",
"      <a class=\"graphic graphic_figure graphicRef50120 \" href=\"mobipreview.htm?10/21/10579\">",
"       figure 4",
"      </a>",
"      ). Obstruction of the ostiomeatal complex predisposes to recurrent sinus infections and chronic mucosal thickening.",
"     </li>",
"     <li>",
"      <strong>",
"       Sinus opacification",
"      </strong>",
"      : Sinus opacification is complete filling of a sinus with inflammatory material or fluid. Opacification may be seen with persistent bacterial infection, purulent secretions, mucus inspissation, polypoid mucosal thickening, or an accumulation of allergic mucin (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef77812 \" href=\"mobipreview.htm?8/3/8241\">",
"       image 2",
"      </a>",
"      ). CT combined with MRI is useful in differentiating among the different causes of sinus opacification [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/30\">",
"       30",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H33\">",
"       'Sinus MRI'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A number of other findings may also be seen on sinus CT:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Mucus retention cysts",
"      </strong>",
"      : Mucus retention cysts are most often seen in the maxillary sinus. These result from obstruction of the ducts of mucosal serous",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      mucinous glands. They are usually small and clinically silent, although they rarely enlarge sufficiently to fill a sinus cavity.",
"     </li>",
"     <li>",
"      <strong>",
"       Mucoceles",
"      </strong>",
"      : Mucoceles are epithelium-lined cysts filled with mucus, which may also appear as cystic lesions on sinus CT. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/44/16072?source=see_link&amp;anchor=H16#H16\">",
"       \"Etiologies of nasal symptoms: An overview\", section on 'Mucoceles'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Bony changes",
"      </strong>",
"      : Less common findings include sclerosis of the wall of the sinus, unusual bony septations, bony erosions, and bowing of bony structures associated with sinus opacification.",
"     </li>",
"     <li>",
"      <strong>",
"       Isolated sphenoid involvement",
"      </strong>",
"      : Uncommonly, patients present with symptoms of chronic rhinosinusitis and are found to have isolated sphenoid sinusitis on sinus CT. Such patients typically have symptoms of retroorbital or frontal headache or visual disturbance, but they may have less common symptoms, such as occipital or vertex headaches [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/93-96\">",
"       93-96",
"      </a>",
"      ]. Isolated sphenoid abnormalities may be found incidentally on sinus or brain imaging studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/96\">",
"       96",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Because the symptoms of sphenoid sinus involvement are atypical and sometimes insidious, there is a risk that the patient will present with a more advanced disease process. Bony erosion and extrasinus extension of disease or infection may be present [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/94,96\">",
"       94,96",
"      </a>",
"      ]. Lesions that cause anatomic distortion of a sinus wall on CT scan warrant evaluation by MRI scan [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/96\">",
"       96",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In isolated sphenoid disease, pathologies other than acute or chronic rhinosinusitis are present in a significant number of cases. Disorders such as fungal rhinosinusitis, fungus ball, mucocele, fibrous dysplasia, meningoencephalocele, inverted papilloma, epidermoid carcinoma, liquor fistula, rhabdomyosarcoma, chordoma, and carotid artery pseudoaneurysm should be considered [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/93,94\">",
"       93,94",
"      </a>",
"      ]. CT findings in sphenoid sinusitis are described below. Following medical treatment of isolated sphenoid sinusitis, repeat imaging to ensure that there is no evidence of persistent pathology is suggested.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h4\">",
"     Sinus MRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data about the use of MRI to diagnose CRS is limited, although sinus MRI correlated well with CT in one study of 89 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The combination of CT and MRI imaging techniques can provide a more precise differentiation of mucus accumulation and mucosal thickening within sinus cavities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/1,7\">",
"     1,7",
"    </a>",
"    ]. This is particularly useful for distinguishing the allergic mucin of AFRS from other material in an opacified sinus (such as infected fluid or trapped secretions). Allergic mucin produces characteristic hyperdensities on CT, which appear as hypoattenuated (or hypointense) areas on T2-weighted MR images (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77812 \" href=\"mobipreview.htm?8/3/8241\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/1\">",
"     1",
"    </a>",
"    ]. These radiographic phenomena may correspond to accumulations of calcium and heavy metals within the mucin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/98,99\">",
"     98,99",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Sinus cultures",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with persistent symptoms despite previous antibiotic treatment, the possibility of infection with either gram-negative or drug-resistant bacteria should be considered. Documenting the presence of such an infection requires obtaining bacterial",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fungal cultures directly from the sinus ostia, either endoscopically or by sinus puncture. Nasal swabs are not reflective of sinus contents and should NOT be used to guide treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/58/26537?source=see_link\">",
"     \"Microbiology and antibiotic management of chronic rhinosinusitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Allergy evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perennial allergens, including those from dust mite, cockroach, animal danders, and fungi, are believed to be of particular pathogenic importance in CRS. In our opinion and that of some guidelines, all patients with CRS should be evaluated for sensitization to environmental allergens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/53/22362?source=see_link\">",
"     \"Allergic rhinitis: Clinical manifestations, epidemiology, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Consider immune evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Defects in antibody production or function should be suspected if the patient has recurrent or persistent purulent secretions. Immunodeficiency is most common in CRS without NP. (See",
"    <a class=\"local\" href=\"#H22932626\">",
"     'Risk factors and associated conditions'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Selective antibody deficiency (polysaccharide nonresponse) and various forms of hypogammaglobulinemia are identified in approximately 12 percent of patients with CRS without NP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/18\">",
"     18",
"    </a>",
"    ]. Testing for antibody defects includes measurement of immunoglobulins and specific antibody responses to vaccination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/8/12422?source=see_link\">",
"     pneumococcal polysaccharide vaccine",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/58/43945?source=see_link\">",
"     \"Laboratory evaluation of the immune system\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/51/17209?source=see_link\">",
"     \"Selective antibody deficiency with normal immunoglobulins\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Consider evaluation for systemic diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed previously, CRS may be the presenting disorder granulomatosis with polyangiitis (Wegener&rsquo;s), Churg-Strauss vasculitis (CSS), or occasionally cystic fibrosis, sarcoidosis, or primary ciliary dyskinesia. Certain signs and symptoms should raise suspicion for these diseases. (See",
"    <a class=\"local\" href=\"#H22932626\">",
"     'Risk factors and associated conditions'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    If concerning signs or symptoms are present, then initial laboratories should include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete blood counts with differential",
"     </li>",
"     <li>",
"      Erythrocyte sedimentation rate",
"     </li>",
"     <li>",
"      Antineutrophil cytoplasmic antibodies (ANCA), which are found in 40 to 60 percent of patients with CSS and 60 to 90 percent of those with granulomatosis with polyangiitis",
"     </li>",
"     <li>",
"      A serum angiotensin converting enzyme (ACE) level, which is elevated in 75 percent of untreated patients with sarcoidosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnosis of these diseases ultimately requires histologic confirmation in diseased sinus (or other) tissue. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/14/21738?source=see_link\">",
"     \"Respiratory tract involvement in granulomatosis with polyangiitis (Wegener's)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/56/21383?source=see_link\">",
"     \"Epidemiology, pathogenesis, and pathology of Churg-Strauss syndrome (allergic granulomatosis and angiitis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/25/21914?source=see_link\">",
"     \"Clinical manifestations and diagnosis of sarcoidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of CRS is based upon the presence of suggestive symptoms, in combination with objective evidence of mucosal inflammation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3254002\">",
"    <span class=\"h2\">",
"     Suggestive signs and symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of CRS is based upon the presence of at least TWO of the four cardinal",
"    <span class=\"nowrap\">",
"     signs/symptoms",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/3,4,86\">",
"     3,4,86",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Anterior",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      posterior nasal mucopurulent drainage",
"     </li>",
"     <li>",
"      Nasal",
"      <span class=\"nowrap\">",
"       obstruction/nasal",
"      </span>",
"      <span class=\"nowrap\">",
"       blockage/congestion",
"      </span>",
"     </li>",
"     <li>",
"      Facial pain, pressure,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fullness",
"     </li>",
"     <li>",
"      Reduction or loss of sense of smell",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some guidelines specify that patients must have drainage or nasal obstruction as one of the two [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/4\">",
"     4",
"    </a>",
"    ]. The cardinal",
"    <span class=\"nowrap\">",
"     signs/symptoms",
"    </span>",
"    should be present for",
"    <strong>",
"     12 weeks or longer",
"    </strong>",
"    despite attempts at medical management.",
"   </p>",
"   <p>",
"    Although symptoms must be present to consider the diagnosis, there is a poor correlation between the symptoms of CRS and objective findings upon imaging or endoscopy of the paranasal sinuses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/88,100,101\">",
"     88,100,101",
"    </a>",
"    ]. Thus, objective measures of mucosal inflammation are also required for the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3254012\">",
"    <span class=\"h2\">",
"     Objective evidence of inflammation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition, establishing the diagnosis requires objective evidence of sinus mucosal disease on sinus CT imaging or direct endoscopic examination, because symptoms alone are not sufficiently specific. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Demonstration of mucosal disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Objective evidence of mucosal inflammation requires demonstration of one or more of the following findings, using nasal endoscopy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    CT imaging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Purulent (not clear) mucus or edema in the middle meatus or ethmoid regions (",
"      <a class=\"graphic graphic_picture graphicRef59556 \" href=\"mobipreview.htm?34/63/35838\">",
"       picture 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Polyps in the nasal cavity or the middle meatus",
"     </li>",
"     <li>",
"      Radiographic imaging demonstrating mucosal thickening, or partial or complete opacification of the paranasal sinuses",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The performance of these diagnostic criteria was evaluated in a prospective study of 202 consecutive patients presenting to an otolaryngology practice for evaluation of possible CRS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/88\">",
"     88",
"    </a>",
"    ]. Patients completed questionnaires about symptoms and then underwent rigid nasal endoscopy by a clinician blinded to symptom scores. This was followed by sinus CT, which served as the gold standard for determining the presence or absence of CRS. Within this referral population, 178 had two or more of the four cardinal symptoms. Of these subjects, only 40 percent (71 of 178) had CRS based upon CT. Thus, symptoms alone had a sensitivity of 89 percent, a specificity of just 12 percent, and a positive predictive value (PPV) of only 40 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/88\">",
"     88",
"    </a>",
"    ]. The addition of nasal endoscopy increased the PPV to 66 percent. Overall, the combination of symptoms and endoscopy findings had a sensitivity of 47 percent and a specificity of 84 percent for CRS. The primary advantage of nasal endoscopy, compared with CT, is that it spares the patient some radiation, as discussed above. (See",
"    <a class=\"local\" href=\"#H23061096\">",
"     'Rhinoscopy and endoscopy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Determining the subtype of disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the diagnosis of CRS has been established, the subtype of disease present should be defined as clearly as possible. Findings on sinus CT (most commonly) or tissue biopsy (if available) assist in differentiation among the three subtypes of CRS (",
"    <a class=\"graphic graphic_table graphicRef53734 \" href=\"mobipreview.htm?40/6/41067\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CRS with NP is characterized by the presence of bilateral nasal polyposis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/1\">",
"       1",
"      </a>",
"      ]. Medical records documenting removal of bilateral nasal polyps during previous surgery also satisfy this requirement. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'CRS with nasal polyposis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      AFRS should be suspected when CT shows polypoid mucosal thickening, one or more opacified sinuses despite extensive medical therapy, and characteristic hyperdensities within the opacified sinuses (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef77812 \" href=\"mobipreview.htm?8/3/8241\">",
"       image 2",
"      </a>",
"      ). Note that these hyperdensities are not entirely specific for AFRS and are not required to make the diagnosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/18\">",
"       18",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Surgery is required to establish the diagnosis by confirming the presence of allergic mucin containing degranulating eosinophils and fungal hyphae (as demonstrated by fungal staining or culture) that do not invade the underlying mucosa. Evidence of IgE mediated allergy to one or more fungi must be demonstrated, either with skin testing or IgE immunoassays. Finally, diabetes mellitus or other immunodeficiency states should be excluded, and there should be no evidence of invasive fungal disease. All of these elements are required to make the diagnosis of AFRS. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Allergic fungal rhinosinusitis'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Some cases of CRS have allergic mucin but lack the other features of AFRS. These have been labeled \"eosinophilic mucin rhinosinusitis\" by some authors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/102\">",
"       102",
"      </a>",
"      ]. When the patient has allergic mucin and evidence of fungal allergy but no fungi by staining or culture, the patient can be considered to be an \"AFRS candidate\" [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/103\">",
"       103",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      CRS without NP is characterized by sinus opacification or sinus ostial obstruction with nonpolypoid mucosal thickening of the associated sinus cavity (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef64365 \" href=\"mobipreview.htm?27/8/27779\">",
"       image 3",
"      </a>",
"      ). Chronic infection should be considered when these findings are present. (See",
"      <a class=\"local\" href=\"#H1858077\">",
"       'CRS without nasal polyposis'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      When purulent drainage is present, it may be helpful to obtain cultures from the middle meatus or sinus cavities. Antral puncture of the maxillary sinus to obtain cultures is typically reserved for research studies. (See",
"      <a class=\"local\" href=\"#H23061096\">",
"       'Rhinoscopy and endoscopy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The symptoms of CRS overlap with those of other rhinogenic and nonrhinogenic conditions. CRS can also coexist with these other conditions.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Pain syndromes",
"      </strong>",
"      : Prominent facial pain can be seen with migraine headaches, tension headaches, cluster headaches, and other poorly understood facial pain syndromes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/104\">",
"       104",
"      </a>",
"      ]. In these conditions, pain overshadows other symptoms, and imaging does not show sinus pathology. However, headaches and pain syndromes coexist with CRS in a substantial proportion of patients. In coexistent disease, a careful review of the patient's symptoms usually reveals more than one pattern of pain. Headache syndromes are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/34/3624?source=see_link\">",
"       \"Headache syndromes other than migraine\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34615?source=see_link\">",
"       \"Evaluation of headache in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/8/35977?source=see_link&amp;anchor=H661158064#H661158064\">",
"       \"Approach to the child with headache\", section on 'Primary headache'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Rhinitis without sinusitis",
"      </strong>",
"      : Anterior or posterior nasal drainage may be a symptom of seasonal or perennial allergic rhinitis, nonallergic vasomotor (or idiopathic) rhinitis, rhinitis medicamentosa, and rhinitis associated with medication use. However, patients with these conditions do not fulfill the other criteria for CRS. Uncommon causes include CSF rhinorrhea, nasal and sinus secreting tumors, inverted papilloma, and nasal foreign bodies. The nasal secretions in these disorders are not usually mucopurulent in appearance. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/17/30999?source=see_link\">",
"       \"An overview of rhinitis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/44/16072?source=see_link\">",
"       \"Etiologies of nasal symptoms: An overview\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Laryngopharyngeal reflux",
"      </strong>",
"      : Occasionally, the perception of mucus buildup in the throat may be a symptom of laryngopharyngeal reflux (LPR), a variant of gastroesophageal reflux (GERD) in which acidic gastric fluids reflux up into the larynx",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pharynx. Other associated symptoms include heartburn, chronic throat clearing, and hoarseness [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/34/35370/abstract/105\">",
"       105",
"      </a>",
"      ]. This disorder can both mimic CRS and contribute to the symptomatology of CRS in patients with both conditions. LPR is reviewed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/10/33960?source=see_link\">",
"       \"Laryngopharyngeal reflux\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Disorders of olfaction",
"      </strong>",
"      :",
"      <span class=\"nowrap\">",
"       Nasal/paranasal",
"      </span>",
"      sinus disease is the most common cause of decreased sense of smell. Head trauma and medications (including zinc supplements) are other possible causes. Cacosmia is not suggestive of CRS. Disorders of olfaction are reviewed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/30/13801?source=see_link\">",
"       \"Anatomy and etiology of taste and smell disorders\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?14/37/14930?source=see_link\">",
"       \"Patient information: Chronic sinusitis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/58/42915?source=see_link\">",
"       \"Patient information: Chronic rhinosinusitis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic rhinosinusitis (CRS) is an inflammatory condition involving the paranasal sinuses and the lining of the nasal passages, lasting 12 weeks or longer, despite attempts at medical management. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Definition'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The four cardinal symptoms of CRS are mucopurulent drainage, nasal obstruction, facial pain",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pressure, and decreased olfaction. At least two of these four must be present to consider the diagnosis of CRS. These symptoms are not specific for CRS, do not distinguish reliably among the different subtypes, and do not correlate well with objective findings upon imaging. (See",
"      <a class=\"local\" href=\"#H3250712\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CRS may be subdivided into three distinct clinical syndromes, with different contributing factors and responses to medical or surgical management: CRS with nasal polyposis (CRS with NP), CRS without nasal polyposis (CRS without NP), and allergic fungal rhinosinusitis (AFRS) (",
"      <a class=\"graphic graphic_table graphicRef53734 \" href=\"mobipreview.htm?40/6/41067\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Features of specific subtypes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CRS, particularly CRS with NP, is strongly associated with asthma and with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      exacerbated respiratory disease (AERD). A variety of factors may contribute to the development of CRS, independent of the subtype, including environmental allergies, aspirin sensitivity, inhaled irritants, viral infections, immunodeficiency, systemic diseases, and anatomic abnormalities (",
"      <a class=\"graphic graphic_table graphicRef74779 \" href=\"mobipreview.htm?8/20/8523\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H22932626\">",
"       'Risk factors and associated conditions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The evaluation of chronic rhinosinusitis involves a clinical history and objective documentation of mucosal disease with either sinus CT imaging, or rhinoscopy or nasal endoscopy with decongestion. Allergy evaluation should be pursued in all patients, and immunologic defects and infectious complications should be considered. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of CRS requires the presence of at least two of the four cardinal symptoms of CRS lasting 12 weeks or longer, despite attempts at medical management, PLUS objective evidence of sinus mucosal disease on sinus CT imaging or direct examination. Each subtype of CRS has characteristic findings on CT imaging. (See",
"      <a class=\"local\" href=\"#H39\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of CRS includes headache and facial pain syndromes, various forms of rhinitis without sinusitis, laryngopharyngeal reflux, and disorders of olfaction. (See",
"      <a class=\"local\" href=\"#H44\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/1\">",
"      Meltzer EO, Hamilos DL, Hadley JA, et al. Rhinosinusitis: establishing definitions for clinical research and patient care. J Allergy Clin Immunol 2004; 114:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/2\">",
"      Scadding GK, Durham SR, Mirakian R, et al. BSACI guidelines for the management of rhinosinusitis and nasal polyposis. Clin Exp Allergy 2008; 38:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/3\">",
"      Rosenfeld RM, Andes D, Bhattacharyya N, et al. Clinical practice guideline: adult sinusitis. Otolaryngol Head Neck Surg 2007; 137:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/4\">",
"      Fokkens WJ, Lund VJ, Mullol J, et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology 2012; 50:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/5\">",
"      Slavin RG, Spector SL, Bernstein IL, et al. The diagnosis and management of sinusitis: a practice parameter update. J Allergy Clin Immunol 2005; 116:S13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/6\">",
"      Lanza DC, Kennedy DW. Adult rhinosinusitis defined. Otolaryngol Head Neck Surg 1997; 117:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/7\">",
"      Fokkens W, Lund V, Bachert C, et al. EAACI position paper on rhinosinusitis and nasal polyps executive summary. Allergy 2005; 60:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/8\">",
"      Shashy RG, Moore EJ, Weaver A. Prevalence of the chronic sinusitis diagnosis in Olmsted County, Minnesota. Arch Otolaryngol Head Neck Surg 2004; 130:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/9\">",
"      Blackwell DL, Collins JG, Coles R. Summary health statistics for U.S. adults: National Health Interview Survey, 1997. Vital Health Stat 10 2002; :1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/10\">",
"      Hastan D, Fokkens WJ, Bachert C, et al. Chronic rhinosinusitis in Europe--an underestimated disease. A GA&sup2;LEN study. Allergy 2011; 66:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/11\">",
"      Ahsan SF, Jumans S, Nunez DA. Chronic rhinosinusitis: a comparative study of disease occurrence in North of Scotland and Southern Caribbean otolaryngology outpatient clinics over a two month period. Scott Med J 2004; 49:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/12\">",
"      Pilan RR, Pinna FR, Bezerra TF, et al. Prevalence of chronic rhinosinusitis in Sao Paulo. Rhinology 2012; 50:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/13\">",
"      Lusk R. Chronic rhinosinusitis: contrasts between children and adult patients. Clin Allergy Immunol 2007; 20:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/14\">",
"      Bhattacharyya N. The economic burden and symptom manifestations of chronic rhinosinusitis. Am J Rhinol 2003; 17:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/15\">",
"      DelGaudio JM, Wise SK, Wise JC. Association of radiological evidence of frontal sinus disease with the presence of frontal pain. Am J Rhinol 2005; 19:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/16\">",
"      Jones NS. Midfacial segment pain: implications for rhinitis and sinusitis. Curr Allergy Asthma Rep 2004; 4:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/17\">",
"      Rosbe KW, Jones KR. Usefulness of patient symptoms and nasal endoscopy in the diagnosis of chronic sinusitis. Am J Rhinol 1998; 12:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/18\">",
"      Hamilos DL. Chronic rhinosinusitis patterns of illness. Clin Allergy Immunol 2007; 20:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/19\">",
"      Harvey RJ, Lund VJ. Biofilms and chronic rhinosinusitis: systematic review of evidence, current concepts and directions for research. Rhinology 2007; 45:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/20\">",
"      Senior BA, Glaze C, Benninger MS. Use of the Rhinosinusitis Disability Index (RSDI) in rhinologic disease. Am J Rhinol 2001; 15:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/21\">",
"      Bhattacharyya N. Functional limitations and workdays lost associated with chronic rhinosinusitis and allergic rhinitis. Am J Rhinol Allergy 2012; 26:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/22\">",
"      Gliklich RE, Metson R. The health impact of chronic sinusitis in patients seeking otolaryngologic care. Otolaryngol Head Neck Surg 1995; 113:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/23\">",
"      Van Crombruggen K, Zhang N, Gevaert P, et al. Pathogenesis of chronic rhinosinusitis: inflammation. J Allergy Clin Immunol 2011; 128:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/24\">",
"      Tomassen P, Van Zele T, Zhang N, et al. Pathophysiology of chronic rhinosinusitis. Proc Am Thorac Soc 2011; 8:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/25\">",
"      Johansson L, Akerlund A, Holmberg K, et al. Prevalence of nasal polyps in adults: the Sk&ouml;vde population-based study. Ann Otol Rhinol Laryngol 2003; 112:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/26\">",
"      Klossek JM, Neukirch F, Pribil C, et al. Prevalence of nasal polyposis in France: a cross-sectional, case-control study. Allergy 2005; 60:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/27\">",
"      Hamilos DL. Nasal polyps as immunoreactive tissue. Allergy Asthma Proc 1996; 17:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/28\">",
"      Arslan HH, Hidir Y, Durmaz A, et al. Unexpected tumor incidence in surgically removed unilateral and bilateral nasal polyps. J Craniofac Surg 2011; 22:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/29\">",
"      Chang JE, White A, Simon RA, Stevenson DD. Aspirin-exacerbated respiratory disease: burden of disease. Allergy Asthma Proc 2012; 33:117.",
"     </a>",
"    </li>",
"    <li>",
"     Mafee MF. Imaging of the nasal cavities, paranasal sinuses, nasopharynx, orbits, infratemporal fossa, pterygomaxillary fissure, parapharyngeal space, and base of skull. In: Ballenger's otorhinolaryngology head and neck surgery, 16th ed, Ballenger JJ, Show JB (Eds), BC Decker, Canada 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/31\">",
"      Hamilos DL, Leung DY, Wood R, et al. Chronic hyperplastic sinusitis: association of tissue eosinophilia with mRNA expression of granulocyte-macrophage colony-stimulating factor and interleukin-3. J Allergy Clin Immunol 1993; 92:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/32\">",
"      Ponikau JU, Sherris DA, Kephart GM, et al. Features of airway remodeling and eosinophilic inflammation in chronic rhinosinusitis: is the histopathology similar to asthma? J Allergy Clin Immunol 2003; 112:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/33\">",
"      Jani AL, Hamilos DL. Current thinking on the relationship between rhinosinusitis and asthma. J Asthma 2005; 42:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/34\">",
"      Malekzadeh S, Hamburger MD, Whelan PJ, et al. Density of middle turbinate subepithelial mucous glands in patients with chronic rhinosinusitis. Otolaryngol Head Neck Surg 2002; 127:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/35\">",
"      Drake-Lee AB, McLaughlan P. Clinical symptoms, free histamine and IgE in patients with nasal polyposis. Int Arch Allergy Appl Immunol 1982; 69:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/36\">",
"      Van Zele T, Gevaert P, Watelet JB, et al. Staphylococcus aureus colonization and IgE antibody formation to enterotoxins is increased in nasal polyposis. J Allergy Clin Immunol 2004; 114:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/37\">",
"      Bernstein JM, Kansal R. Superantigen hypothesis for the early development of chronic hyperplastic sinusitis with massive nasal polyposis. Curr Opin Otolaryngol Head Neck Surg 2005; 13:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/38\">",
"      Bernstein JM, Allen C, Rich G, et al. Further observations on the role of Staphylococcus aureus exotoxins and IgE in the pathogenesis of nasal polyposis. Laryngoscope 2011; 121:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/39\">",
"      Hutcheson PS, Schubert MS, Slavin RG. Distinctions between allergic fungal rhinosinusitis and chronic rhinosinusitis. Am J Rhinol Allergy 2010; 24:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/40\">",
"      Thorp BD, McKinney KA, Rose AS, Ebert CS Jr. Allergic fungal sinusitis in children. Otolaryngol Clin North Am 2012; 45:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/41\">",
"      Cyriac JT, Cherian T, Hadi WA, Jose J. Optic neuropathy due to allergic fungal rhinosinusitis. J Neurosci Rural Pract 2011; 2:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/42\">",
"      Campbell JM, Graham M, Gray HC, et al. Allergic fungal sinusitis in children. Ann Allergy Asthma Immunol 2006; 96:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/43\">",
"      Schubert MS, Goetz DW. Evaluation and treatment of allergic fungal sinusitis. I. Demographics and diagnosis. J Allergy Clin Immunol 1998; 102:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/44\">",
"      Nussenbaum B, Marple BF, Schwade ND. Characteristics of bony erosion in allergic fungal rhinosinusitis. Otolaryngol Head Neck Surg 2001; 124:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/45\">",
"      Mafee MF. Imaging of paranasal sinuses and rhinosinusitis. Clin Allergy Immunol 2007; 20:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/46\">",
"      Guo C, Ghadersohi S, Kephart GM, et al. Improving the detection of fungi in eosinophilic mucin: seeing what we could not see before. Otolaryngol Head Neck Surg 2012; 147:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/47\">",
"      Bhattacharyya N, Lee KH. Chronic recurrent rhinosinusitis: disease severity and clinical characterization. Laryngoscope 2005; 115:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/48\">",
"      Cryer J, Schipor I, Perloff JR, Palmer JN. Evidence of bacterial biofilms in human chronic sinusitis. ORL J Otorhinolaryngol Relat Spec 2004; 66:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/49\">",
"      Ferguson BJ, Stolz DB. Demonstration of biofilm in human bacterial chronic rhinosinusitis. Am J Rhinol 2005; 19:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/50\">",
"      Sanclement JA, Webster P, Thomas J, Ramadan HH. Bacterial biofilms in surgical specimens of patients with chronic rhinosinusitis. Laryngoscope 2005; 115:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/51\">",
"      Singhal D, Psaltis AJ, Foreman A, Wormald PJ. The impact of biofilms on outcomes after endoscopic sinus surgery. Am J Rhinol Allergy 2010; 24:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/52\">",
"      Ponikau JU, Sherris DA, Kern EB, et al. The diagnosis and incidence of allergic fungal sinusitis. Mayo Clin Proc 1999; 74:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/53\">",
"      Shin SH, Ponikau JU, Sherris DA, et al. Chronic rhinosinusitis: an enhanced immune response to ubiquitous airborne fungi. J Allergy Clin Immunol 2004; 114:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/54\">",
"      Emanuel IA, Shah SB. Chronic rhinosinusitis: allergy and sinus computed tomography relationships. Otolaryngol Head Neck Surg 2000; 123:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/55\">",
"      Poachanukoon O, Nanthapisal S, Chaumrattanakul U. Pediatric acute and chronic rhinosinusitis: comparison of clinical characteristics and outcome of treatment. Asian Pac J Allergy Immunol 2012; 30:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/56\">",
"      Kim YS, Kim NH, Seong SY, et al. Prevalence and risk factors of chronic rhinosinusitis in Korea. Am J Rhinol Allergy 2011; 25:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/57\">",
"      Berrettini S, Carabelli A, Sellari-Franceschini S, et al. Perennial allergic rhinitis and chronic sinusitis: correlation with rhinologic risk factors. Allergy 1999; 54:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/58\">",
"      Jarvis D, Newson R, Lotvall J, et al. Asthma in adults and its association with chronic rhinosinusitis: the GA2LEN survey in Europe. Allergy 2012; 67:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/59\">",
"      Lieu JE, Feinstein AR. Confirmations and surprises in the association of tobacco use with sinusitis. Arch Otolaryngol Head Neck Surg 2000; 126:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/60\">",
"      Reh DD, Higgins TS, Smith TL. Impact of tobacco smoke on chronic rhinosinusitis: a review of the literature. Int Forum Allergy Rhinol 2012; 2:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/61\">",
"      Pinto JM, Naclerio RM. Environmental and allergic factors in chronic rhinosinusitis. Clin Allergy Immunol 2007; 20:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/62\">",
"      Bhattacharyya N. Air quality influences the prevalence of hay fever and sinusitis. Laryngoscope 2009; 119:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/63\">",
"      Carr TF, Koterba AP, Chandra R, et al. Characterization of specific antibody deficiency in adults with medically refractory chronic rhinosinusitis. Am J Rhinol Allergy 2011; 25:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/64\">",
"      Shapiro GG, Virant FS, Furukawa CT, et al. Immunologic defects in patients with refractory sinusitis. Pediatrics 1991; 87:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/65\">",
"      Vanlerberghe L, Joniau S, Jorissen M. The prevalence of humoral immunodeficiency in refractory rhinosinusitis: a retrospective analysis. B-ENT 2006; 2:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/66\">",
"      Dahl M, Tybjaerg-Hansen A, Schnohr P, Nordestgaard BG. A population-based study of morbidity and mortality in mannose-binding lectin deficiency. J Exp Med 2004; 199:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/67\">",
"      Psaltis AJ, Bruhn MA, Ooi EH, et al. Nasal mucosa expression of lactoferrin in patients with chronic rhinosinusitis. Laryngoscope 2007; 117:2030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/68\">",
"      Tan BK, Schleimer RP, Kern RC. Perspectives on the etiology of chronic rhinosinusitis. Curr Opin Otolaryngol Head Neck Surg 2010; 18:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/69\">",
"      Tewfik MA, Latterich M, DiFalco MR, Samaha M. Proteomics of nasal mucus in chronic rhinosinusitis. Am J Rhinol 2007; 21:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/70\">",
"      Baroody FM. Mucociliary transport in chronic rhinosinusitis. Clin Allergy Immunol 2007; 20:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/71\">",
"      Jang YJ, Kwon HJ, Park HW, Lee BJ. Detection of rhinovirus in turbinate epithelial cells of chronic sinusitis. Am J Rhinol 2006; 20:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/72\">",
"      Lohrmann C, Uhl M, Warnatz K, et al. Sinonasal computed tomography in patients with Wegener's granulomatosis. J Comput Assist Tomogr 2006; 30:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/73\">",
"      Alobid I, Guilemany JM, Mullol J. Nasal manifestations of systemic illnesses. Curr Allergy Asthma Rep 2004; 4:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/74\">",
"      Reed J, deShazo RD, Houle TT, et al. Clinical features of sarcoid rhinosinusitis. Am J Med 2010; 123:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/75\">",
"      Brook I. Sinusitis of odontogenic origin. Otolaryngol Head Neck Surg 2006; 135:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/76\">",
"      Bomeli SR, Branstetter BF 4th, Ferguson BJ. Frequency of a dental source for acute maxillary sinusitis. Laryngoscope 2009; 119:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/77\">",
"      Longhini AB, Branstetter BF, Ferguson BJ. Unrecognized odontogenic maxillary sinusitis: a cause of endoscopic sinus surgery failure. Am J Rhinol Allergy 2010; 24:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/78\">",
"      Lusk RP, McAlister B, el Fouley A. Anatomic variation in pediatric chronic sinusitis: a CT study. Otolaryngol Clin North Am 1996; 29:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/79\">",
"      Bolger WE, Butzin CA, Parsons DS. Paranasal sinus bony anatomic variations and mucosal abnormalities: CT analysis for endoscopic sinus surgery. Laryngoscope 1991; 101:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/80\">",
"      Jones NS, Strobl A, Holland I. A study of the CT findings in 100 patients with rhinosinusitis and 100 controls. Clin Otolaryngol Allied Sci 1997; 22:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/81\">",
"      Danese M, Duvoisin B, Agrifoglio A, et al. [Influence of naso-sinusal anatomic variants on recurrent, persistent or chronic sinusitis. X-ray computed tomographic evaluation in 112 patients]. J Radiol 1997; 78:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/82\">",
"      Holbrook EH, Brown CL, Lyden ER, Leopold DA. Lack of significant correlation between rhinosinusitis symptoms and specific regions of sinus computer tomography scans. Am J Rhinol 2005; 19:382.",
"     </a>",
"    </li>",
"    <li>",
"     Committee on Damp Indoor Spaces and Health. Damp indoor spaces and health. The National Academies Press; Board of Health Promotion and Disease Prevention, Institute of Medicine of the National Academies, Washington, DC, 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/84\">",
"      Ramadan HH. Chronic rhinosinusitis and bacterial biofilms. Curr Opin Otolaryngol Head Neck Surg 2006; 14:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/85\">",
"      Kowalski ML, Cie��lak M, P&eacute;rez-Novo CA, et al. Clinical and immunological determinants of severe/refractory asthma (SRA): association with Staphylococcal superantigen-specific IgE antibodies. Allergy 2011; 66:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/86\">",
"      Benninger MS, Ferguson BJ, Hadley JA, et al. Adult chronic rhinosinusitis: definitions, diagnosis, epidemiology, and pathophysiology. Otolaryngol Head Neck Surg 2003; 129:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/87\">",
"      Lee JT, Kennedy DW, Palmer JN, et al. The incidence of concurrent osteitis in patients with chronic rhinosinusitis: a clinicopathological study. Am J Rhinol 2006; 20:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/88\">",
"      Bhattacharyya N, Lee LN. Evaluating the diagnosis of chronic rhinosinusitis based on clinical guidelines and endoscopy. Otolaryngol Head Neck Surg 2010; 143:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/89\">",
"      Tichenor WS, Adinoff A, Smart B, Hamilos DL. Nasal and sinus endoscopy for medical management of resistant rhinosinusitis, including postsurgical patients. J Allergy Clin Immunol 2008; 121:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/90\">",
"      Bhattacharyya N, Fried MP. The accuracy of computed tomography in the diagnosis of chronic rhinosinusitis. Laryngoscope 2003; 113:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/91\">",
"      Berrington de Gonz&aacute;lez A, Mahesh M, Kim KP, et al. Projected cancer risks from computed tomographic scans performed in the United States in 2007. Arch Intern Med 2009; 169:2071.",
"     </a>",
"    </li>",
"    <li>",
"     Stammberger H. Functional Endoscopic Sinus Surgery, BC Decker, Philadelphia 1991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/93\">",
"      Socher JA, Cassano M, Filheiro CA, et al. Diagnosis and treatment of isolated sphenoid sinus disease: a review of 109 cases. Acta Otolaryngol 2008; 128:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/94\">",
"      Nour YA, Al-Madani A, El-Daly A, Gaafar A. Isolated sphenoid sinus pathology: spectrum of diagnostic and treatment modalities. Auris Nasus Larynx 2008; 35:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/95\">",
"      G&uuml;ven&ccedil; MG, Kaytaz A, Ozbilen Acar G, Ada M. Current management of isolated sphenoiditis. Eur Arch Otorhinolaryngol 2009; 266:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/96\">",
"      Grillone GA, Kasznica P. Isolated sphenoid sinus disease. Otolaryngol Clin North Am 2004; 37:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/97\">",
"      Lin HW, Bhattacharyya N. Diagnostic and staging accuracy of magnetic resonance imaging for the assessment of sinonasal disease. Am J Rhinol Allergy 2009; 23:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/98\">",
"      Zinreich SJ, Kennedy DW, Malat J, et al. Fungal sinusitis: diagnosis with CT and MR imaging. Radiology 1988; 169:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/99\">",
"      Mukherji SK, Figueroa RE, Ginsberg LE, et al. Allergic fungal sinusitis: CT findings. Radiology 1998; 207:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/100\">",
"      Bhattacharyya T, Piccirillo J, Wippold FJ 2nd. Relationship between patient-based descriptions of sinusitis and paranasal sinus computed tomographic findings. Arch Otolaryngol Head Neck Surg 1997; 123:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/101\">",
"      Hopkins C, Browne JP, Slack R, et al. The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict? Otolaryngol Head Neck Surg 2007; 137:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/102\">",
"      Ferguson BJ. Eosinophilic mucin rhinosinusitis: a distinct clinicopathological entity. Laryngoscope 2000; 110:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/103\">",
"      Schubert MS. Allergic fungal sinusitis. Clin Allergy Immunol 2007; 20:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/104\">",
"      Jones NS. The prevalence of facial pain and purulent sinusitis. Curr Opin Otolaryngol Head Neck Surg 2009; 17:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/34/35370/abstract/105\">",
"      Ozturk O, Oz F, Karakullukcu B, et al. Hoarseness and laryngopharyngeal reflux: a cause and effect relationship or coincidence? Eur Arch Otorhinolaryngol 2006; 263:935.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7528 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-122.72.80.101-F770B2E4D0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_34_35370=[""].join("\n");
var outline_f34_34_35370=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H50\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H368890043\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1858543\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3250712\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3250739\">",
"      Signs and symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3255792\">",
"      Warning signs and complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3250746\">",
"      Impact on quality of life",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      FEATURES OF SPECIFIC SUBTYPES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CRS with nasal polyposis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4984464\">",
"      - Presentation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20818307\">",
"      - Imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20818430\">",
"      - Histologic findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4984597\">",
"      - Pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Allergic fungal rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4984667\">",
"      - Presentation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22932127\">",
"      - Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20818833\">",
"      - Imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20818862\">",
"      - Histologic findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1858077\">",
"      CRS without nasal polyposis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4984675\">",
"      - Presentation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20819199\">",
"      - Imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20819125\">",
"      - Histology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4984737\">",
"      - Pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22932626\">",
"      RISK FACTORS AND ASSOCIATED CONDITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4984293\">",
"      Role of bacterial infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Demonstration of mucosal disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23061096\">",
"      - Rhinoscopy and endoscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3255902\">",
"      - Sinus imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Sinus CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Sinus MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Sinus cultures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Allergy evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Consider immune evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Consider evaluation for systemic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3254002\">",
"      Suggestive signs and symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3254012\">",
"      Objective evidence of inflammation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Determining the subtype of disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H50\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/7528\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/7528|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?38/50/39715\" title=\"diagnostic image 1\">",
"      CRS NP CR rhinoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?8/3/8241\" title=\"diagnostic image 2\">",
"      AFRS CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?27/8/27779\" title=\"diagnostic image 3\">",
"      CRS S NP pre post tx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?34/31/35313\" title=\"diagnostic image 4\">",
"      Normal sinus CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/7528|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/36/16962\" title=\"figure 1\">",
"      Sinuses and OMC external",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/4/26688\" title=\"figure 2\">",
"      Nasal polyps in nostril",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?11/43/11967\" title=\"figure 3\">",
"      Internal nasal exam",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?10/21/10579\" title=\"figure 4\">",
"      Ostio-meatal complex",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/7528|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?3/43/3761\" title=\"picture 1\">",
"      Surgically removed polyp",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?39/35/40510\" title=\"picture 2\">",
"      Allergic mucin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?34/63/35838\" title=\"picture 3\">",
"      Endoscopy nasal cavity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/7528|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?40/6/41067\" title=\"table 1\">",
"      Categories of CRS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/20/8523\" title=\"table 2\">",
"      Factors contrib CRS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/48/39688?source=related_link\">",
"      Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/53/22362?source=related_link\">",
"      Allergic rhinitis: Clinical manifestations, epidemiology, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/17/30999?source=related_link\">",
"      An overview of rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/30/13801?source=related_link\">",
"      Anatomy and etiology of taste and smell disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/8/35977?source=related_link\">",
"      Approach to the child with headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/0/39944?source=related_link\">",
"      Aspirin exacerbated respiratory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/5/18519?source=related_link\">",
"      Atrophic rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/61/12250?source=related_link\">",
"      Chronic nonallergic rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/62/17386?source=related_link\">",
"      Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/25/21914?source=related_link\">",
"      Clinical manifestations and diagnosis of sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/49/28442?source=related_link\">",
"      Cystic fibrosis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/56/21383?source=related_link\">",
"      Epidemiology, pathogenesis, and pathology of Churg-Strauss syndrome (allergic granulomatosis and angiitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/44/16072?source=related_link\">",
"      Etiologies of nasal symptoms: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34615?source=related_link\">",
"      Evaluation of headache in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/36/8775?source=related_link\">",
"      Fungal rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/34/3624?source=related_link\">",
"      Headache syndromes other than migraine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/58/43945?source=related_link\">",
"      Laboratory evaluation of the immune system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/10/33960?source=related_link\">",
"      Laryngopharyngeal reflux",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/4/30794?source=related_link\">",
"      Management of chronic rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/58/26537?source=related_link\">",
"      Microbiology and antibiotic management of chronic rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/58/42915?source=related_link\">",
"      Patient information: Chronic rhinosinusitis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?14/37/14930?source=related_link\">",
"      Patient information: Chronic sinusitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/37/9817?source=related_link\">",
"      Primary ciliary dyskinesia (immotile-cilia syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/48/24326?source=related_link\">",
"      Primary humoral immune deficiencies: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/17/21785?source=related_link\">",
"      Radiation-related risks of imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/14/21738?source=related_link\">",
"      Respiratory tract involvement in granulomatosis with polyangiitis (Wegener's)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/51/17209?source=related_link\">",
"      Selective antibody deficiency with normal immunoglobulins",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_34_35371="Hepatitis scoring system";
var content_f34_34_35371=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F51662&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F51662&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Scoring system for necroinflammatory activity and fibrosis in chronic hepatitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Grade",
"       </td>",
"       <td class=\"subtitle1\">",
"        Portal/periportal activity",
"       </td>",
"       <td class=\"subtitle1\">",
"        Lobular activity",
"       </td>",
"       <td class=\"subtitle1\">",
"        Fibrosis*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        None or minimal",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        Portal inflammation (CPH)",
"       </td>",
"       <td>",
"        Inflammation but no necrosis",
"       </td>",
"       <td>",
"        Enlarged fibrotic portal tracts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        Mild piecemeal necrosis (mild CAH)",
"       </td>",
"       <td>",
"        Focal necrosis or acidophil bodies",
"       </td>",
"       <td>",
"        Periportal or portal-portal septa but intact architecture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        Moderate piecemeal necrosis (moderate CAH)",
"       </td>",
"       <td>",
"        Severe focal cell damage",
"       </td>",
"       <td>",
"        Fibrosis with architetural distortion but no cirrhosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        Severe piecemeal necrosis (severe CAH)",
"       </td>",
"       <td>",
"        Damage includes bridging necrosis",
"       </td>",
"       <td>",
"        Probable or definite cirrhosis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     *Alternatively, cirrhosis can be separately scored from fibrosis into the following categories: probably absent; developing, suspected; cannot be assessed.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Scheuer, PJ, J Hepatol 1991; 13:372.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_34_35371=[""].join("\n");
var outline_f34_34_35371=null;
var title_f34_34_35372="ECG disturbances stroke";
var content_f34_34_35372=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F51965&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F51965&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Rates of ECG abnormalities and arrhythmias following stroke",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Type",
"of arrhythmia",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Rate, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Goldstein",
"       </td>",
"       <td class=\"subtitle2\">",
"        Ramani et al",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prolonged QT",
"       </td>",
"       <td>",
"        37",
"       </td>",
"       <td>",
"        28",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        U waves/tall U waves",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ST depression/changes",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        25",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T wave inversion/changes",
"       </td>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        34",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tachycardia/sinus tachycardia",
"       </td>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Left ventricular hypertrophy",
"       </td>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Q waves",
"       </td>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Atrial fibrillation",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Premature ventricular contractions",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased heart rate/sinus bradycardia",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Right bundle branch block",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        First degree heart block",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Premature atrial contractures",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Left atrial enlargement/hypertrophy",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ST elevation",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Left bundle branch block",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The rates are compared in two studies. The first (Goldstein) evaluated 150 patients with stroke, including those with a history of heart disease. The second (Ramani et al.) evaluated 100 patients with stroke and no prior history of heart disease.",
"    <div class=\"footnotes\">",
"     NR: not reported.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Goldstein, DS. The electrocardiogram in stroke: relationship to pathophysiological type and comparison with prior tracings. Strok 1979; 10:253.; and Ramani, A, Shetty, U, Kundaje, GN. Electrocardiographic abnormalities in cerebrovascular accidents. Angiology 1990; 41:681.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_34_35372=[""].join("\n");
var outline_f34_34_35372=null;
var title_f34_34_35373="Neurotox cytotoxic agents";
var content_f34_34_35373=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F67516&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F67516&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Neurotoxicity associated with cytotoxic chemotherapy agents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Onset dose",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Clinical manifestations",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Recovery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Sensory",
"       </td>",
"       <td class=\"subtitle2\">",
"        Motor",
"       </td>",
"       <td class=\"subtitle2\">",
"        Reflexes",
"       </td>",
"       <td class=\"subtitle2\">",
"        Autonomic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        Platinum compounds",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cisplatin",
"       </td>",
"       <td>",
"        300 mg/m",
"        <sup>",
"         2",
"        </sup>",
"       </td>",
"       <td>",
"        Distal, symmetric loss of sensation to all modalities; painful paresthesias or numbness",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        In proportion to sensory loss",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Partial; may progress for several months after drug is discontinued",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Carboplatin",
"       </td>",
"       <td>",
"        800 to 1600 mg/m",
"        <sup>",
"         2",
"        </sup>",
"       </td>",
"       <td>",
"        Similar but less severe than with cisplatin",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Usually normal",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Similar to cisplatin",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        Oxaliplatin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Acute",
"       </td>",
"       <td>",
"        Any",
"       </td>",
"       <td>",
"        Cold-induced dysesthesias in mouth, throat and upper limbs",
"       </td>",
"       <td>",
"        Cramps and/or muscle spasm in throat muscles",
"       </td>",
"       <td>",
"        Usually normal",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Resolves within one week",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chronic",
"       </td>",
"       <td>",
"        750 to 850 mg/m",
"        <sup>",
"         2",
"        </sup>",
"       </td>",
"       <td>",
"        Similar to cisplatin",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Usually normal",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Usually resolves within three months; rarely persists long term",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        Vinca alkaloids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vincristine",
"       </td>",
"       <td rowspan=\"4\">",
"        4 to 10 mg",
"       </td>",
"       <td rowspan=\"4\">",
"        Distal sensory loss lower extremities, rarely affects upper extremities; vinblastine and vinorelbine are less neurotoxic; vincristine - rare mononeuropathies",
"       </td>",
"       <td rowspan=\"4\">",
"        Less common; distal symmetric weakness in lower limbs progressing to foot drop",
"       </td>",
"       <td rowspan=\"4\">",
"        Early decrease or absent",
"       </td>",
"       <td rowspan=\"4\">",
"        Constipation common (especially vincristine), orthostatic hypotension less common",
"       </td>",
"       <td rowspan=\"4\">",
"        Usually resolves within three months; may persist with vincristine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vinblastine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vinorelbine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vindesine",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        Taxanes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Paclitaxel",
"       </td>",
"       <td>",
"        100 to 300 mg/m",
"        <sup>",
"         2",
"        </sup>",
"       </td>",
"       <td rowspan=\"2\">",
"        Mild distal loss of sensation to all modalities, feet greater than hands, painful paresthesias",
"       </td>",
"       <td rowspan=\"2\">",
"        Occasional mild weakness in foot muscles",
"       </td>",
"       <td rowspan=\"2\">",
"        Reduced ankle reflexes",
"       </td>",
"       <td rowspan=\"2\">",
"        Rare",
"       </td>",
"       <td rowspan=\"2\">",
"        Usually resolves within three months; may persist",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Docetaxel",
"       </td>",
"       <td>",
"        75 to 100 mg/m",
"        <sup>",
"         2",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Bortezomib",
"        </strong>",
"       </td>",
"       <td>",
"        1.3 mg/m",
"        <sup>",
"         2",
"        </sup>",
"       </td>",
"       <td>",
"        Mild to moderate distal symmetric loss of sensation to all modalities in lower extremities; painful paresthesias",
"       </td>",
"       <td>",
"        Occasional mild distal weakness in lower limbs; rare severe distal weakness; muscle cramps and fasciculations rare",
"       </td>",
"       <td>",
"        In proportion to sensory loss",
"       </td>",
"       <td>",
"        Occasional, including orthostatic hypotension, diarrhea,&nbsp;and constipation",
"       </td>",
"       <td>",
"        Usually resolves within three months; may persist",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Ixabepilone",
"        </strong>",
"       </td>",
"       <td>",
"        40 to 120 mg/m",
"        <sup>",
"         2",
"        </sup>",
"       </td>",
"       <td>",
"        Painful paresthesias; distal loss of sensation",
"       </td>",
"       <td>",
"        10 to 16 percent have weakness",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Resolves within four to six weeks",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Thalidomide",
"        </strong>",
"       </td>",
"       <td>",
"        20 g",
"       </td>",
"       <td>",
"        Symmetric mild to moderate distal loss to all sensory modalities",
"       </td>",
"       <td>",
"        Weakness and tremor in 30 to 40 percent; muscle crampls and fasciculations common",
"       </td>",
"       <td>",
"        In proportion to sensory loss",
"       </td>",
"       <td>",
"        Constipation; other manifestations (impotence, bradycardia) are rare",
"       </td>",
"       <td>",
"        Partially reversible; may persist for over one year",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_34_35373=[""].join("\n");
var outline_f34_34_35373=null;
var title_f34_34_35374="Natural hx FBA";
var content_f34_34_35374=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F68288&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F68288&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Natural course of foreign body aspiration",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 441px; height: 398px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_34_35374=[""].join("\n");
var outline_f34_34_35374=null;
var title_f34_34_35375="Survival revasc vs med rx";
var content_f34_34_35375=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F78579&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F78579&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 546px\">",
"   <div class=\"ttl\">",
"    Kaplan-Meier long-term survival of all patients and those discharged alive following hospitalization",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 526px; height: 655px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Among all patients, the survival rates in the early revascularization (ERV) and initial medical stabilization (IMS) groups, respectively, were 41.4 versus 28.3 percent at three years and 32.8 versus 19.6 percent at six years. With exclusion of eight patients with aortic dissection, tamponade, or severe mitral regurgitation identified shortly after randomization, the survival curves remained significantly different (P = .02), with a 14.0 percent absolute difference at six years. Among hospital survivors, the survival rates in the ERV and IMS groups, respectively, were 78.8 versus 64.3 percent at three years and 62.4 versus 44.4 percent at six years.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction. JAMA 2006; 295:2511. Copyright &copy;2006 American Medical Association. All Rights Reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_34_35375=[""].join("\n");
var outline_f34_34_35375=null;
